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I N T R O D U C T I O N
Prostate cancer (PCa) is a commonly diagnosed malignancy among men in the 
Western world. As in to the US, PCa is the second leading cause of cancer death in 
the Netherlands.1,2 In 1997, at the start of this project, 6,402 men were diagnosed 
with PCa in the Netherlands, and 2,367 died from the disease.1 
During the last 10 years with the rising incidence and increased public awareness of 
the disease, research on PCa has entered a new era. Many research groups over the 
world are focussing on a number of promising etiological leads, encompassing 
genetic, hormonal, and lifestyle factors. Still, besides age and race, family history 
remains the only well established risk factor of PCa.
‘Common’ cancers, including cancer of the breast, colon, urothelial cell carcinoma, 
and prostate, are considered to be mainly ‘sporadic’, i.e. most of these cancers do 
not adhere to Mendelian inheritance laws. In 1973, Knudson et al. proposed that 
virtually all cancer sites include a relatively small subgroup in which a hereditary, 
Mendelian, component operates as a major etiological factor.3 Through the study of 
retinoblastoma, Knudson hypothesized that two successive mutational events (or 
‘hits’) are needed to result in retinoblastoma. The first hit may be somatic (sporadic 
cancer) or germinal (hereditary cancer). The second hit later in life initiates 
carcinogenesis. In molecular biology, the class of genes that adhered to the two-hit 
model was designated tumor suppressor gene (TSG). The involvement of TSGs may 
be indicated by allelic loss or imbalance (AI) in tumor tissue.
Indeed, in several cancers, including breast and colon cancer, such TSGs have been 
observed to account for the occurrence of multiplex families.4 Furthermore, it has 
been shown that mutations in such genes may cause cancer at different sites. For 
example, mutations in BRCA1 have been implicated in the causation of both breast 
and ovarian cancer.
The first clues to whether an inherited subtype of cancer exists is provided by 
evidence of familial aggregation.5 Here, the risk of cancer among relatives of cancer 
cases is compared to either the risk of that cancer in the general population or the 
risk of cancer among relatives of control subjects.5 Of course, in case familial 
aggregation is observed, shared environment, genetic factors, a combination of both, 
or even chance may explain the excess risk among family members of cancer cases. 
In order to evaluate the underlying mechanism of the observed familial aggregation,
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segregation analysis may be the next undertaking.6 Segregation analysis formally 
tests whether the pattern of affected relatives within families of cancer cases is 
consistent with Mendelian inheritance. In case evidence for Mendelian inheritance 
emerges or molecular studies (e.g. allelic imbalance or comparative genomic 
hybridization) indicate the presence of TSGs, linkage analysis may be employed in 
order to pinpoint genomic regions in which cancer susceptibility genes may reside. 
Once a gene has been mapped and identified, sequencing of the gene may reveal 
mutations associated with the disease.
In the etiology of the sporadic and the inherited forms of PCa, the same 
malfunctioning genes may be involved. In other cancers such similarities have been 
observed. For instance, mutations in the APC  (adenomatous polyposis coli) gene 
have been observed in both sporadic colorectal cancer and familial adenomatous 
polyposis, which accounts for approximately 1 percent of all colorectal cancers.7 As 
genetic defects are typically more easily detected in inherited cancer cases, the study 
of inherited PCa may provide important leads for prostatic carcinogenesis in general. 
The ultimate goal of clarifying the role of a (mutated) gene in the carcinogenesis of 
the hereditary and sporadic forms of PCa is that treatment and early detection may 
be improved.
■ Objectives. In the original grant application of this study, the overall goals were 
formulated as “to confirm the existence of an inherited form of PCa and to 
characterize the epidemiologic and molecular biologic characteristics of hereditary 
PCa.”
In order to achieve these goals the following questions will be evaluated in this thesis:
1. To what extent does PCa aggregate within families? And to what extent do other 
types of cancer co-aggregate within PCa families?
2. Is there a Mendelian inheritance pattern of PCa? And if so, what are the gene 
frequency and genotype-specific cumulative risks of PCa?
3. Are there different genetic changes in hereditary and sporadic PCa?
In order to evaluate the questions under 1. and 2. we initiated a large-scale 
population based study including patients diagnosed with PCa. Through postal 
questionnaires and telephone contact we obtained information from these patients and
8
their first-degree relatives. Likewise, information was obtained from the partners of 
the PCa patients and their first-degree relatives.
The familial aggregation of PCa was evaluated by comparing the occurrence of PCa 
among case relatives to that among the relatives of controls (chapter 2). The familial 
aggregation of PCa with cancers at other sites was evaluated similarly, in order to 
assess possible genetic heterogeneity.
Whether the expected familial aggregation adheres to Mendelian inheritance, 
segregation analysis was planned to be performed on the population of PCa cases and 
their first-degree relatives (chapter 5). Additionally, a series of 1,345 PCa cases that 
underwent radical prostatectomy at the Division of Urologic Surgery, Washington 
University, St Louis (USA), was kindly made available to us in order to perform 
segregation analysis (chapter 4). It had been previously shown that men from this 
population with a family history of PCa were at a significantly increased risk for 
PCa.8
The question under 3. was assessed through molecular analysis of tumors resected from 
hereditary and sporadic PCa cases, which were identified in our cohort of PCa cases 
and their first-degree relatives. Additional hereditary tumors were acquired through 
hereditary PCa cases which were selected from the Dutch Foundation for Detection of 
Hereditary Tumors Registry (Leiden, the Netherlands).
At the start of our study, genetic alterations in sporadic PCa had been investigated 
extensively in studies of allelic imbalance and comparative genomic hybridization.9-14 
Data on genetic alterations in hereditary PCa, however, was still sparse.
In order to detect differences in genetic alterations in both sporadic and hereditary 
prostate tumors, allelic imbalance was evaluated using a panel of 35 microsatellite 
markers. These markers were chosen at loci which (1) frequently show AI in 
sporadic PCa; or (2) are believed to have a putative role in the disease (chapter 6). 
Also, in a selection of hereditary tumors, comparative genomic hybridization 
analysis was performed to detect specific genetic alterations at the chromosomal level 
(chapter 7).
In two side studies we investigated low-penetrance susceptibility to PCa of the 
polymorphic HPC2/ELAC2 gene and the E-cadherin gene promoter (chapters 8 and 
9). During the course of our project, these two polymorphisms were implicated to 
have a role in PCa.15-17 To assess the involved genotype-specific risks, we aimed to 
genotype the hereditary and sporadic PCa cases, and additional control subjects.
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C H A P T E R 1 
G E N E T I C S U S C E P T I B I L I T Y T O 
P R O S T A T E C A N C E R : A R E V I E W
■ Abstract. A genetic component in prostate cancer (PCa) has been recognized 
since decades. Through numerous epidemiological and molecular biological studies 
much evidence has accumulated in favor of a significant but heterogeneous 
hereditary component in PCa susceptibility.
Since the mapping of a high-penetrant PCa susceptibility locus at 1q24-25, much 
attention has been paid to the identification of PCa susceptibility genes. So far, seven 
loci have been mapped, and at three of these loci genes have been cloned and 
mutations identified. Yet their role in hereditary and sporadic disease is still under 
debate and probably very modest. Although research on hereditary PCa has 
improved our knowledge of the genetic etiology of the disease, still a lot of questions 
remain unanswered. Here, we aim to review the genetic epidemiological and 
molecular biological research in the field of hereditary PCa and the problems that are 
encountered with this research.
■ Introduction. Although PCa is a common lethal malignancy among men in the 
Western world, many questions concerning its etiology remain unanswered. Besides 
age and race, family history is the only well established risk factor for PCa. Over the 
years, genetic epidemiological evidence has accumulated in favor of a significant 
hereditary component in PCa susceptibility.1 Familial aggregation of PCa, i.e. the 
occurrence of more than one PCa case among first-degree relatives, has been 
recognized for decades. Epidemiological studies show that first-degree relatives of 
PCa patients have a 2 to 3-fold increased risk of PCa. Especially high risks of PCa 
have been observed in men having multiple affected relatives, or relatives diagnosed 
at an early age. This familial risk of PCa has been observed in ethnically different 
populations (Asian-Americans, Caucasians, and African-Americans).2 The 2 to 3-fold 
increased risks may not seem impressive, but one has to realize that under the 
assumption that an inherited form of PCa exists, families consist of a mixed group of a 
few susceptibles (gene carriers) and many non-susceptibles (non-carriers). If it would
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be possible to identify the gene carriers, their risks would be much larger. On the 
other hand, an excess familial risk may be due to a genetic etiology but may also be the 
result of cultural inheritance or clustering of environmental risk factors and their 
interactions. Twin studies can provide a somewhat better indication whether the 
familial aggregation of cancer is due to hereditary or environmental determinants by 
comparing the concordance of cancer in dizygotic and monozygotic twins. In a 
Swedish study 458 PCa cases were identified from a registry of 4840 male twin 
pairs.3 Among all monozygous twins 16 concordant pairs were found (1.0%), while 
only six concordant dizygous twin pairs were found among all dizygous 
twins(0.2%). In another twin study conducted in the United States similar results 
were found. From a national twin registry 1009 twin pairs were identified, of whom 
at least one member had PCa. Compared to only 3.7% of the dizygous twins, 15.7% 
of the monozygous twins were concordant for PCa.4 Moreover, in a study of 44,788 
pairs of twins from Sweden, Denmark, and Finland, it was estimated that 42% (95% 
confidence interval (CI): 29%-50%) of all PCa risk may be attributed to inherited 
factors.5
While the results of studies on familial aggregation of PCa are consistent, the results of 
studies of the clustering of PCa with cancer at other sites have been quite diverse. 
Some investigations found slightly increased risks for tumors of the central nervous 
system (CNS),6,7 gastric cancer,8,9 colorectal cancer,10,11 and breast cancer8,11 among 
first-degree relatives of PCa probands. Others did not observe any associations with 
cancer at other sites.12,13 Although differences in study populations (i.e. genetic 
heterogeneity) may account for these diverse findings, the available data suggest that 
the inherited susceptibility to PCa is relatively ‘site-specific’, and not part of an 
inherited cancer-syndrome like the BRCA1--associated breast and ovary cancer­
syndrome, and the mismatch repair genes-related HNPCC syndrome.
Family studies and twin studies may strongly suggest a genetic component in PCa, but 
cannot be used to infer the specific genetic mode of transmission. In order to 
elucidate the mode of inheritance of PCa within families several segregation analyses 
have been performed.14-19
According to three studies from the US and one Swedish study, the familial 
aggregation of PCa can be best explained by Mendelian autosomal dominant 
inheritance (see table 1.1).14-17 Last year, Cui et al. reported the results of 
segregation analyses of Australian PCa families.18 Through the testing of two-locus 
models it was observed that a dominantly inherited increased risk contributed
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Table 1.1: Segregation analyses o f prostate cancer.
Author (year)
Carter
(1992)14
Gronberg
(1997)15
Schaid
(1998)16
Verhage
(2001)17
Cui
(2001)18
Gong
(2002)19
Number of PCa 
families
691 2,857 4,228 1,199 1,476 1,719
Population source USA Sweden USA USA Australia
USA,
Canada
Population-based
data
no yes no no yes yes
Mean age at 
diagnosis proband
59.3 n.a. 65.6 65.3 61.0 n.a.
Most likely 
transmission model
AD AD AD* AD (AD+AR)f MF
Penetrance (%)
age 55 
age 85
4
88
2
63
3
89
12
97
7 (AD), 23 (AR)$ 
27 (AD), 100 (AR)
-
% of PCa due to age 55 43 n.a. 62 65 n.a. -
disease gene by age 85 9 n.a. 16 8 n.a. -
Disease allele 
frequency (%)
0.4 1.7 0.6 0.4 1.7 (AD), 8.4 (AR) -
n .a .=  not available; AD= autosomal dominant; AR= autosomal recessive; M F= multifactorial 
(non-Mendelian). * Results from segregation analyses including only probands diagnosed at <66 
years (not assuming Hardy-Weinberg equilibrium). f  Results from the best fitting two-locus 
segregation models by Cui et al. are given. $ Penetrances for the AD and AR component of the best 
fitting two-locus model are given for ages 60 and 80.
especially to early-onset PCa, while later-onset PCa was mainly due to recessively 
inherited risks. The frequency of the autosomal dominant component (‘allele’) was 
estimated at 1.7%; the frequency of the autosomal recessive allele was 8.4%. The 
autosomal dominant and recessive alleles gave rise to a lifetime penetrance of 27 % 
and 100%, respectively. The US reports on the segregation analysis of PCa found 
high life-time penetrances in gene carriers varying from 88%14 to 97%,17 with 
disease allele frequencies ranging from 0.30%14 to 0.60%.16 Figure 1.1 displays the 
predicted cumulative risks (penetrances) for carriers of the high-risk allele vs. non­
carriers as reported in the studies by Carter et al.14 and Verhage et al.17 Furthermore, 
the autosomal dominant models from the US studies predict that the high-risk allele 
accounts for a large proportion (43% to 65%) of all PCa cancer cases diagnosed 
before the age of 56. However, of all PCa a relatively small proportion is due to the 
high-risk allele (8% to 9% by the age of 85).14,16
15
Figure 1.1: Predicted cumulative risks for types AA/AB (carriers of the high-risk 
allele) and BB (non-carriers) genotypes. The dotted lines represent the data from the 
Johns Hopkins (JHU) study, the straight line represents the data from the 
Washington University School o f Medicine (St Louis).14’11
age at diagnose, years
The segregation analysis from Sweden revealed a moderate life-time penetrance in 
gene carriers (63%) with a high population frequency (1.67%).15 
Although the families used in the three US studies were not selected for a positive 
family history, they were selected on age, disease stage, and general health14-16 as all 
three studies consisted solely of patients with localized tumors suitable for radical 
prostatectomy. Both the Swedish and Australian studies used population-based data.
In a recent study, Gong et al. found that a multifactorial model (the risk of PCa 
within families is determined by both environmental and genetic factors) explained 
the data better than did the Mendelian models.19 This finding is in line with the 
aggregate evidence from linkage studies (high-penetrant PCa susceptibility) and 
studies of low-penetrant PCa susceptibility. Although some multiplex families may 
be due to Mendelian high-penetrant genes, the major part of familial occurrence of 
PCa may be attributed to multiple low-penetrant genes. The suggested multiplicity of 
low-penetrance genes, and their probably varying modes of inheritance, complicate 
the identification of susceptibility genes.
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As current segregation analyses techniques assume that only 1 (or 2) major gene(s) 
may account for the observed familial aggregation of PCa, the estimates of 
population frequency of the PCa gene and its specific penetrance may not be valid. 
Nevertheless, segregation analyses produced convincing evidence supporting the 
hypothesis that hereditary PCa (HPC) is, at least partly, inherited as a Mendelian 
autosomal trait with high life-time penetrance. Furthermore, estimates from 
segregation analyses may facilitate the mapping of PCa susceptibility genes through 
parametric linkage methods.20
■ Mapping high-penetrant prostate cancer susceptibility genes: linkage analyses.
Since 1996, genome wide scans have yielded several loci which may harbor PCa 
susceptibility genes. Table 1.2 summarizes the PCa susceptibility loci identified 
through linkage analyses, which have been confirmed in independent populations.
Table 1.2: Hereditary prostate cancer loci identified through linkage analyses (and 
confirmed in independent populations).
Locus
First reported by 
(year)
Country
Number of 
HPC families
Multipoint 
LOD score*
lq24-25 (HPC1) Smith (1996)21 US, Sweden 91 5.43
lq42.2-43 (PCAP) Berthon (1998)30 France, Germany 47 3.10
Xq27-q28 (HPCX) Xu (1998)31 US, Sweden, Finland 360 3.85
lp36 (CAPB) Gibbs (1999)32 US, Canada 12f 2.24
20ql3 (HPC20) Berry (2000)33 US 162 3.02
8p22-23 Xu (2001)34 US 159 1.84$
17pl 1 (HPC2/ELAC2) Tavtigian (2001)4 US 33 4.53§
* Assuming heterogeneity, either parametric or non-parametric score. f  Only families included with 
family history of both brain and PCa. $ Late onset families (proband diagnosis> 65 years, n=  80) 
had a lod score of 2.64. § Two-point linkage method used.
Smith et al. were the first to report a PCa susceptibility locus linked to 1q24-25 
(HPC1, hereditary prostate cancer 1).21 A maximum multipoint LOD score of 5.43 
(i.e. 10543 : 1 or 270,000 : 1 odds in favor of linkage at a specified recombination 
fraction ‘0 ’) was obtained, with 34% of the PCa families linked to HPC1. Whereas 
Smith et al. did not report of any particular subgroups to be more or less likely 
linked to HPC1, others later reported that HPC1 is observed more often in families
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with early-onset PCa (<  66 years at diagnosis) and is more easily detected in large 
families with many (>5) affected members.22,23 Given the strength of evidence for 
linkage in the initial report and the confirmation in other studies24,25 it is surprising 
that others did not find evidence for linkage to the 1q24-25 locus.26,27 These negative 
reports on HPC1 provided the first indication that the endeavor at mapping and 
subsequent cloning of PCa susceptibility genes might prove to be more complex and 
arduous than originally anticipated. Six years after the initial linkage report of 
HPC1, Carpten et al. cloned and described mutations in the ribonuclease L gene 
(RNASEL) at 1q24-25.28 Rokman et al. confirmed the germline mutations in RNASEL 
in a Finnish population, but also concluded that the role of RNASEL sequence 
variants in overall PCa is limited.29
After the report on HPC1 the mapping of HPC loci at 1q42.2-43 (PCAP), Xq27-28 
(HPCX), 1p36 (CAPB), 20q13 (HPC20), and 8p22-23 followed (table 1.2).30-34 
In a French-German research consortium linkage to 1q42.2-43 (PCAP) was first 
found.30 Strongest evidence for linkage to 1q42.2-43 was observed among families 
with early onset PCa (< 6 0  years). Berthon et al. estimated 50% of the families to be 
linked to 1q42.2-43, making the PCAP locus the most frequently known locus 
causing multiplex PCa families in Western and Southern Europe.30,35 By contrast, 
Gibbs et al reported that in 152 American HPC families PCAP may only account for 
a relatively small proportion (4-9%).36 So far, no candidate gene has been proposed 
nor has a gene in the 1q42.2-43 region been cloned.
In 1998 linkage to Xq27-28 (HPCX) was detected in multiplex PCa families from the 
US, Sweden, and Finland.31 The success of mapping HPCX was mainly due to 
stratification of families by apparent mode of transmission, with the strongest 
evidence for linkage coming from families without male-to-male transmission. HPCX 
was found to account for 15% of the US and 41% of the Finnish HPC cases. 
Additional to the no male-to-male transmission, Schleutker et al. reported that in 57 
Finnish HPC families HPCX is characterized by a late age at diagnosis (> 6 5  
years).37
The observed co-aggregation of PCa with tumors of the CNS in earlier studies 
suggested a shared etiological factor in the causation of both types of cancer.7,8 Gibbs 
et al. mapped a PCa-brain susceptibility locus to 1p36 through linkage analysis of 
families with a family history of both PCa and primary brain cancer.32 The mapping 
of the CAPB locus was of particular interest as allelic imbalance was observed 
frequently in the 1p36 region. As evidence accumulates in favor of a genetic 
heterogeneic etiology of PCa, this study illustrates the power of subset identification.
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The PCa susceptibility locus at 20q13 was first reported by Berry et al. in families 
with less than five affecteds, a late average age at onset (> 6 5  years), and no 
evidence for male-to-male transmission.33 These findings were confirmed in 
independent populations by some,39 but not by others.40
The genomewide scan performed by Smith et al.21 and the frequent observation of 
loss of heterozygosity (LOH) at 8p22-2338 suggested that this chromosomal region 
may contain a tumor suppressor gene (TSG). These hints incented Xu et al. to 
perform linkage analysis in 159 HPC families using 21 microsatellite markers, 
spanning a 35 cM area, at 8p22-23. The investigation provided evidence for a sixth 
PCa susceptibility locus at 8p22-23.34 Evidence for linkage was found to be 
particularly strong in families with a late age at onset (> 6 5  years). Very recently, 
the same research group reported germline mutations and sequence variants in the 
macrophage scavenger receptor 1 gene (MSR1, also known as SR-A) located at the 
8p22 locus.41 Six rare missense mutations and one nonsense mutation appeared to co­
segregate with PCa in HPC families. Furthermore, in a population study, the 
prevalence of MSR1 mutations among PCa patients from European descent (n=317) 
was found to be 4.4% compared to 0.8% among unaffected men (n=256, p=0.009). 
Among African Americans, these values were 12.5% and 1.8%, respectively. Future 
studies will provide more insight in the importance of the MSR1 gene in prostatic 
carcinogenesis.
Tavtigian et al. were the first to clone a PCa susceptibility gene at 17p11, named 
HPC2/ELAC2.42 A genome-wide scan of eight large Utah pedigrees provided 
suggestive evidence for linkage near marker D17S520. Fine mapping in a larger set 
of 33 families, using dense markers in the 17p11 region, revealed significant 
evidence for linkage (maximum 2-point LOD score of 4.53 at D17S1289). The 
HPC2/ELAC2 gene will be discussed in more detail in the next section.
The natural history of PCa presents several problems which directly affects efforts to 
map PCa loci.20 First, due to a high lifetime probability of PCa, a high rate of 
phenocopies occurs, i.e. PCa from non-Mendelian causes. Second, there is a lack of 
available tissue and blood samples from probands’ previous generations because PCa 
has a relatively late age at onset. Third, there are no specific clinical nor pathological 
features of HPC, apart from an earlier age at onset compared to sporadic disease, 
that allow subgrouping to account for potential genetic heterogeneity. The latter 
complication in linkage studies will be discussed below.
Thus, linkage analyses of HPC have mapped several susceptibility loci and three 
genes have been successfully cloned within the linked loci (RNASEL at 1q24-25,
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MSR1 at 8p22-23, and HPC2/ELAC2 at 17p11). These three genes, however, may 
only explain a small proportion of the occurrence of HPC.
■ Low penetrance susceptibility to prostate cancer. Linkage studies partly explain 
the excess risk of PCa due to rare, highly penetrant gene(s) in selected multiplex PCa 
families. However, the majority of all PCa (~90% ) is ‘sporadic’, or better, non- 
Mendelian. A low penetrance PCa susceptibility gene may increase the risk of PCa 
while not causing multiplex families. As such genes often have high allele 
frequencies, they may play, from a public health perspective, a more important role 
in PCa etiology than the previously discussed high-penetrant PCa susceptibility 
genes. A number of genes have been implicated to confer a modestly increased PCa 
risk. In this section we will review the most important lower penetrance PCa 
susceptibility genes that have been studied so far. These include genes encoding the 
androgen receptor (AR), the 5a-reductase enzyme (SRD5A2), the vitamin D receptor 
(VDR), and the HPC2/ELAC2 gene.42-60 Table 1.3 shows the 4 genes and their 
polymorphisms which we will discuss in this section.
Table 1.3: Low penetrance prostate cancer susceptibility loci.
Gene Polymorphism
Reported 
Odds Ratio’s
Risk associated with References
AR  (Xql 1-12) CAG repeats 1 .0 -  1.7 Shorter repeats (< 23) [43-46]
GGN repeats 1.6 Shorter repeats (< 16) [45,46]
SRD5A2 (2p23) TA repeats 0.5 -  1.9 Longer repeats (>  103 bp) [43,47]
V89L 1.0 -  1.3 Leucine allele [49,50]
A49T 1 .0 -  3.3 Threonine allele [51]
VDR ( 12ql2-14) Poly-A 0.7 -  4.5 Longer poly-A allele [43,52,53]
TaqI 0.3 -  1.3 Taql-t allele [53,54]
HPC2/ELAC2 (17pll) Ala541Thr 1 .0 -2 .4 Threonine allele [42,55-60]
GGN= guanine, guananine, (any) nucleotide. For a comprehensive review of these low-pentrance 
genes see Coughlin et a l.61
The AR gene is polymorphic with respect to a variable number of trinucleotide 
microsatellite repeats of CAG and GGN in exon 1. The CAG repeats, for example, 
range from 8 to 31 with an average of about 20. Longer AR variants display 
decreased transactivation activity and decreased binding affinity for androgens.
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Conversely, the relative increased responsiveness of short variants may increase PCa 
risk through chronic androgen overstimulation. So far, studies on the AR gene have 
yielded conflicting results.43-46 Whereas Hsing et al. found a statistically significant 
elevated risk of PCa for cases with shorter CAG repeats,46 others did not, although 
all observed a trend towards a higher risk through shorter alleles.43-45 The same was 
observed for the GGN (‘N ’ represents any nucleotide) polymorphism: while Stanford 
et al.45 found that shorter GGN-alleles predispose to PCa, Hsing et al. did not.46 
The SRD5A2 gene is expressed in the prostate and in the androgen-sensitive genital 
skin where it converts testosterone irreversibly into dihydrotestosterone (DHT).47 
Although not all studies could provide statistically significant evidence,48-50 it appears 
that certain variants predispose to PCa.47,51 Longer TA alleles have been 
hypothesized to enhance the enzyme activity. This in turn leads to an increased level 
of DHT, which increases the risk of PCa.47 Furthermore, the valine to leucine 
substitution at codon 89 (V89L) and the alanine to threonine substitution at codon 49 
(A49T) have been observed to affect enzyme activity, and therefore modify the risk 
of PCa.49-51
The active hormonal form of vitamin D, 1,25-dihydroxyvitamin D (1,25-D), induces 
cell differentiation and inhibits proliferation through the VDR. Two variants in the 
VDR gene, poly-A and Taq1, have been observed to increase the risk of PCa through 
modification of the transcriptional activity of the gene. Although Ingles et al. found 
that heterozygotes for the long poly-A allele had a 4.5 fold increased risk of PCa 
(95% CI:1.3-16.1),43 others did not find statistically significant evidence.52-54 
In the previously discussed HPC2/ELAC2 gene, sequence analyses revealed four 
variants, a rare frameshift and three missense changes, of which two were found to 
be common in the population: a serine to leucine change at amino acid 217 
(Ser217Leu), and an alanine to threonine change at amino acid 541 (Ala541Thr). 
Rebbeck et al. found in an independent US population of 359 PCa cases, unselected 
for family history, and 266 controls that the 541Thr allele was associated with a 2.4- 
fold increased risk of PCa (541Thr carrier rate for PCa and controls: 7.5% vs. 
3.5%).55
Subsequent studies from the US among HPC,56-58 sporadic (SPC),56 and screen- 
detected PCa families59 failed to demonstrate an increased risk of PCa due to the 
Ala541Thr variant. Moreover, Rokman et al. concluded that the 541Thr carrier rates 
in Finnish HPC and SPC cases did not differ from those in controls (7.5%, 7.7%, 
and 7.4%, respectively).60 The relative importance of the HPC2/ELAC2 variants still 
remain under debate.
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Additional to the variations in low-penetrance genes discussed above, other gene 
polymorphisms have been investigated in relation to PCa risk, i.e. several 
cytochrome P450 (CYP) genes, 3 p-hydroxy steroid dehydrogenase type I and II 
(HSD3B1 and HSD3B2), glutathione S-transferases (GSTs), and N-acetyl transferases 
(NATs). Also, a recent study of our research group suggests that a single nucleotide 
C/A polymorphism in the E-cadherine gene promoter modifies PCa risk. Carriers of 
the A-allele have a 3.6-fold increased risk (95% CI: 2.0-6.4) of PCa.61 A 
comprehensive review on low-penetrance genes in relation to PCa risk is given by 
Coughlin et al..62
To date, only few epidemiological studies have investigated potential gene­
environment interactions or explored associations and interactions of multiple genes 
(gene-gene interactions). The reason for this is probably the lack of large populations 
needed to investigate such associations.
In the future, study-populations of adequate sample size will be needed to fully 
comprehend the complex interactions of genetic variations and environmental 
influences underlying the initiation and progression of PCa. As multiple genetic 
markers and their interactions will be tested, caution is warranted in the 
interpretation of results. False positive results may also occur as the tested markers 
may be in linkage disequilibrium. Therefore, future results must be interpreted 
wisely in the light of biological plausibility.
■ Molecular biological analysis of HPC. Besides linkage analyses, molecular 
studies provide insight in the location of putative disease genes. Many familial 
cancers are known to be the result of mutations in TSGs, such as BRCA1 and BRCA2 
with a high life-time risk for mutation carriers.63,64 TSGs are negative regulators of 
cell growth, which are only inactivated after two successive allele altering events, or 
‘hits’ (Knudson’s two-hit model).65 The first hit may be germinal (hereditary cancer) 
or somatic (sporadic cancer). The loss of the remaining wildtype allele later in life, 
i.e. the second hit, initiates carcinogenesis. Therefore, the involvement of TSGs is 
indicated by allelic loss or imbalance (AI) in tumor tissue. Although there is great 
variability between studies, cumulative data show that the most consistent AIs in 
(sporadic) PCa include regions on chromosomal arms 5q, 7q, 8p, 10q, 13q, 16q, 
17q, and 18q.66
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Table 1.4: Molecular studies (AI and CGH) on hereditary prostate cancer
specimens.
Author (year) Number ofsubjects
Population
source Results
( A I studies ) AI %
Dunsmuir (1998)67 17 UK HPC locus: lq24-25 (HPCly. 7
Bergthorsson (2000)69 
Àhman (2000)68
25
33
Iceland
Sweden
HPC loci: 
HPC loci:
lq24-25 (HPCly. 
lq42.2-43 (PCAP): 
lq24-25 (HPCJ): 
lp36 (CAPB):
7
20
11
11
Verhage (2003)71 28 Netherlands HPC loci:
lq24-25 (HPCJ): 
1q42.2-43 (PCAP): 
20ql3 (HPC20) *
38
26
36
lq25-qter* 33
5q33-qter 44
7q31.1-31.2 33
7q31.1 30
8p22 44
8pter-p23.1 37
Other loci 8p22 44Verhage (2002)71 28 Netherlands ( > 30% AI): 10q24.1*
13q14.1-14.3
30
42
13q14.3-21.2 40
16q13 38
16q24.2 39
17q21 39
17q* 35
18q21* 45
( CGH studies )
losses
Verhagen (2000)72 35 US
gains
3pl2-3p22
7q
10q
16q
6q11-6q21
8q
losses 6ql3-ql6
8p12-pter
Rokman (2001) 72 21 Finland 13q14-q22gains 7q
19p
19q
losses 6q
8p
Hermans (2002)f 9 Netherlands 13q
16q
gains 8q
CGH= comparative genomic hybridization, AI= allelic imbalance. * Difference in percentage AI
between hereditary and sporadic tumor specimens was greater than 20%. f  Unpublished results.
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Only few studies evaluated AI in tumors from HPC families, using a limited set of 
markers.67-69 Table 1.4 summarizes the molecular analyses of HPC, including both 
AI and comparative genomic hybridization (CGH) studies. The first three studies on 
AI of HPC from the UK, Sweden, and Iceland at the linked loci on chromosome 1 
(HPC1, PCAP, and CAPB) reported relatively low percentages of AI in hereditary 
cases (HPC1: 7-11%; PCAP: 20%; CAPB: 11%), as was previously reported in 
sporadic tumors.70 Interestingly, in a study from the Netherlands much higher 
percentages AI were observed (HPC1: 38%; PCAP: 26%; HPC20: 36%).71 
Furthermore, in this study it was observed that at the loci 1q25-qter, 10q24.1 (FAS), 
17q (centromere BRCA1), 18q21(DCC), and 20q13 (HPC20) AI was observed 20% 
more often in HPC compared to sporadic PCa.
Additional research may settle whether these discrepancies are accounted for by 
genetic heterogeneity. Other molecular methods, such as CGH which distinguishes 
between genomic losses and gains, may be of great value for the interpretation of 
results from AI studies. So far, 3 CGH studies on HPC have been performed (one 
unpublished CGH study on HPC by Hermans et al., the Netherlands).72,73 Most 
consistent findings include losses at 6q, 8p, 13q, and 16q, whereas in 2 of the 3 
CGH studies gain at 8q was observed.
■ Clinical and pathological features of HPC.
An accurate clinical definition of hereditary PCa is hard to give, as it has to be 
sufficiently broad to include most families with the inherited form of PCa but at the 
same time should be specific enough to exclude clusters of sporadic PCa. Carter et 
al. defined criteria for HPC, which are used in many studies: (1) A cluster of 3 or 
more 1st degree relatives with PCa; or (2) PCa in each of three generations in the 
paternal or maternal lineage; or (3) 2 or more 1st or 2nd degree relatives with PCa 
under the age of 56.74
Bastacky et al. compared 28 clinically defined HPC patients, 26 patients with a 
family history of PCa but who did not fulfil the criteria for HPC, and 27 sporadic 
patients. No differences were found with respect to clinical stage, pathological stage, 
multifocality of invasive carcinoma, multifocality of high grade prostatic 
intraepithelial neoplasia (PIN 2 to 3), Gleason score, tumor volume, preoperative 
PSA value, and association with unusual non-neoplastic and neoplastic histological 
features.75 Furthermore, the prognosis of these 3 distinct groups of patients was 
found to be similar.76 Moreover, a positive family history had no influence on risk of
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PSA progression following radical prostatectomy.76 These results suggest that the 
biological aggressiveness of hereditary PCa is similar to sporadic disease.
In a study by Keetch et al. clinical and pathological features of radical prostatectomy 
specimen from 50 men with HPC were retrospectively identified and compared with 
50 age and date of surgery matched controls. Median serum PSA concentration, the 
percentage of bilateral tumors, and the percentage of cancers pathologically confined 
to the prostate did not differ between both groups. The mean Gleason score was a 
little higher in sporadic cases (6.2) compared to hereditary cases (5.6).77 Gronberg et 
al. reported that there were no significant differences in either survival or tumor 
grade between hereditary, familial (positive family history, but not fulfilling Carter’s 
HPC criteria), and sporadic PCa cases.78 In another paper, Gronberg et al. reported 
that men from families potentially linked to HPC1 had a significantly lower mean 
age at diagnosis (63.7 vs. 65.9 years); more higher-grade cancers (39% vs. 29%); 
and more often advanced disease (41% vs. 31%) than men from unlinked families.79 
These findings, however, were disputed by others.80,81
In a recent French study, Valeri et al. compared 27 HPC, 73 familial (but not HPC) 
PCa cases, and 143 SPC cases with respect to tumor grade, clinical stage, and PSA 
at diagnosis. No differences were observed between the three distinct PCa groups.82 
In a Swedish study comprising 201 PCa cases from 62 HPC families and 402 age 
and calendar year at diagnosis matched controls, Bratt et al. reported no differences 
regarding tumor grade, symptoms at diagnosis, initial therapy, nor cancer specific 
survival.83
Accurate case definition will become more important in research of prognosis of 
both SPC and HPC. Because of current screening practices, especially in HPC 
families, the detection of many clinically non-significant tumors may obscure 
differences in prognosis as far as they exist.
Overall, no substantial clinical or pathological differences seem to exist between 
clinically defined hereditary, familial and sporadic PCa cases. Of course, it cannot 
be excluded that certain HPC genes may have specific biological characteristics. 
Indeed, by means of sibpair linkage analysis, while taking Gleason score as a 
quantitative measure of PCa aggressiveness into account, Witte et al. found linkage 
to candidate regions 5q31-33, 7q32, and 19q12 which may contain genes that 
influence the progression of PCa from latent to invasive disease.84 Identification of 
such genes could prove to be valuable for the understanding of the mechanism 
underlying PCa progression and may ultimately modify treatment management for 
specific patients.
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C H A P T E R 2 
S I T E -  S P E C I F I C F A M I L I A L 
A G G R E G A T I O N O F P R O S T A T E C A N C E R
■ Abstract. Over the last decade epidemiological evidence has accumulated in favor 
of a significant but heterogeneous hereditary component in prostate cancer (PCa) 
susceptibility. In order to map and clone PCa susceptibility genes, stratification of 
PCa families into genetically homogeneous groups appears to be a key issue. Subset 
definition based on age at diagnosis, presumed mode of inheritance, number of 
affecteds per family, and co-aggregation of PCa with other cancers has already 
proven successful in some studies. Previously, the finding of the co-aggregation of 
malignancies of the central nervous system within PCa families, helped to link a 
prostate-brain cancer susceptibility gene (CAPB) to chromosome 1p36. In this study 
we evaluate the risk of PCa, and malignancies at other sites, among first-degree 
relatives of a large population-based group of Dutch PCa patients.
A population-based family case-control study was initiated including Caucasian PCa 
patients newly diagnosed between July 1996 and December 1999. Information on 
12,575 first-degree relatives of 704 PCa patients and 1,371 controls was collected 
through postal questionnaires and telephone interviews. All reported PCa in first- 
degree relatives was verified through medical records.
In our population, PCa has a strong familial component which is reflected by a 2.9- 
fold increased risk (95% Confidence Interval (CI): 2.2-3.9) of PCa for first-degree 
relatives of PCa patients. This familial risk was somewhat higher among brothers 
(3.9, 95% CI: 2.4-6.4) compared to fathers (2.5, 95% CI: 1.7-3.6). Cancers at other 
sites did not co-aggregate with PCa. Our data suggest that familial PCa, at least in 
this Western European population, is ‘site-specific’, and not part of an inherited 
cancer-syndrome.
■ Introduction. Although PCa is a common lethal malignancy among men in the 
Western world, much of its etiology remains unclear. Age, race, and family history 
are the only well established risk factors of PCa. Epidemiological evidence has 
accumulated over the years in favor of a significant hereditary component in PCa
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susceptibility.1 From a recent twin study it was estimated that as much as 42% (95% 
CI: 29%-50%) of the risk of PCa may be accounted for by heritable factors.2 
Familial aggregation of PCa, i.e. the occurrence of more than one PCa case among 
first-degree relatives, has been recognized for decades. Epidemiological studies show 
that first-degree relatives of PCa patients have a 2- to 3-fold increased risk of PCa.1 
High risks of PCa have been observed especially for men having multiple affected 
relatives, and for men having relatives diagnosed at an early age. Furthermore, this 
familial risk of PCa has also been observed in ethnically different populations 
(Asian-Americans, Caucasians, and African-Americans).3
Segregation analyses point out that the familial aggregation of PCa can best be 
explained by autosomal-dominant inheritance of one or more rare high-risk 
susceptibility genes.4-8 Since 1996, inherited predisposition to PCa has been linked to 
several chromosomal regions. These include 1q24-25 (HPC1),910 1q42.2-43 (PCaP),11 
Xq27-28 (HPCX),12 1p36 (CAPB).13 More recent linkage studies suggest that 16q,14 
20q13 (HPC20),15 and 8p22-23,16 may harbor susceptibility loci as well.
Although genes have successfully been cloned in three of the linked loci (RNASEL at 
1q24-25,1718 MSR1 at 8p22-23,19 and HPC2/ELAC2 at 17p112021), the relative 
importance of mutations or polymorphisms within these genes to hereditary and 
sporadic disease are still under debate.
The mapping and cloning of PCa susceptibility genes is complicated by the large 
number of ‘sporadic’ patients in the population. This implies that among multiplex 
PCa families it is likely that phenocopies occur, i.e. affected individuals not carrying 
a high-risk mutation within a PCa susceptibility gene.
In order to map and clone PCa susceptibility genes, stratification of PCa families into 
genetically homogeneous groups appears to be a key issue. Indeed, this approach has 
already proven to be successful. Linkage to HPC1 appeared to be strongest in 
families with an early diagnosis (< 6 5  years) and in families with five or more 
affected men.10 The success of mapping HPCX was due to stratification of families 
by apparent mode of transmission, with the strongest linkage to Xq27-28 coming, of 
course, from families without evidence of paternal transmission.12 Similarly, the 
strongest evidence for linkage to 20q13 (HPC20) was observed by Berry et al. in 
families with less than five affecteds, a late age at diagnosis, and no evidence of 
male-to-male transmission.15 While previous examples illustrate the effectiveness of 
stratification by presumed mode of inheritance, age at diagnosis, and number of 
affecteds per family, the mapping of the CAPB locus was facilitated by subset 
identification through detailed family history of cancer.13 Focussing on PCa families
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with confirmed family history of primary brain cancer a prostate-brain cancer 
susceptibility locus was linked to 1p36 with a maximum two-point LOD score of 
3.22 (at 0=0.06).
To date, several studies examined the co-aggregation of PCa with malignancies at 
other sites.22-30 The outcomes of these investigations, however, have been quite 
diverse, possibly because different populations were studied, i.e. genetic 
heterogeneity. Among first-degree relatives of PCa cases the most consistent findings 
are slightly increased risks for tumors of the central nervous system,22-23 gastric 
cancer,27-30 colorectal cancer,26,27 and breast cancer.27,29
In this study we evaluate the relative risk of PCa, and more generally of 
malignancies at other sites, among first-degree relatives of PCa cases from the 
Netherlands while taking smoking behavior and the inherent dependency in family 
data into account.
■ Subjects & Methods. Study design. A family case-control design was used in this 
study. The outcome of interest in this design is disease occurrence among relatives, 
known as the familial risk. Familial aggregation of the disease exists if the risk of 
disease among case-relatives is higher than that among control relatives. An 
important difference exists between the conventional case-control design and this 
family case-control design. In the former a comparison is made between cases’ 
characteristics and controls’ characteristics, e.g. family history. In the latter design, 
however, the comparison takes place between the relatives of cases and the relatives 
of controls. The statistical comparison of these two cohorts of relatives can take 
place with a cohort-type analysis while taking the familial dependency of relatives 
and other covariates into account.
Subjects and Data collection. Case-families were ascertained through PCa patients 
(probands) newly diagnosed between July 1st 1996 and December 31st 1999, and 
registered by one of two population-based cancer registries held by the 
Comprehensive Cancer Center (CCC) East and CCC Rotterdam in the Netherlands. 
A total of 1,435 probands with histologically confirmed adenocarcinoma of the 
prostate were identified (International Classification of Diseases for Oncology, site 
code T185 / C61, morphology code 8 14031). Inclusion criteria were: diagnosed 
under the age of 75 years, Caucasian, living in the catchment area of the CCC East 
and CCC Rotterdam at date of diagnosis, and being capable of reading and
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understanding the Dutch language. All recruited PCa cases from the CCC East area 
were diagnosed in either the University Medical Centre Nijmegen (Nijmegen), 
Canisius-Wilhelmina Hospital (Nijmegen), Maas Hospital (Boxmeer), Rijnstate 
Hospital (Arnhem), or the Hospital Velp (Velp). PCa cases from the CCC Rotterdam 
area were diagnosed in either the Erasmus University Medical Center Rotterdam 
(Rotterdam), or the Sint Franciscus Gasthuis (Rotterdam).
Information on demographic factors, smoking behavior, occupation, history of 
cancer, history of prostatic diseases, and history of chronic diseases was collected by 
a postal questionnaire. In the same questionnaire similar information was requested 
on first-degree relatives (demographic factors, smoking behavior, longest held 
occupation, history of cancer and history of prostatic diseases).
Control families consisted of (1) the family of the PCa probands’ partner, and (2) the 
family of partners of bladder cancer probands. The latter control group was 
identified in a similar study from our institute on familial bladder cancer, performed 
parallel to this investigation.32
Controls filled out the same questionnaire. If the PCa proband was deceased or 
unable to provide information, the partner was requested to fill out both 
questionnaires.
Before any of the subjects were contacted, the treating urologist was asked for 
permission for his patients to participate in the study. For 41 cases (3%), this 
permission was denied. The remaining 1,394 probands and their partners received an 
invitation letter, additional information and a reply card. They were asked to fill out 
and return the reply card indicating whether or not they were willing to participate. 
Seventy-five probands were excluded after sending the invitations because they 
appeared to be unable to read and understand the Dutch language, or because they 
were deceased and no partner was available, or because their addresses appeared to 
be incorrect. When no reply was received within 3 weeks, a reminder was sent.
A questionnaire was sent to all subjects who were willing to participate. Another 
reminder was sent when the questionnaires were not returned within 3 weeks. 
Subjects who did not return the questionnaire within approximately 6 weeks were 
contacted by telephone. When a returned questionnaire was incomplete, subsequent 
telephone calls were made for additional information.
Verification. All data on PCa among relatives of the PCa probands and their partners 
was verified with medical records, after obtaining written consent from these patients 
themselves or, in the case of death, from their partners or next of kin. Verification
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was possible in 46% of all PCa affected relatives (46% of all affected case-relatives 
and 45% of all affected control-relatives). All questionnaire data on PCa appeared to 
be correct. Verification was not possible in all cases because the diagnosis had been 
made too long ago and the medical records were no longer available.
Statistical Analysis. To evaluate familial aggregation of PCa, the risk of PCa among 
case-relatives was compared to the risk of PCa among control-relatives by using a 
Cox proportional hazards model to which a random effect for family relatedness was 
added. The random effect is defined as a categorical variable which describes excess 
risk, or frailty for a family. The frailty is usually viewed as an unobserved covariate. 
In this way the inherent dependency in family data is taken into account. All 
presented Hazard Ratios (HR) and 95% confidence intervals (95% CI) are adjusted 
for this family dependency.
Only parents and (full) siblings were included in the analyses because the children 
are shared by PCa cases and their partners and are therefore non-informative.
The dependent variable was defined as age at diagnosis of PCa, age at time of 
interview, or age at time of death, depending on which came first. The independent 
variable was defined as relative of a PCa case or relative of a control. Smoking was 
taken into account as a dichotomous variable (ever smoked vs. never smoked).
To detect possible genetic heterogeneity, aggregation of PCa with other types of 
cancer was also studied. Analyses were performed in SAS version 6.12 for 
Windows33 and S-plus version 2000.34
The study was approved by the Institutional Review Boards of the participating 
hospitals.
■ Results. The response to the initial invitation was 76% (1,007 PCa patients). In 
total 711 partners were also willing to participate in the study (the total number of 
partners is not known because information from non-responding patients is 
unavailable). Subsequently, 710 PCa patients (71%) and 518 partners (73%) returned 
a questionnaire with sufficient information for the analyses. The 518 partners of PCa 
probands were combined with 853 partners of UCC patients32 to a total of 1,371 
control families. In further analyses, 6 PCa probands and their families were 
excluded as they appeared to be non-Caucasian.
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Reasons for not returning or not completing the questionnaire were: “no contact with 
relatives”, “too much effort”, “too emotional”, “too complicated to retrieve all data 
on relatives” and “no permission from relatives to give information”.
Table 2.1 summarizes the characteristics of the PCa probands included in the 
analyses.
Table 2.1: Characteristics o f prostate cancer probands.
Number of PCa probands 704
Mean age at diagnose, years (±  SD, range) 66.0 (±  5.8, 48 -  75)
Ever smoked, n (% of total) 497 (70.6)
Screen-detected PCa, n  (% of total) 120 (17.0)
Family history of PCa, n (% of total) 103 (14.6)
I 279 (39.6)
Grade, n (% of total)
II 320 (45.5)
III 88 (12.5)
unknown 17 (2.4)
TO and T1 159 (22.6)
T2 371 (52.7)
Stage, n (% of total) T3 and T4 130 (18.5)
N( + ) or M( + ) 60 (8.5)
unknown 44 (6.3)
BPH 73 (10.4)
History of, n (% of total)
Prostatitis 49 (7.0)
Circumcision 23 (3.3)
Vasectomy 145 (20.6)
Mean age at diagnosis of the 704 PCa probands was 66.0 years (SD=5.8).
Of all PCa probands, 17.0% (n = 120) were screen-detected patients from the 
Rotterdam branch of the European Randomized Study of Screening for Prostate 
Cancer (ERSPC).35 These probands were diagnosed at a younger age compared to 
the symptom-diagnosed (non-screened) probands (64.9 vs. 66.3 years, respectively, 
p=0.02). Furthermore, tumors of screen-detected patients were more often of lower 
grade compared to non-screened patients (p=0.001).
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Table 2.2: Characteristics o f  case-relatives and control-relatives.
Case- Control- Control- Control-
relatives relatives* relatives! relatives^
(n = 3,982) {n = 2,920) (n = 5,673) (n = 8,593)
Type of 
relative,
n (%)
Father 704 (17.7) 518 (17.7) 853 (15.0) 1,371 (16.0)
Mother 704 (17.7) 518 (17.7) 853 (15.0) 1,371 (16.0)
Brother 1,306 (32.8) 965 (33.1) 2,032 (35.8) 2,997 (34.9)
Sister 1,268 (31.8) 919(31.5) 1,935 (34.1) 2,854 (33.2)
Gender, n (%)
Male 2,010(50.5) 1,483 (50.8) 2,885 (50.9) 4,368 (50.8)
Female 1,972 (49.5) 1,437 (49.2) 2,788 (49.1) 4,225 (49.2)
Ever smoked,
n (%)
Yes 1,968 (49.4) 1,519(52.0) 3,063 (53.9) 4,582 (53.3)
No 1,586 (39.8) 1,105 (37.8) 2,193 (38.7) 3,298 (38.4)
Unknown 428 (10.8) 296 (10.1) 417 (7.4) 713 (8.3)
Mean age§, years (±  SD) 65.9(16.2) 64.9 (16.6) 63.0 (16.9) 63.6(16.8)
* Relatives of partners of PCa cases. f  Relatives of partners of bladder cancer cases. $ Relatives of 
partners of both PCa and bladder cancer cases. § Age at diagnosis of cancer, age at time of 
interview, or age at time of death, whichever came first.
Familial clustering of PCa. Table 2.2 shows characteristics of first-degree relatives 
of cases (n=3,982) and controls (n=8,593). There were no marked differences in 
the distributions of the type of relative, sex, and smoking behavior. As PCa cases 
generally have younger spouses, brothers of PCa cases were older than control- 
brothers (61.4 vs. 57.7 years, p=0.0001) (data not shown in table). Similarly, case- 
sisters were older compared to control-sisters 61.7 vs. 59.2 years, p=0.0001).
PCa was diagnosed 125 times among the 2,010 male first-degree relatives of cases. 
Of the 704 probands used in the analyses, 103 (14.6%) had a positive family history: 
50 probands had an affected father only; 43 probands had 1 affected brother, and 5 
of these probands had an affected father as well; 8 probands had 2 affected brothers, 
of whom 2 also had an affected father; 1 proband had 4 affected brothers; and 1 
proband had 5 affected brothers.
The mean age at diagnosis of PCa among affected case-relatives was equal to that of 
affected control-relatives (p=0.99). The majority of both affected case-relatives and 
control relatives had smoked (90.8% and 86.2%, respectively).
The cumulative risk of PCa among case-relatives was 6.6% compared to 2.0% 
among control-relatives. The overall unadjusted Hazard Ratio (HR) of PCa for case- 
relatives compared to control-relatives was 3.0 (95% CI: 2.2-3.9). The proportional 
hazards model, adjusted for age and family dependency, showed a HR of 2.9 (95%
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CI: 2.2-3.9) (table 2.3). This risk appeared to be somewhat higher among case- 
brothers compared to case-fathers (HR=3.9 vs. 2.5, respectively). As expected, 
case-relatives of young (< 60 years at diagnosis) PCa probands had a higher risk of 
PCa (HR=3.7, 95% CI: 2.3-6.0) compared to PCa case relatives of old (>70 years 
at diagnosis) probands (HR=1.9, 95% CI: 1.3-3.1). Case-relatives of screen- 
detected PCa probands had a HR of 2.1 (95% CI: 1.2-3.9), compared to a HR of 3.1 
(95% CI: 2.2-4.1) among the relatives of non-screened PCa probands. Case-relatives 
of low-grade (grade I) PCa probands were at higher risk for PCa, compared to case- 
relatives of high-grade (grade III) PCa probands (HR=3.1 and 1.4, respectively).
Table 2.3: Familial aggregation of prostate cancer (case-relatives vs. control­
relatives).
Hazard Ratio (95% CI)*
All 2.9 (2 .2 -3 .9 )
Male relative Fathers 2.5 (1.7 - 3.6)
Brothers 3.9 (2 .4 -6 .4 )
< 60 yrs 3.7 (2.3 - 6.0)
Age at diagnosis proband 60 yrs> and < 70 yrs 3.3 (2 .4 -4 .6 )
> 70 yrs 1.9 (1.3 - 3.1)
Screening
Yes 2.1 (1.2 - 3.9)
No 3.1 (2 .2 -4 .1 )
I 3.1 (2.1 -4 .5)
Grade II 3.3 (2.3 -4 .6)
III 1.4 (0.7 - 3.0)
TO and T1 3.9 (2.5 - 5.8)
TNM
T2 2.9 (2 .0 -4 .1 )
T3 and T4 2.6 (1 .6 -4 .2 )
N( + ) or M( + ) 2.4 (1 .2 -4 .7 )
* Hazard Ratios (95% Confidence Interval) were adjusted for age, and family dependence using a random 
coefficient proportional hazards model.
Familial clustering of PCa with other types o f cancer. All the tumors reported among 
relatives were classified into 13 different sites. The occurrence of cancer was equal 
in both subgroups of controls (results not shown). Table 2.4 shows the aggregation 
of PCa with cancers at other sites.
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Table 2.4: Familial aggregation o f prostate cancer with other types o f cancer (case-
relatives vs. control-relatives).
Hazard Ratio (95% confidence interval)*
Males Females All
Mouth & pharynx 1.3 (0.7-2.6) 0.7 (0.2-2.5) 1.2 (0 .6-2 .1)
Digestive tract 0 .8  (0 .6-1 .1) 1.1 (0 .8 -1 .4) 0.9 (0.8-1.2)
Respiratory tract 1.0  (0 .8-1 .3) 1.8 (1.1-3.1) 1.1 (0.9-1.4)
Bone & soft tissue 1.4 (0.7-2.7) 1.4 (0.7-2.7) 1.0  (0 .6-1 .7)
Skin 0.5 (0.3-1.0) 1.2 (0 .6 -2 .1) 0.8 (0.5-1.3)
Male genital organs 0.5 (0.1-4.8) - -
Breast f 1.0 (0.7-1.3) -
Female genital organs - 0.7 (0.4-1.1) -
Urinary tract $ 1.1 (0.5-2.6) 0 .6  (0 .2 -2 .1) 0.9 (0.5-1.8)
Eye & CNS 1.1 (0 .6-2 .1) 1.4 (0.7-3.1) 1.2 (0.7-2.1)
Endocrine glands 1.1 (0.1-11.4) 1.7 (0.4-7.5) 1.5 (0.4-6.2)
Haematolymphopoietic system 0.7 (0.4-1.4) 1.3 (0.8-2.3) 1.0 (0.7-1.6)
Bladder 0 .6  (0.3-1.2 ) 1.3 (0.4-4.1) 0.7 (0.4-1.3)
Unknown & Other 1.0 (0.5-1.9) 0 .8  (0.5-1.4) 0.9 (0.6-1.4)
All non-PCa 1.1 (0.9-1.3) 1.0  (0 .8 -1 .2 ) 1.1 (0.9-1.2 )
* HRs (95 % CI) were adjusted for age, gender, smoking, and family dependence using a random 
coefficient proportional hazards model, f  No cases were found among case-relatives. $ Tumors of 
the urinary tract minus cancers of bladder, ureter, renal pelvis.
Overall, relatives of PCa probands had no increased risk of cancer, other than PCa, 
compared to relatives of controls (H R=1.1, 95% CI: 0.9-1.2). None of the cancers 
at other sites than the prostate appeared to cluster with PCa.
Subgroup analyses showed that there were no differences in the occurrence of cancer 
among (1) male and female case- and control-relatives, (2) different types of case- 
and control-relatives (fathers, mothers, brothers, sisters), (3) relatives of young (< 
60 years at diagnosis) PCa probands vs. control-relatives, and (4) relatives of non­
screened PCa probands vs. control-relatives.
Table 2.5 shows the aggregation of PCa with cancers at other sites within PCa 
families with more than 1 PCa («=103 PCa families).
Overall, relatives of PCa probands had no increased risk of cancer compared to 
relatives of controls (HR=0.9, 95% CI: 0.7-1.1). However, male-relatives had a 
decreased risk of non-prostatic cancer compared to male relatives of controls 
(HR=0.7, 95% CI: 0.5-1.0). More specifically, decreased risks of cancer of the
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digestive and respiratory tract were observed for male case-relatives from PCa 
families with more than 1 PCa (HR=0.4, 95% CI: 0.2-0.8, and H R=0.4, 95% CI: 
0.2-0.8, respectively).
Table 2.5: Familial aggregation of prostate cancer with other types of cancer. Case- 
families with more than 1 prostate cancer included only (n = 103; case-relatives vs. 
control-relatives).
Hazard Ratio (95% confidence interval) *
Males Females All
Mouth & pharynx 1.4 (0.4-4.6) f -
Digestive tract 0.4 (0.2-0.8) 1.2 (0.7-2.1) 0.7 (0.5-1.1)
Respiratory tract 0.4 (0.2-0.8) 2.4 (0.8-6.7) 0.6 (0.3-1.1)
Bone & soft tissue 2.2 (0.8-5.6) 1.1 (0.3-4.3) 1.7 (0.7-3.7)
Skin 0 .6  (0 .2 -2 .4) 0.4(0.1-3.0) 0 .6  (0 .2 -1 .7)
Male genital organs f - -
Breast - 1.1 (0 .6-2 .0) -
Female genital organs - 1.0  (0.4-2.4) -
Urinary tract $ 2.4 (0.7-8.4) f -
Eye & CNS 0.9 (0.2-3.6) 0.8 (0.1-5.7) 1.6 (0.6-4.9)
Endocrine glands 5.1 (0.0-5.6) f -
Haematolymphopoietic system 0.3 (0.0-2.2) 1.3 (0.4-4.3) 0.7 (0.3-2.0)
Bladder 1.1 (0.4-2.9) 1.8 (0.2-19.4) 1.3 (0.5-3.1)
Unknown & Other 0.9 (0.2-3.2) 0.7 (0.2-2.7) 0.8 (0.3-2.1)
All non-PCa 0.7 (0.5-1.0) 1.1 (0 .8 -1 .5) 0.9 (0.7-1.1)
* HRs (95% CI) were adjusted for age, gender, smoking, and family dependence using a random 
coefficient proportional hazards model, f  No cases were found among case-relatives. $ Tumors of 
the urinary tract minus cancers of bladder, ureter, renal pelvis.
■ Discussion. In line with the literature,1 our data show that PCa has a strong 
familial component reflected in a 2.9-fold increased risk of PCa for first-degree 
relatives of PCa probands. This risk was more pronounced for brothers of PCa 
probands (HR=3.9, 95% CI: 2.4-6.4), which has been reported previously.36 The 
risk estimate of PCa for male family members of non-screened PCa probands was 
3.1 (95% CI: 2.2-4.1). Among first-degree relatives of screen-detected PCa cases, a 
statistically significant familial aggregation of PCa was also observed (HR=2.1, 
95% CI: 1.2-3.9).
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Overall, first-degree relatives of PCa probands had no increased risk for non-PCa 
malignancies (HR=1.1, 95% CI: 0.9-1.2). Besides co-aggregation of cancer of the 
respiratory tract among female case-relatives (HR =1.8, 95% CI= 1.1-3.1), and a 
decreased risk of skin cancer among male case-relatives (HR=0.5, 95% CI = 0.3­
1.0), our study did not reveal a significantly increased risk of any of the investigated
13 tumor-sites. In our population, familial PCa appears to be site-specific, and not 
part of an inherited cancer-syndrome, such as the BRCA1 -associated breast and 
ovarium cancers.37 These conclusions did not change after re-examination of our data 
using families of young (< 60 years at diagnosis) PCa probands only in the case­
relative group, or after we excluded families of screen-detected PCa probands.
In table 2.6 we summarized earlier studies on the co-aggregation of PCa and 
malignancies at other sites.22-30 The most consistent findings include slightly 
increased relative risks for tumors of the central nervous system,22,23 gastric 
cancer,27,30 colorectal cancer,26,27 and breast cancer.27,29 among first-degree relatives 
of PCa probands. As these findings were not replicated more than once, evidence for 
the co-aggregation of PCa and other cancer is still debatable. Discrepancies between 
previous studies and this study may be the result of differences in study populations, 
heterogeneity of PCa susceptibility genes in different populations, or chance 
clustering of cancer cases in the same families.
We found statistically significant co-aggregation of cancer of the respiratory tract and 
PCa among female case-relatives, which was due to excess occurrence of cancer of 
the respiratory tract among sisters of PCa probands compared to control-sisters 
(HR=2.2, 95% CI: 1.0-4.8, results not shown in table). This co-aggregation was 
seen neither among male case-relatives nor among case-mothers, which leads us to 
speculate that this association is false-positive. It is important to emphasize that we, 
along with previous investigators, have looked for various different effects in our 
data, i.e. tested the aggregation of PCa and other malignancies at many different 
sites. This may have resulted in false-positive findings due to type I errors.
In the similar study on familial aggregation of urothelial cell carcinoma (UCC) from 
our institute we assessed the quality of the reported data on the occurrence of other 
types of cancer among relatives.32 Both the studies on the familial aggregation of 
UCC and PCa used the same eligibility-criteria for cancer probands and the same 
questionnaires. The verification was performed by linking questionnaire data to the 
population-based CCC South, which is considered to be complete since 1975.
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Table 2.6: Summary o f selected studies o f familial aggregation o f pea and malignancies at other sites.
Author (year), population Design Measure
n index 
PCa cases
Risk of PCa
Risk of 
other cancer
Outcome Remarks
Colon 1.3 (1.1 - 1.4)
Goldgar (1994). USA20 Cohort FRR 6.350 2.2 (2.1 -2 .4 )
NHL
Rectum
CNS
1.2 (1.1 -
1.3 (1.1 -
1.3 (1.0 -
1.5)
1.5)
1.5)
Isaacs (1995). USA21 Case-control OR 690 1.8 (1.3 -2 .4 ) CNS 3.0 (1.1 - 8.4) *
Keetch (1995). USA22 Case-control OR 1.084 3.4 (2.6 -4 .4 ) None -
No details of the co­
aggregation analyses given.
Bratt (1997). Sweden23 Cohort SIR 89
1.4 (0.8 -2 .3 ) t
3.4 (1 .4 -6 .9 )  $
None -
Only PCa probands diagnosed 
< 5 1  yrs included.
Damber (1998). Sweden24 Cohort SIR 5.402 1.7 (1.5 - 1.8) Colorectal 1.5 (1.1 - 2.0)
Offspring of index cases 
analyzed
Gronberg (2000). Sweden25 Cohort SIR
62 H PC'
families
-
Stomach
Breast
Kidney
2.9 (1.6 - 
1.6 (1.0 - 
2.5 (1.2 -
4.5) § 
2.4) || 
4.8)
Hemminki (2000). Sweden26 Cohort SIR 1.035 2.4 (2.1 -2 .8 ) Skin 3.6 (1.3 - 6.9)
Valeri (2000). France27 Case-control OR 691 - Breast 2.3 (1.3 - 4.3) t
Matikainen (2001). Finland28 Cohort SIR 557 2.5 (1.9 -3 .2 ) Stomach 1.9 (1.3 - 2.7) §
Only PCa probands diagnosed 
< 60 yrs included
SIR= standardized incidence ratio, OR= odds ratio, CNS= central nervous system. FRR= familial relative risk, NHL= non-hodgkin 
lymphoma, * Observed in a population of 75 HPC families, f  First-degree relatives all ages at diagnose PCa. $ First-degree relatives age 
at diagnose PCa < 70 years. § Only seen among male relatives. || Only seen among female relatives. 1 Sporadic PCa vs. familial PCa.
Only cancer occurrence among relatives who had been living in the catchment area 
of the registry since 1975 was checked by matching the reported data to the cancer 
registry to quantify under- and overreporting of cancer. A total of 339 relatives of 
UCC case- and control-relatives were reported to have had at least 1 malignancy 
diagnosed since 1975. Data linkage was successful in 301 of these relatives.
In 77% of the tumors, the site recorded by the CCC South and the site mentioned in 
the questionnaire were identical. For the 38 relatives who could not be linked, 
additional information was obtained through the proband or family. Fifteen relatives 
had been diagnosed or treated at hospitals outside the catchment area of the CCC 
South. Therefore, definitive positive linkage was achieved in 93% of all reported 
cancer. The remaining 23 relatives could not be linked for various reasons, such as 
inaccurate date of birth on the questionnaire, patient death within a few days after 
clinical diagnosis (no pathology report), or diagnosis made at a nursing home (also 
no pathology report).
Verification of negative family history was also performed. The UCC probands and 
partners reported that 3,472 relatives (1,940 case-relatives and 1,532 control­
relatives) who were born before 1955 and were living in the catchment area of the 
CCC South did not have any malignancies. The cut-off point of 1955 was chosen 
arbitrarily to include relatives who were old enough to have developed cancer. The 
relatives of the partners of the UCC cases (which are used in this study as controls) 
appeared to underreport the occurrence of cancer in their families by 2.5% (to every 
100 reported malignancies 2.5 were missed). These 2.5% included different cancer 
sites (tongue, colon, rectum, pancreas, nasal cavity, lung, stomach, bone, skin, 
prostate, mamma, cervix, ovary, kidney, bladder, leukemia, bone marrow, primary 
site unknown). It is possible that the relative had not mentioned his/her diagnosis to 
the family, or some of these patients had not been informed about the fact they had 
cancer.
In order to evaluate possible selection bias, in the similar study on the familial 
aggregation and segregation analysis of urothelial cell carcinoma (UCC) a random 
sample of non-responders were contacted to obtain information on family history. 
Regarding the positive family history of UCC, responders and non-responders did 
not differ (8.0 vs. 7.5%, respectively).32
Overall, our findings confirm the familial aggregation of PCa. Cancers at other sites 
did not co-aggregate within the total observed population of PCa families, nor within 
PCa families with more than 1 affected from the Netherlands. Our data therefore
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suggest that in our population familial PCa is ‘site-specific’, and not part of an
inherited cancer-syndrome.
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C H A P T E R 3 
S P O U S E C O N T R O L S I N 
C A S E -  C O N T R O L F A M I L Y S T U D I E S :
A M E T H O D O L O G I C A L C O N S I D E R A T I O N
■ Abstract. In case control studies on familial aggregation of disease spouses may 
be chosen as convenient controls. In this paper the pros and cons of this control 
group are discussed. It is argued that the use of spouse controls can be time and cost 
efficient, because of easy accessibility and their ability to provide proxy data on the 
patients’ relatives if necessary. Furthermore, with spouse controls a higher response 
rate and less recall bias can be expected compared to population controls. A 
theoretical drawback is the possibility of assortative mating related to genetic 
susceptibility of disease under study.
Using a simulation study it is illustrated that even strong assortative mating on a 
factor, which is strongly correlated with a true risk factor under study, will have a 
negligible effect on the observed extent of familial aggregation.
■ Introduction. The study of familial aggregation is one of the central themes in 
genetic epidemiology. For this, both case control and cohort designs can be used.1 
The case control study design is adapted often for family studies. The main 
difference between the conventional case-control study and a case-control study 
designed to study familial aggregation is that the comparison takes place between the 
relatives of cases and controls and not between cases and controls themselves. After 
all, family history is not a property of cases and controls but depends on many 
factors. These include family size, the prevalence of the disease in the population, 
the age distribution of relatives, the etiologic heterogeneity of the disease, and the 
biological relationships to the index cases and controls. For example, the number of 
cases with a positive family history should increase with the number of relatives, 
even in the absence of any biological basis for familial aggregation of disease. When 
family sizes differ between cases and controls this may be a problem. Therefore, 
instead of regarding family history as an exposure in case-control studies, one may 
transform the case-control design into a cohort design. Here, cohorts of relatives of
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cases and controls are evaluated for the presence or absence of disease in relation to 
their own risk factor information, age distribution, and relationship to either the 
index case or control (which becomes the exposure variable for the relatives). 
Rothman points out that the objective in selecting controls is to choose individuals 
representative of those who, had they developed disease, would have been selected 
as cases and to choose these controls independently of exposure.2 In other words, the 
controls should be a sample from the population from which the cases arose.3 For 
pragmatic reasons, however, controls have been selected from hospital patients, peer 
workers, neighbors, friends and relatives (when focussing on environmental 
factors).4-6 In case-control studies of familial aggregation, spouses (or more generally 
partners) are an attractive alternative.7-10
Unfortunately, spouse controls may introduce selection bias in the study through 
assortative mating, resulting in a distorted estimate of familial aggregation of 
disease.
Here we discuss the advantages and disadvantages inherent in the selection of 
spouses as controls in the study of familial aggregation of disease (table 3.1). In 
addition, we try to quantify the bias in the familial aggregation estimate by means of 
a simulation study.
Table 3.1: Advantages and disadvantages o f spouse controls.
Advantages Disadvantages
• Better feasibility of the study • Different sex and age distributions among
• Higher response rate among controls cases and controls and their relatives
• Comparability of recall among relatives in • Same offspring
case and control group • Assortative mating
• Time and cost efficient • Overmatching on ‘lifestyle’
• Controls can provide proxy data on the
patients’ relatives in case of death of the
patient and vice versa
Advantages of spouse controls. Spouse controls will usually provide a higher 
response rate compared to population controls. In contrast to population controls, 
spouse controls will be committed to their spouse’s disease, which may make 
recruitment easier. Motivation is often essential in research on familial aggregation, 
as extended interviews are used to obtain information about other family members. 
Because of the easy accessibility of the patients’ spouses (shared address)
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considerable time and financial effort may be saved. Another practical advantage is 
that spouse controls usually can provide accurate proxy data on the patients’ own 
relatives in case of death of the patient or cognitive dysfunction (e.g. Alzheimer 
disease) when applying the family history approach.1 Furthermore, there will be 
better comparability of recall about disease among relatives in both the case and 
control group, because of their partner’s experience.
Disadvantages o f spouse controls. The choice of spouse controls will often lead to a 
different sex distribution among cases and controls, if the risk of the condition under 
study is unequal among men and women. An unequal sex distribution in cases and 
controls results directly in a different sex distribution of their siblings: assuming a 
male/female ratio of 0.50, the (posterior) probability of a male case having a brother 
is lower than the probability of his spouse having a brother since the overall sex ratio 
is constant.
Secondly, men tend to marry younger women. For example, in the Netherlands in 
1997 men were three years older than women were at the time of marriage.11 In 
many parts of the world this difference may be more extreme. This implies that the 
age of siblings and parents of cases and controls may differ as well.
These two drawbacks may be a problem, depending on the sex- and age-specific 
penetrance of the condition under study, especially with the increasing tendency 
towards small families in many populations (in the Netherlands in 1997, 90% of the 
nuclear families consist of 2 children or less.11 However, when the age and sex 
distributions overlap, the family cohort design offers the opportunity to adjust for 
these different distributions in the analysis.
A third disadvantage of the use of a spouse control is that case and control (in most 
occasions) will have the same offspring. When a disease with late onset is studied 
this will be of minor consequence as offspring will usually not be very informative in 
the analyses. In case the condition under study has an early onset, for example testis 
carcinoma or leukemia, valuable information from offspring may not be available.
A fourth disadvantage of spouse controls is the possibility of assortative mating. 
Assortative mating occurs when mating partners are non-randomly selected with 
respect to one or more (phenotypic) traits. In humans, assortative mating has been 
reported for such characteristics as race, age, IQ, height, weight, education, 
occupational level, and physical and personality characteristics.12-20 
If one presumes that the phenotypic traits, on which the non-random selection of 
mating partners takes place, are genetically related to the predisposition of the
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condition under study, selection bias may be introduced by using spouse controls. In 
case of positive assortative mating (mating partners are chosen on similarity in 
phenotypical traits), familial aggregation may be underestimated. For example, in a 
study on familial aggregation of prostate cancer assortative mating may exist on adult 
weight. Through estrogen metabolism, weight may also be a risk factor for prostate 
cancer while it has a strong genetic component itself. In this situation spouse controls 
may lead to an underestimation of the extent of familial clustering of prostate cancer 
because male relatives of female spouse controls may be heavier and themselves 
have a higher risk of prostate cancer. Likewise, negative assortative mating (choice 
of mating partner based on dissimilarity in phenotype) may lead to an overestimation 
of familial aggregation.
In the present paper we examine the quantitative influence of assortative mating by a 
simulation study on familial clustering of prostate cancer (PCa).
■ Simulation study: an illustration. The general purpose of the computer 
simulation is to assess the quantitative bias of assortative mating on familial 
clustering of PCa as measured in a case-control design. In short, nuclear families 
(parents and offspring) were generated, and to each family member age, age at 
exam, age at death, gender, a risk factor R for the disease, and a mating factor M , 
associated with the risk factor R but no causal factor for the disease in itself, were 
assigned. Both risk factor R and a mating factor M are continuous variables with a 
mean value of 0. Subsequently, according to age and the value for R , age at onset of 
PCa was simulated for each father and male offspring. Whenever age at onset of PCa 
preceded age at death and age at exam, the family member was considered to be an 
incident PCa case.
All incident PCa cases in the offspring were coupled to a spouse in two ways: (1) At 
random: a female was coupled on the basis of age alone; (2) non-randomly 
(‘assortative mating’): a female was coupled on the basis of age and similarity of 
mating factor M  (figure 3.1). Consequently, 2 cohorts were defined: 1st degree 
relatives of cases and spouses (figure 3.2). Using Cox proportional hazards 
modelling, the risk of PCa in male relatives of cases in the random mating situation 
was compared to the risks in two different assortative mating situations. 
Additionally, the impact of the association between risk factor R and mating factor M  
on the estimate of familial aggregation was assessed. Below, the simulation is 
explained in more detail.
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Simulated population. Simulation methods that are capable of generating family data 
for disease models in which age and a risk factor R contribute to the disease status 
were developed. Family data consist of nuclear families (parents and offspring) with 
sibships ranging from 1 to 8 persons. Family sizes were generated from a 
multinomial distribution with probabilities 0.15, 0.25, 0.20, 0.13, 0.10, 0.07, 0.06 
and 0.04 for nuclear families of sizes 3, 4, 5, 6, 7, 8, 9, and 10, respectively, based 
on the distribution of sibship size in the Netherlands.11 In total, 50 simulation-runs 
were performed, each run generating 20,000 nuclear families (step 1 in figure 3.1). 
Values for gender of individuals in sibships were obtained from a binomial 
distribution, with probability 0.5 for each sex. Age, risk factor R, and mating factor 
M  values for each individual were drawn from a multivariate normal distribution 
(step 2 in figure 3.1).
Time from age 35 until PCa diagnosis was assumed to result from two competing 
and independent risks. One is the risk of developing PCa, the other is the risk of 
death. Let X  denote the time (in years) from age 35 until diagnosis of PCa. X  was 
assumed to follow a Gompertz distribution which is characterized by 2 parameters, a  
and p. The cumulative distribution function is given by:
F x  (x | a , p) = 1 -  exp( [-exp(a +  px)] / p +  exp(a) / p), x > 0
The natural logarithm of the hazard function hx(x) under this model is:
ln[ hx(x) ] = a  +  px
PCa incidence rates, in 5 years age groups, from the Netherlands Cancer Registry21 
are used to estimate the parameters a  and p. The estimated values are given in 
appendix table A1 (see appendix). Let Y denote the time in years from age 30 until 
death unrelated to PCa (note that X  and Y differ 5 years in starting age). We assume 
that Y follows a Gompertz distribution with parameters a and b . The distribution 
function is given by:
F y  (y | a, b) = 1 -  exp( [-exp(a +  by)] / b +  exp(a) / b), y> 0 
The natural logarithm of the hazard function hY(y) is given by: 
ln[ hY(y) ] = a +  by
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Figure 3.1: Successive steps in the simulation of families and mating procedures. 
Pedigrees depict nuclear families, i.e. parents and offspring. Rounds represent 
females, squares represent males (black-filled squares represent affected males).
....................................................................................................................................................................................... .
1. Simulation of 1,000,000 nuclear families (50 x 20,000). |
PCa case 1:
Age= 59.4
M = + 1.19
R = + 1.95
PCa case 2: 
Age= 55.3 
M = +1.35 
R = +2.12 
PCa index case
2. For each member of each family a risk factor R  and a mating factor M  is simulated. Factor R , 
as factor M, correlates within the family with a given value. The last incident PCa case in the 
offspring of a nuclear family is the index PCa case who will be coupled to a spouse.
PCa index case:
Age= 55.3 
M = +1.35 
R = +2.12
Spouse:
Age= 53. 8
M = +0. 15
R = -0. 43
1 a
3A. Random mating. Incident PCa case is coupled to a spouse on the basis of similarity of age 
alone.
Spouse:
Age= 54 5
M = +1 40
R = +2 03
3B. Assortative mating. Incident PCa case is coupled to a spouse on the basis of similarity of age 
and mating factor M. Depending on the inter-spouse correlation for mating factor M  (degree of 
assortative mating), and the correlation between mating factor M  and risk factor R , the occurrence 
of PCa will be more alike among the coupled families.
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Figure 3.2: Definition o f the case-relatives and control relatives cohorts fo r  analysis.
^  Mating ^  
^  Mating ^
^  Mating ^
y
— — — *
v
Case-relatives cohort < -------- ANALYSIS
------ ► Control-relatives cohort
The life tables of Statistics Netherlands of ages 30 to 110 were used to estimate 
parameters a and b  separately for males and females, and are given in appendix table 
A2.
If X denotes the time in years from age 35 until PCa diagnosis and Y the time after 
age 30 until death, two events may follow: (1) x +  5 < y, PCa is diagnosed x years 
after age 35; and (2) x +  5 > y, death occurs before PCa is diagnosed.
The time until PCa is made dependent on risk factor R as follows:
ln[ fo(x) ] = a  +  fix +  2 R
The standard normal distributed risk factor R , was (arbitrarily) weighted twice to 
increase the relative importance of factor R in the determination of the time until 
PCa.
In this simulation study an arbitrary time period of 10 years was defined for 
inclusion of incident PCa cases in a hypothetical study on familial PCa. At t0 age is 
specified as shown in appendix table A3. The chosen correlations between the values
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of age, risk factor R, and mating factor M, within the nuclear families are given in 
appendix table A4 (a nuclear family of n= 4  is given as an example, but the 
correlations apply to families of all sizes.
Probabilities of events (occurrence of PCa) can be calculated when the parameters of 
the two Gompertz functions are known or estimated. For example, the probability 
that a healthy man (without PCa) of age 35 has PCa before death from other causes 
is the conditional probability Pr[X < Y -  5 | Y > 5] and is given by:
to to to
{ j  f x  (* )[ j  f i  (y )dy ]dx} /{I -  F Y (5)} = { j  f x  (x )[! -  F y (x + 5)]dx} /{I -  FY (5)}
Mating. In each nuclear family with PCa in the offspring, the last incident case in the 
offspring occurring during the 10 year entry period was chosen to be the index case. 
For each index case with a given age and mating factor M, a spouse was selected.
The selection of spouses occurred in two ways: randomly and non-randomly 
(‘assortative mating’) (steps 3A and 3B in figure 3.1). In the latter situation spouses 
were selected on the basis of similarity towards mating factor M . This was done for 
two ‘degrees of similarity’: the correlation of the mating factor M  between cases and 
spouses was 0.25 and 0.50, respectively. The values for correlations between cases 
and spouses were based on values derived from the literature, where correlations of
0.50 and 0.25 translate as ‘strong’ and ‘moderate’ assortative mating, respectively.12-
20
Analysis o f  familial aggregation. To determine the extent of familial risk of PCa 
among first-degree relatives (fathers and brothers) of PCa cases, the risk of PCa 
among male relatives of the cases was compared to the risk of PCa among relatives 
of the spouses by using a Cox proportional hazards model. The hazard ratio was 
used as a measure of familial aggregation.
The dependent variable was defined as either time to diagnosis of PCa (in years), 
time to interview or time to death, whichever came first. The independent variable 
was defined as case-relative (1) or spouse-relative (0). All analyses were conducted 
using SAS Release 6.12.22
Results. Results of the simulation and mating procedures are given in table 3.2. 
Results from analysis of these data are shown in table 3.3. The analysis of the data 
under random-mating conditions, yielded unbiased hazard ratio’s (HR’s) of 1.87 for
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male relatives (fathers and brothers) of cases versus male relatives of spouses. 
Assortative mating with an inter-spouse correlation for mating factor M= 0.50 
diminished the HR from 1.87 to 1.62 and 1.84, for correlations between the risk 
factor R and mating factor M  within the families of 0.50 and 0.25, respectively. 
Assortative mating with an inter-spouse correlation of mating factor M= 0.25 
diminished the HR of 1.87 to 1.85 and 1.86, for correlations between the risk factor 
R and mating factor M  within the families of 0.50 and 0.25, respectively.
Table 3.2: Overview of results from the simulation and mating procedures.
Random mating Assortative mating*
PCa index cases spouses spouses
{n = 30,676) {n = 30,676) (n = 30,676)
Percentage 0.305 0.185 0.195
affected fathers (9,342 / 30,676) (5,689 / 30,676) (5,727 / 29,395)f
Percentage 0.162 0.089 0.099
affected brothers (8,403 / 51,811) (4,822 / 54,019) (6,637 / 67,266)
Mean age at 
diagnosis fathers
63.3 65.4 65.1
Mean age at 
diagnosis brothers
53.3 54.4 54.7
Mean factor 
R  and M  fathers
0.5, 0.5 0.0, 0.0 0.1, 0.1
Mean factor 
R  and M  brothers
0.5, 0.5 0.0, 0.0 0.1, 0.1
In 1,000,000 families (50 simulations of 20,000 families) 30,676 (3.1%) PCa index cases occurred. 
* Assortative mating, where the correlation of both the risk factor R  and mating factor M  within 
nuclear families is 0.50, and where the inter-spouse correlation for mating factor M  is 0.50. f  The 
total number of fathers is not equal in the random and assortative mating situation because PCa 
index cases were coupled to spouses, originating from the same nuclear families. This occurred in 
4.2% of all matings in this specific assortative mating situation.
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Table 3.3: Results o f the Cox proportional hazards analysis: Hazard Ratio’s (HRs) 
for first degree male relatives o f cases compared to first degree male relatives of 
spouses.
Random mating Assortative mating
p2f  = 0.50 p2f  = 0.25
p1 * HRist degree HR1st degree HR1st degree
0.50 1.87 1.62 1.85
0.25 1.87 1.84 1.86
* pi : correlation risk factor R  and mating factor M.
f  p2 : inter-spouse correlation for mating factor M  (degree of assortative mating).
■ Discussion. In family studies using the case-control method spouses can be used 
as controls, even when the condition under study is sex specific, as the comparison 
of disease frequency takes place among relatives of cases and controls and not among 
cases and controls themselves. Spouses are an option for selection of controls: they 
have a better incentive to participate, potential recall bias is minimized, considerable 
time and financial effort is saved, and proxy data can be provided if necessary. The 
fact that some men are unmarried or widowed constitutes an efficiency issue and will 
not affect the validity of the study.
Assortative mating has been observed for several different traits. The magnitude at 
which assortative mating takes place depends on the characteristic. Some 
characteristics display high inter-spouse correlations (0.50 or over), such as age 
religion, race, or IQ.13,14,20 Other characteristics, like weight, have been observed in 
several populations to range from 0 .0 i to 0.30.i2
The results from our simulation (table 3.3) show that when strong assortative mating 
(correlation of mating factor M  between spouses = 0.50) occurs on an unobserved 
mating factor M  strongly associated with the ‘real’ risk factor for disease R 
(correlation = 0.50), the HR is diminished from 1.87 in the random situation to 
1.62. Of course, the situation of negative assortative mating (choice of mating 
partner based on dissimilarity in phenotype) may have lead to an overestimation of 
familial aggregation.
On the one hand, this outcome shows that under the (fairly unrealistic) condition that 
strong assortative mating occurs on a factor that is strongly associated with the risk 
factor for disease (which is also strongly correlated among family members), bias 
introduced by assortative mating can be substantial. On the other hand, these 
simulations also show that in situations where either 1. the correlation of mating
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factor M  between spouses, or 2. the correlation between risk factor R and mating 
factor M, or 3. both correlations are weaker (0.25 instead of 0.50), the estimate of 
familial aggregation is hardly biased through assortative mating. Of course, the 
simulation is at best an approximation of reality. In practice, diseases may occur 
through a wide variety of risk factors and partner selection will depend on many 
factors.
In our view, assortative mating will not lead to substantial selection bias in multi­
factorial diseases when using the case-control family study. Either because a 
suspected mating factor is so obviously related to the risk of disease (and therefore 
not interesting anymore), so that a stratified analysis is possible (e.g. race and PCa), 
or because there are many inter-depending factors determining the magnitude of the 
resulting selection bias. First, to be of any quantitative consequence assortative 
mating must occur with respect to a common phenotypical trait (mating factor M  in 
this simulation). The choice of a mating partner has to depend to a large extent on 
this common phenotype (i.e. there must be a large inter-spouse correlation of M). 
When assortative mating on a certain trait only accounts for a small percentage of all 
mating partner choices, its influence will be limited. This selective phenotype, 
subsequently, has to be strongly linked to the predisposition of the condition under 
study (the correlation between risk factor R and mating factor M  here). Suppose only 
a fraction of disease among cases in families can be attributed to the predisposition 
linked to the selective trait (e.g. because of etiological heterogeneity of the disease), 
then the influence of assortative mating will again be limited. Furthermore, the 
predisposition of the disease also has to be present in the other family members (i.e. 
there must be a large inter-spouse correlation of risk factor R) in order to have a 
noticeable effect on familial aggregation.
We therefore suggest that spouses are valid controls in studies of familial aggregation 
of disease, with regard to the likely negligible assortative mating effect.
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■ Appendix
Table A1: Parameter estimates for time X to prostate cancer after age 35.
Age group Incidence* P (PCa)f
35-39 0.1 18.4
40-44 0 .6 29.1
45-49 3.9 45.9
50-54 19.2 72.4
55-59 60.4 114.4
60-64 155.6 180.5
65-69 326.1 284.8
70-74 554.3 449.3
75-79 781.9 708.5
80-84 955.4 1116.3
Paremeter estimates Gompertz distribution X: a  = -8.28845, b = 0.091338. * Observed CBS 1997 
prostate cancer rates per 100,000 person years. 11 f  Predicted rate from the fitted Gompertz model.
Table A2: Parameter estimates for survival after age 30.
Parameter estimates Gompertz distribution
Y
Life expectation in years for age 30
a b LEgomperz * LEcBS1997 f
Males -7.08780 +0.09498 44.24 44.44
Females -8.1537 +0.10567 50.59 50.61
* LEgompertz: life expectation according to model, following a Gompertz distribution 
f  LEcbs1997: life expectation according to CBS figures 1997.11
Table A3: Specification of mean ages for all families (sizes 3 to 10) in years at 
moment o f cross-section (to)
Parents Ranking of children
Family size Father Mother 1 2 3 4 5 6 7 8
3 70 68 45 - - - - - - -
4 71 69 44 46 - - - - - -
5 72 70 43 45 47 - - - - -
6 73 71 42 44 46 48 - - - -
7 74 72 41 43 45 47 49 - - -
8 75 73 40 42 44 46 48 50 - -
9 76 74 39 41 43 45 47 49 51 -
10 77 75 38 40 42 44 46 48 50 52
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05ro Table A4: Correlation specification fo r  family with 4 members. On the main diagonal the variances are given.
Age Risk factor R Mating factor M
Father Modier Child 1 Child 2 Father Modier Child 1 Child 2 Fadier Mother Child 1 Child 2
Father 25 0.8 0.60 0.60 0 0 0 0 0 0 0 0
Age
Mother - 25 0.60 0.60 0 0 0 0 0 0 0 0
Child 1 - 0.25 0.35 0 0 0 0 0 0 0 0
Child 2 - - 0.81 0 0 0 0 0 0 0 0
Father - - - 1 0.50 0.50 0.50 X * X X X
Risk Modier - - - - 1 0.50 0.50 X X X X
factor R Child 1 - - - - - 1 0.50 X X X X
Child 2 - - - - - - 1 X X X X
Father - - - - - - - 1 0.50 0.50 0.50
Mating Modier - - - - - - - - 1 0.50 0.50
factor M Child 1 - - - - - - - - - 1 0.50
Child 2 - - - - - - - - - - 1
* In the analyses two values for X were used: 0.50 and 0.25
C H A P T E R 4 
S E G R E G A T I O N A N A L Y S I S I : 
T H E S T L O U I S E X P E R I E N C E
■ Abstract. Numerous studies have shown that prostate cancer (PCa) aggregates in 
families. Until now, three segregation analyses suggested the existence of an 
inherited form of PCa with an autosomal dominant inheritance mode. This study was 
initiated to confirm the findings of these three reports in a large independent cohort 
of PCa families.
Between January 1991 and December 1993 1,199 pedigrees were ascertained 
through single, unrelated, PCa probands who presented for radical prostatectomy at 
the Division of Urologic Surgery, Washington University in St Louis, MO. 
Maximum likelihood segregation analysis was used to test specifically for Mendelian 
inheritance of PCa.
Segregation analyses revealed that the familial aggregation of PCa can be best 
explained by autosomal dominant inheritance of a rare (q=0.0037) high-risk allele. 
According to the best fitting autosomal dominant model, 97% of all carriers will be 
affected by the age of 85 compared to 10% of the non-carriers. Furthermore, the 
autosomal dominant model predicts that the high-risk allele accounts for a large 
proportion (65%) of all PCa cases diagnosed prior to the age of 56. However, of all 
PCa a relatively small proportion is inherited (8% by the age of 85).
These results are in agreement with earlier reports on segregation analyses of PCa 
and strengthen the evidence that PCa is inherited in a Mendelian fashion within a 
subset of families.
■ Introduction. After non-melanoma skin cancer, PCa is the most common 
malignant cancer among men living in the United States. Besides age, race, and 
family history there are no clear risk factors for the disease. Numerous studies have 
reported on the familial aggregation of PCa.1 Overall, first-degree relatives of PCa 
patients have a 2 to 3 times increased risk of PCa. According to three segregation 
analyses the aggregation of PCa in families can be best explained by Mendelian 
autosomal dominant inheritance.2-4 In 1992, Carter and colleagues from Johns
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Hopkins University in Baltimore were the first to report that familial PCa may be 
caused by a rare (q=0.003), highly penetrant, dominant gene (or genes).2 Their 
model predicted that 88 percent of the gene carriers develop PCa by the age of 85 
years. Furthermore, it was suggested that this inherited form of PCa may account for 
a significant proportion of early onset PCa (43% of patients with age at diagnosis 
<55 years), but only a small proportion of PCa cases overall (9% by age 85).2 In 
1997, Gronberg et al. from Umea University in Sweden and Schaid et al. from the 
Mayo Clinic in Rochester confirmed these results.3,4 Gronberg and colleagues 
reported a high-risk allele inherited in a dominant fashion, with a higher population 
frequency (q = 0.0167) and a moderate lifetime penetrance (63%). Schaid et al. 
reported a population frequency of the autosomal dominant gene of q = 0.006 and a 
risk of PCa of 89% among carriers by the age of 85. Other investigators, however, 
suggested that an X-linked or recessive genetic model might be more accurate. This 
suggestion was based on the finding that brothers have a higher risk of PCa 
compared with fathers and sons.1,5 The purpose of the present study is to determine 
whether results from previous complex segregation analyses can be confirmed in a 
large independent cohort of PCa families.
■ Subjects & Methods. Subjects. Between January 1991 and December 1993 1,345 
men underwent radical prostatectomy for T1/T2 PCa at the Division of Urologic 
Surgery, Washington University, St Louis, MO. Detailed family history and 
demographic data were collected in 1994 through telephone interview or postal 
questionnaire. For non-affected first-degree relatives, current age or age at death was 
also recorded. Confirmation that all consecutive patients between January 1991 and 
December 1993 were identified was obtained by cross-referencing the Division of 
Urologic Surgery billing records for this time period against the patients list. Patients 
for whom a family history questionnaire was not available were contacted by phone 
or mailed questionnaire. A more detailed description of the data collection is given 
elsewhere.6
Ultimately, family history data were available for 1,199 of 1,345 men. In an earlier 
report from this study it was shown that men with a family history of PCa are at a 
significantly increased risk for PCa: the relative risk for PCa was 3.5 (95% 
confidence interval (CI): 2.4-5.0) in the case of an affected father and 4.7 (95% CI: 
3.0-7.5) in the case of an affected brother.6
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Segregation analysis. To test specifically for Mendelian inheritance of PCa in the 
collected pedigrees, maximum likelihood segregation analyses were performed on 
the age at diagnosis expressed as a censored trait using the Statistical Analysis for 
Genetic Epidemiology (S.A.G.E) program REGTL, third release.7 Using this 
program one can either assume that the presence (or absence) of the putative disease 
allele influences age at onset (model 1) or influences susceptibility (model 2). Age at 
diagnosis was used as a proxy for age at onset.
For this analysis model 1 was chosen, using the class A regressive models.8 Age at 
onset for PCa is assumed to follow a logistic distribution described by two 
parameters, a  and p, with the probability distribution function according to Elston et
al. .9
f(age)= [yae(Pi + a * age) ] / [1 + e (Pi + a * age) ]2 (1)
This symmetric distribution is similar to a normal distribution with mean -p / a , and 
variance, n3 / 3a2 (n has the value of 3.1416).
PCa was defined as a dichotomous variable (Y), where Y=1  if affected and Y=0 if 
unaffected (censored). Parameters estimated in the analysis include: qA, the 
frequency of the putative high-risk allele A; Pi baseline parameters, where i 
represents an individual’s type (AA, AB, BB); a , the age coefficient, and y, the 
susceptibility coefficient. The susceptibility parameter y describes the cumulative 
probability that a man develops PCa if he lives long enough.10 Susceptibility y was 
fixed at zero for females.
The probability (or penetrance) that an individual is affected by a certain age specific 
penetrance was calculated for each type as:
P(Y | genotype i, age) = Y[e(Pi + a * age) ] / [1 + e (Pi + a * age) ] (2)
If the observed age at diagnosis does not follow a logistic distribution, this model 
may still be appropriate after transformation. The observed ages at diagnosis were 
therefore transformed according to: aG1 * ln(age), where aG1 is the geometric mean 
age at diagnosis of the affected non-probands.11 After transformation, the penetrance 
function can still be calculated according to:
P(Y | genotype i, age) = Y[e(Pi + a * (age * aG1)) ] / [1 + e (Pi + a * (age* aG1)) ] (3)
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Tests for genetic control were implemented by postulating three types of individuals 
(AA, AB, and BB) with three corresponding transmission parameters ( t a a ,  t a b ,  and 
t b b )  describing the probability that a parent of a given type transmits the disease- 
producing factor A to his or her offspring.12,13 Under hypotheses of Mendelian 
transmission, these transmission parameters are constrained to t a a = 1 . 0 ,  t a b = 0 . 5 ,  
and t b b = 0 ,  respectively. This model further assumes that the three types of parents 
(AA, AB, and BB) occur in the population with frequencies q2, 2q(1 - q), and (1 - 
q)2 (Hardy-Weinberg equilibrium). Five models of disease transmission were tested 
against the general unrestricted model to identify the best model for these data. The 
‘no major gene’ model assumes that baseline risk is not influenced by ‘type’: all 
persons have the same age-specific risk of PCa. Single locus Mendelian models 
assume a major locus with two alleles that act either in a codominant, dominant, or 
recessive fashion. The dominant and recessive models are special cases of the 
codominant model, where each genotype has a distinct arbitrary age at onset 
distribution. An environmental model with potentially distinct types of individuals 
was also tested, but here the transmission probability was held constant for all 
individuals. X-linked transmission of a disease allele could not be evaluated, as the 
statistical package is unable to test for sex-linked transmission.
The likelihood ratio test (LRT) was used to test each of the five models against the 
general, unrestricted model and was computed as minus twice the natural log 
likelihood (-2ln(L)) of the general model subtracted from that for a restricted sub­
model. This difference is asymptotically distributed as a x2 distribution with degrees 
of freedom equal to the difference in the number of parameters estimated in the two 
models. To correct for ascertainment bias, the likelihood of each pedigree was 
conditioned on the proband’s affection status using his age at diagnosis as 
recorded.13,14
■ Results. Population characteristics. The 1,199 pedigrees contained 3,965 males 
(of which 1,567 brothers and 1,199 fathers) and 2526 females. Age (or age at 
diagnosis in case of an affected non-proband) was missing for 712 subjects, or 11% 
of the total cohort. Of these 712 subjects, 334 (47%) were female and 378 were male 
(53%). Three percent of the 378 males (n = 11) were affected non-probands.
Among all participants 93% were Caucasian, 5% were African-American and 2% 
were Asian or Hispanic. Because of the relatively small number of non-Caucasian 
families, it was decided not to conduct any stratified analyses.
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Of the 1,199 probands used in the analyses, 218 (18%) had a positive family history: 
113 probands had an affected father only; 75 probands had 1 affected brother only; 
15 probands had an affected father and an affected brother; 11 probands had 2 
affected brothers; 2 probands had an affected father and two affected brothers; 2 
probands had 3 affected brothers.
As expected, the mean age at diagnosis of PCa in the affected non-probands was 
significantly higher compared to the mean age at diagnosis of the radical 
prostatectomy probands (69.4 ± 8.9 years vs. 65.0 ± 6.3 years, p <  0.001). The 
geometric mean age at diagnosis for affected non-probands was also 69.4 years.
Segregation analysis. The parameter estimates and test statistics from the segregation 
analyses are given in table 4.1. The two non-Mendelian models did not fit the data. 
The no major gene model, in which q was fixed at 1.0, was clearly rejected, when 
compared to the general unrestricted model (x2=29.18, p <  0.001). The 
environmental model, which has equal transmission parameters for all three types of 
individuals AA, AB, and BB, also differed significantly from the general model 
(x2 = 8.34, p=0.015). The major gene models were tested with fixed values 1.0, 0.5, 
and 0.0 for the transmission parameters t a a ,  t a b ,  and t b b ,  respectively. Of these 
Mendelian models, the recessive model, defined by P a a ^  P a b =  P bb ,  was clearly 
rejected (x2=24.92, p=0.001). The codominant model, allowing for three genotype- 
specific age at onset distributions, fitted the data well (x2=6.74, p=0.23). The 
autosomal dominant (AD) model, assuming P a a =  P a b ^  P bb ,  proved to fit the data 
best (x2=3.74, p=0.43). The codominant model did not give an improvement in fit 
over the AD model (x2=3.00, p>0.05).
The allele frequency in the AD model was estimated to be 0.0037. The estimated 
cumulative risk (penetrance) of PCa for types AA/AB (‘carriers’) and BB (‘non­
carriers’), as predicted by the AD model, is given in figure 4.1. The dotted lines 
show the predicted cumulative risks of PCa in the Johns Hopkins study.
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Table 4.1: Parameter estimates from segregation analysis o f  prostate cancer in 1,199 families ascertained 
through a single prostate cancer proband.
Hypothesis: -2 In L Df x 2 p  - value qA
Parameter estimates
TAA TAB TBB P a a P ab P bb a y
No major gene 2803.10 6 29.18 < 0 . 0 0 1 [1 .0 ] - - - -49.35 =  P a a =  P a a 0.17 0.36
Dominant 2777.66 4 3.74 0.430 0.0037 [1 .0 ] [0.5] [0 ] -51.49 =  P a a -57.15 0.18 1 . 0
Codominant 2780.66 3 6.74 0.234 0.0265 [1 .0 ] [0.5] [0 ] -26.73 -66.39 -70.05 0.24 0.41
Recessive 2798.84 4 24.92 0.001 0.7611 [1 .0 ] [0.5] [0 ] -66.93 -49.38 =  P ab 0.17 0.56
Environmental 2782.26 2 8.34 0.015 0.6192 0.441 =  TAA =  TAA -59.23 -83.23 -56.09 0 . 2 0 1 . 0
General 2773.92 - - - 0.6624 1 . 0 0.43 0 -92.60 -94.17 -50.62 0.17 1 . 0
y 2 is defined as (-2 In L) of the data under the hypothesis minus (-2 In L) of the data under the general model. Numbers in 
brackets are fixed at the indicated value; q: the frequency of the putative high-risk allele; x: transmission parameter denoting the 
probability that a parent of a given type transmits the disease-producing factor A to his or her offspring; P: baseline parameter; 
a : age adjustment parameter; y: susceptibility parameter describing the cumulative probability of prostate cancer (assuming 
infinite lifespan).
Figure 4.1: Predicted cumulative risks fo r  types AA/AB (carriers o f the high-risk 
allele) and BB (non-carriers) genotypes. The dotted lines represent the data from the 
Johns Hopkins (JHU) study.2
age at diagnose, years
■  Discussion. This report shows that familial aggregation of PCa can best be 
explained by an autosomal dominant inheritance of a rare but highly penetrant high­
risk allele. The estimated gene frequency of 0.0037 implies that 0.74% of the St 
Louis population would carry the putative gene. Carriers of this susceptibility gene 
have a much earlier age at diagnosis, relative to non-carriers (figure 4.1).
These findings are consistent with previous reports on the mode of inheritance of 
PCa.2-4 The methods of ascertainment (through a single proband receiving a radical 
prostatectomy for clinically localized PCa) and segregation analyses we have used in 
this study were similar to those of Carter et a l . from the Johns Hopkins University2 
and Schaid et a l.4 from the Mayo Clinic.
PCa patients in this study were diagnosed at a similar age as the probands in the 
study of Schaid et al. (65.3 vs. 65.6 years, respectively), but were older than the 
probands in the study by Carter (59.3 years). The frequency of the high-risk allele 
reported herein was equal to the frequency Carter et al. found, but lower than Schaid 
et al. reported (q=0.0060).
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The AD model predicted that the high-risk allele is responsible for a large proportion 
(65%) of all PCa cases diagnosed prior to the age of 56. Of all PCa a relatively 
small proportion is due to the inherited form of PCa (8% by age 85). Although the 
standard errors of parameter estimates from segregation analysis are large, these 
proportions seem to be higher than reported by Carter et al. for early onset PCa 
(65% vs. 43%), and approximately similar for total PCa occurrence (8% vs. 9%).
In figure 4.1 the predicted cumulative risks of PCa are given for carriers and non­
carriers (based on the AD model). Carriers of the high-risk allele had cumulative 
probabilities of being affected by the ages of 55, 70 and 85 years of 12.2%, 73.4%, 
and 96.8%, respectively. The penetrances of the high-risk allele in the Johns 
Hopkins study for ages of 55, 70 and 85 years were 4%, 41%, and 88%, 
respectively. Thus, the estimated age-specific penetrances for carriers appear 
somewhat higher compared to the findings in the Johns Hopkins study. Non-carriers 
had cumulative probabilities of being affected by the ages of 55, 70 and 85 years of
0.01%, 0.2%, and 9.6%, respectively. The corresponding percentages in the Johns 
Hopkins study were 0.03%, 0.5%, and 6.8%, respectively. The somewhat higher 
risk estimates in our study compared to those from the Johns Hopkins study may be 
due to the fact that the data in the Johns Hopkins study were collected prior to the 
PSA era.
The estimated lifetime penetrance among non-carriers, who constitute the vast 
majority among all PCa cases, is somewhat lower than the population-based PCa risk 
reported by the NCI SEER program.5 The most likely explanation for this 
discrepancy is that older brothers and fathers of probands died prior to the 
widespread use of PSA screening in the US.
Linkage studies of highly selected PCa pedigrees have shown that several loci, on 
chromosomes 116-20 and X21, are candidates for the first PCa susceptibility gene. 
Recent linkage analyses suggest that chromosomes 1622 and 2023 may harbor a 
susceptibility loci as well. Although none of these PCa susceptibility genes have been 
cloned yet, it is estimated that in total only 5 to 10 percent of all PCa is accounted 
for by these hereditary factors.24 This implies that among multiplex families with 
PCa it is likely that phenocopies, i.e. affected individuals not carrying the high-risk 
allele, occur. In linkage analysis this constitutes a problem, as the discrimination 
between genetic and sporadic cases is based on age at diagnosis alone.
Keetch et al., using partly the same population as in this report, found that mean 
Gleason score (± standard deviation) in 50 men with sporadic cancer was 6.2 ± 1 
compared to 5.6 ± 0.9 in those with ‘hereditary disease’ (p=0.008). There appeared
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to be no other substantial clinical or pathological differences.25 Others did not find 
any clear distinct clinical features of hereditary cases either, which further hampers 
the search for PCa susceptibility genes in linkage analysis.26 Gronberg et al. reported 
that men from families potentially linked to HPC1 had a significantly lower mean 
age at diagnosis (63.7 vs. 65.9 years), more higher-grade (grade 3) cancers (39% vs. 
29%), and more often advanced disease (41% vs. 31%) than men from unlinked 
families.27 However, others challenge these results, and suggest that ascertainment bias 
occurred leading towards a more advanced stage.28,29
While family members in, e.g. hereditary breast cancer families and hereditary 
nonpolyposis colon cancer families have an increased risk for several types of cancer, 
including PCa,30 other types of cancer do not seem to cluster evidently in HPC 
families.6,31 Only modest increases in occurrence of cancer of the breast, colon, and 
brain were seen in first-degree relatives of PCa patients.31,32 Isaacs et al. showed that 
members of HPC families have an increased relative risk for tumors of the central 
nervous system (RR=3.02; 95% CI: 1.08-8.41).31 Gibbs et al. recently reported a 
potential hereditary PCa susceptibility locus on chromosome 1p36.20 They suggest that 
the excess of brain cancers within a subset of families with a high risk for PCa, as well 
as the frequent loss of heterozygosity at 1p36 in brain cancer, is due to the same 
genetic cause.
In the present study nuclear families were ascertained through a single PCa patient, 
presented at the Division of Urologic Surgery, Washington University for radical 
prostatectomy. Eligibility criteria for this surgery are age, confined disease and general 
health. Through this ascertainment, our results may not apply to all ages and stages of 
disease. Furthermore, this study was unable to address the issue of race heterogeneity 
because of the relatively small strata of non-Caucasians (5% African-American, 2% 
Asian or Hispanic).
In summary, our findings strengthen the statistical evidence of an autosomal 
dominant mode of inheritance of PCa.
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C H A P T E R 5 
S E G R E G A T I O N A N A L Y S I S I I:
T H E N E T H E R L A N D S E X P E R I E N C E
■  Abstract. Previous segregation analyses suggest that the familial aggregation of 
prostate cancer (PCa) is due a cancer susceptibility gene, inherited in an autosomal 
dominant inheritance fashion. To date, two population-based study presented results 
from a segregati-on analysis of PCa. This study was initiated to confirm these 
population-based findings in an independent cohort of PCa families from the 
Netherlands..
PCa patients were identified through the population-based cancer-registry in the 
Netherlands and subsequently contacted through their treating urologist. Family 
history of PCa was obtained from 704 PCa probands through postal questionnaires 
and telephone contact. Maximum likelihood segregation analysis was used to test for 
Mendelian inheritance.
As none of the initially tested models adequately explained the familial clustering of 
PCa, we performed stratified analysis. In both families of young (< 66  years at 
diagnosis) and older (>66 years) symptom-diagnosed probands, the autosomal 
recessive model described the data best. The model predicted that the high-risk allele 
accounts for a large proportion (70%) of all PCa diagnosed before the age of 56, 
while for all PCa (by age 85) 7% is due to the inherited form of PCa. The life-time 
risk of PCa due to the inherited high-risk allele(s) was found to be similar to 
previous studies.
The results of this study support the hypothesis of the existence of a rare recessively 
inherited PCa susceptibility gene that causes an early age at diagnosis among 
homozygote carriers. These results strengthen the evidence that PCa is inherited in a 
Mendelian fashion within a subset of families.
■  Introduction. Similar to most Western countries, PCa (PCa) is the second most 
common cancer among males in the Netherlands, constituting 20% of all male cancer 
diagnoses.1 Besides age, race, and family history, studies on the etiology of PCa do 
not reveal any clear risk factor for the disease.
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Studies on the familial aggregation of PCa have shown that first-degree relatives of 
PCa patients have a 2 to 3 times increased risk of PCa.2,3 According to three US and 
one Swedish study, the familial aggregation of PCa can be best explained by 
Mendelian autosomal dominant inheritance (see table 5.1).4-7
Table 5.1: Segregation analyses o f prostate cancer.
Author (year)
Carter
(1992)4
Grönberg
(1997)5
Schaid
(1998)6
Verhage 
(2001)7
Cui 
(2001)8
Number of PCa 
families
691 2,857 4,228 1,199 1,476
Population source USA Sweden USA USA Australia
Population-based
data
no yes no no yes
Mean age at 
diagnosis proband
59.3 n.a. 65.6 65.3 61.0
Most likely 
Transmission model
AD AD AD* AD (AD+AR)f
Penetrance (%)
age 55
age 85 5° oo
2
63
3
89
12
97
7 (AD), 23 (AR) $ 
27 (AD), 100 (AR)
% of PCa due to age 55 43 n.a. 62 65 n.a.
disease gene by age 85 9 n.a. 16 8 n.a.
Disease allele 
frequency (%)
0.4 1.7 0.6 0.4 1.7 (AD), 8.4 (AR)
n .a .=  not available; AD= autosomal dominant; AR= autosomal recessive. *Results from 
segregation analyses including only probands diagnosed at <66 years (not assuming Hardy- 
Weinberg equilibrium). f  Results from the best fitting two-locus segregation models by Cui et al. 
are given. $ Penetrances for the AD and AR component of the best fitting two-locus model are given 
for ages 60 and 80.
Last year, Cui et al. reported segregation analyses of Australian PCa families.8 
Through the testing of two-locus models it was observed that a dominantly inherited 
increased risk contributed especially to early-onset PCa, while later onset PCa was 
mainly due to recessively inherited risks. The frequency of the autosomal dominant 
component (‘allele’) was estimated to be 1.7%, while the frequency of the autosomal 
recessive allele was 8.4%. The autosomal dominant and recessive alleles gave rise to 
a lifetime penetrance of 27% and 100%, respectively. The US reports on the 
segregation analysis of PCa found high life-time penetrances in gene carriers varying
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from 88%4 to 97%,7 with disease allele frequencies ranging from 0.3%4 to 0.6%.6 
Furthermore, the autosomal dominant models from the US studies predict that the 
high-risk allele accounts for a large proportion (43-65%) of all PCa cancer cases 
diagnosed prior to the age of 56. However, of all PCa a relatively small proportion 
is due to the high-risk allele (8-9% by the age of 85).4,7 The segregation analysis 
from Sweden reported a moderate life-time penetrance in gene carriers (63%) with a 
high population allele frequency (1.7%).5 Although the families used in the three US 
studies were not selected for a positive family history, they were selected on age, 
disease stage, and general health,4,6,7 as all three proband series used in the US 
studies consisted solely of patients with localized tumors suitable for radical 
prostatectomy. Both the Swedish and Australian studies used population-based data. 
Through estimates for presumed mode of inheritance, penetrance and frequency of 
the putative PCa disease gene, segregation analyses may facilitate the mapping of 
PCa susceptibility genes through parametric linkage methods.9 
In a previous investigation from our institute it was shown that men with a family 
history of PCa are at significantly increased risk for PCa (HR=2.9, 95% confidence 
interval (CI): 2.2-3.9). This relative risk for PCa was 2.5 (95% CI: 1.7-3.6) in the 
case of an affected father and 3.9 (95% CI: 2.4-6.4) in the case of an affected 
brother (Verhage et al. unpublished data).
The aim of the present study is to determine the mode of inheritance underlying the 
observed familial aggregation in our population of PCa probands from the 
Netherlands, and whether results from previous complex segregation analyses can be 
confirmed in an independent and unselected population of PCa families.
■ Subjects & Methods. Subjects and data collection. Case-families were 
ascertained through PCa patients (probands) newly diagnosed between July 1st 1996 
and December 31st 1999, and registered by two population-based cancer registries 
held by the Comprehensive Cancer Center (CCC) East and Rotterdam in the 
Netherlands. A total of 1,435 probands with histologically confirmed 
adenocarcinoma of the prostate were identified (International Classification of 
Diseases for Oncology, site code T185 / C61, morphology codes 8140).10 Inclusion 
criteria were: diagnosed under the age of 75 years, Caucasian, living in the 
catchment area of the CCC East and CCC Rotterdam at date of diagnosis, and being 
capable of reading and understanding the Dutch language. All recruited PCa cases 
from the CCC East area were diagnosed in either the University Medical Centre
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Nijmegen (Nijmegen), Canisius-Wilhelmina Hospital (Nijmegen), Maas Hospital 
(Boxmeer), Rijnstate Hospital (Arnhem), or the Hospital Velp (Velp). PCa cases 
from the CCC Rotterdam area were diagnosed in either the Erasmus University 
Medical Centre Rotterdam (Rotterdam, the Netherlands), or the Sint Franciscus 
Gasthuis (Rotterdam, the Netherlands).
Information on demographic factors, smoking behavior, occupation, history of 
cancer, history of prostatic diseases, and history of chronic diseases was collected by 
a postal questionnaire. In the same questionnaire similar information was requested 
on first-degree relatives.
If the PCa proband was deceased or unable to provide information, the partner was 
requested to fill out both questionnaires. Before any of the subjects were contacted, 
the treating urologist was asked for permission for his patients to participate in the 
study. For 41 cases (3%), this permission was denied. The remaining 1,394 PCa 
probands received an invitation letter, additional information and a reply card. They 
were asked to fill out and return the reply card indicating whether or not they were 
willing to participate. Seventy-five probands were excluded after sending the 
invitations because they appeared to be unable to read and understand the Dutch 
language, because they were deceased and no partner was available, or because the 
probands’ addresses were unknown.
When no reply was received within 3 weeks, a reminder was sent. A questionnaire 
was sent to all subjects who were willing to participate. Another reminder was sent 
when the questionnaire was not returned within 3 weeks. Subjects who did not return 
the questionnaires within approximately 6 weeks were contacted by telephone. When 
a returned questionnaire was incomplete, subsequent telephone calls were made for 
additional information.
Verification. All data on PCa among relatives of the PCa probands were verified 
with medical records, after obtaining written consent from these patients themselves 
or, in the case of death, from their partners or next of kin. Verification was possible 
in 49% of all PCa affected relatives. All questionnaire data on PCa appeared to be 
correct. Verification was not possible in the remaining 51% of the cases because the 
diagnosis had been made too long ago and the medical records were no longer 
available.
Segregation analysis. Maximum likelihood segregation analyses were performed on 
the age at diagnosis expressed as a censored trait using the Statistical Analysis for
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Genetic Epidemiology (S.A.G.E.) program REGTL, third release, in order to test 
specifically for Mendelian inheritance of PCa in the collected pedigrees.11 Using this 
program one can either assume that the presence (or absence) of the putative disease 
allele influences age at onset (model 1) or influences susceptibility (model 2).
For this analysis model 1 was chosen, using the class A regressive models.12 Age at 
diagnosis was used as a proxy for age at onset and is assumed to follow a logistic 
distribution described by two parameters, a  and P, with the probability distribution 
function according to Elston et a l..13 Furthermore, a susceptibility parameter y was 
used to describe the cumulative probability of PCa (assuming infinite lifespan).
f(age)= [Yae(Pi + a * age) ] / [1 +e (Pi + a * age) ]2 (1)
This symmetric distribution is similar to a normal distribution with mean -P / a, and 
variance, n3 / 3 a 2 (, where n has the value of 3.1416).
PCa was defined as a dichotomous variable (Y), where Y =1 if affected and Y= 0  if 
unaffected (censored). Parameters estimated in the analysis include: (1) qA, the 
frequency of the putative high-risk allele A; (2) Pi baseline parameters, where i 
represents an individual’s type (AA, AB, BB); (3) a, the age coefficient; and (4) y , 
the susceptibility coefficient. The susceptibility-parameter y describes the cumulative 
probability that a man develops PCa under the assumption of an infinite life-span.14 
Susceptibility y was fixed at zero for females.
The probability, or penetrance, that an individual is affected by a certain age was 
calculated for each type as:
P(Y | genotype i, age) = Y[e(Pi + a * age) ] / [1 +e (Pi + a * age) ] (2)
If the observed age at diagnosis does not follow a logistic distribution, this model 
may still be appropriate after transformation. The observed ages at diagnosis were 
therefore transformed according to: aG1 * ln(age),15 where aG1 is the geometric 
mean age at diagnosis of all non-probands (66.2 years). After transformation, the 
penetrance function can still be calculated according to:
P(Y | genotype i, age) = Y[e(Pi + a * (age * aG1)) ] / [1 +e (Pi + a * (age* aG1)) ] (3)
Tests for genetic control were implemented by postulating three types of individuals 
(AA, AB, and BB) with three corresponding transmission parameters ( t a a , t a b , and
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tb b )  describing the probability that a disease-producing factor A is transmitted from 
parent to offspring.16,17 Under hypotheses of Mendelian transmission, these 
transmission parameters are constrained to t a a = 1 . 0 ,  t a b = 0 . 5 ,  and t b b = 0 ,  
respectively. This model further assumes that the three types of parents (AA, AB, 
and BB) are in Hardy-Weinberg equilibrium, i.e. occur in the population with 
frequencies q2, 2q(1 - q), and (1 - q)2. Five models of disease transmission were 
tested against the general unrestricted model to identify the best model for these data. 
The ‘no major gene’ model assumes that baseline risk is not influenced by ‘type’,
i.e. all persons have the same age-specific risk of PCa. Single-locus Mendelian 
models assume one major locus with two alleles that act either in a codominant, 
dominant, or recessive fashion. In the codominant model each of the three genotypes 
(AA, AB, BB) have a distinct age at onset distribution, whereas the dominant and 
recessive models have two separate age at onset distributions. In the dominant model 
the AA and AB age at onset distributions overlap, in the recessive model the AB and 
BB age at onset distributions overlap.
An environmental model with potentially distinct types of individuals was also tested, 
but here the transmission probability was held constant for all individuals. X-linked 
transmission of a disease allele could not be evaluated, as the statistical package is 
unable to test for sex-linked transmission.
The likelihood ratio test (LRT) was used to test each of the five models against the 
general, unrestricted model and was computed as minus twice the natural log 
likelihood (-2ln(L)) of the general model subtracted from that for a restricted sub­
model. This difference is asymptotically distributed as a x2 distribution with degrees 
of freedom equal to the difference in the number of parameters estimated in the two 
models. To correct for ascertainment bias, the likelihood of each pedigree was 
conditioned on the proband’s affection status using his age at diagnosis as 
recorded.17,18 All study subjects with age at exam < 20 years were excluded from 
analyses.
The study protocol was approved by the Institutional Review Boards of the 
University Medical Centre Nijmegen and Erasmus University Medical Centre 
Rotterdam.
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■ Subjects & Methods. Population characteristics. The response to the invitation 
was 76% (1,007 PCa patients). Subsequently, 710 PCa patients (71%) and 518 
partners (73%) returned a questionnaire with sufficient information for the analyses. 
In further analyses, 6 PCa cases were excluded as they were non-Caucasian.
Reasons for not returning or not completing the questionnaire were: “no contact with 
relatives”, “too much effort”, “too emotional”, “too complicated to retrieve all data 
on relatives” and “no permission from relatives to give information”.
Table 5.2 summarizes the characteristics of the 704 PCa probands and their 3,982 
first-degree relatives included in the analyses. Mean age at diagnosis of the 704 PCa 
probands was 66.0 years (SD=5.8). Of all PCa probands, 17.0% (n=120) were 
screen-detected patients from the Rotterdam branch of the European Randomized 
Study of Screening for Prostate Cancer (ERSPC).19 These probands were diagnosed 
at a younger age compared to the symptom diagnosed (‘non-screened’) probands 
(64.9 vs. 66.3 years, respectively, p=0.02). Furthermore, tumors of screen-detected 
PCa probands were more often of lower grade compared to non-screened patients 
(p=0.001).
PCa was diagnosed 125 times among the 2,010 male first-degree relatives of cases 
(table 5.3). Of the probands used in the analyses, 103 (14.6%) had a positive family 
history: 50 probands had an affected father only; 43 probands had 1 affected brother, 
and 5 of these probands had an affected father as well; 8 probands had 2 affected 
brothers, of whom 2 also had an affected father; 1 proband had 4 affected brothers; 
and 1 proband had 5 affected brothers.
Segregation analysis. Table 5.4 shows the results of the segregation analyses 
including all 704 PCa proband families. All non-Mendelian and single-gene 
Mendelian models were rejected relative to the unrestricted general model. In an 
attempt to obtain genetically more homogeneous population subsets, we performed 
segregation analyses on the data of young probands (< 6 6  years at diagnose, table 
5.5), and non-screen detected probands (table 5.6).
Although a substantial improvement of fit was achieved in young probands regarding 
the Mendelian codominant and recessive models, none of the tested models 
adequately explained the familial clustering of PCa. Analyses of families of the non­
screen detected probands neither revealed a restricted model that fitted the data. In 
order to further enhance genetic homogeneity we split the data set of non-screen 
detected probands with respect to age at diagnosis of the proband (< 6 6  years in 
table 5.7, and >66 years in table 5.8).
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Table 5.2: Characteristics of 704 prostate cancer probands and 3,982 first degree
relatives.
PCa probands (total n) 704
Mean age at diagnose, years (±  SD, range) 66.0 (±  5.8, 48 -  75)
Ever smoked, n (% of total) 497 (70.6)
Screen-detected PCa, n (% of total) 120 (17.0)
Family history of PCa, n (% of total) 103 (14.6)
I 279 (39.6)
Grade, n (% of total)
II 320 (45.5)
III 88 (12.5)
Unknown 17 (2.4)
TO and T1 159 (22.6)
T2 371 (52.7)
Clinical stage, n (% of total) T3 and T4 130 (18.5)
N( + ) or M( + ) 60 (8.5)
Unknown 44 (6.3)
BPH 73 (10.4)
History of disease, n (% of total)
Prostatitis 49 (7.0)
Circumcision 23 (3.3)
Vasectomy 145 (20.6)
Father 704 (17.7)
Type of first-degree relatives, n (%)
Mother 704 (17.7)
Brother 1,306 (32.8)
Sister 1,268 (31.8)
Mean age relatives*, years (±  SD) 65.9(16.2)
* Age at diagnosis of PCa, age at time of interview, or age at time of death, whichever came first.
The analyses of data from young (<  66 years) non-screen detected probands showed 
that the two non-Mendelian models did not fit the data. The “no major gene” model, 
in which q was fixed at 1.0, was clearly rejected, when compared to the general 
unrestricted model (x2=35.87, p < 0.001). Likewise, the environmental model, 
which has equal transmission parameters for all three types of individuals AA, AB, 
and BB, differed significantly from the general model (x2=14.17, p<0.001). Both 
the dominant model (assuming P aa  = P ab^  P bb)  and the codominant model (allowing 
for three genotype-specific age at onset distributions) did not fit the data. The 
recessive model ( P a a^  P a b =  P bb) ,  however, proved to fit the data well (x2=7.95, 
p=0.093).
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The frequency of the risk-allele was estimated to be 10.1%, which implies that 1.0% 
(95% confidence interval (CI): 0.2%-2.3%) of the population is homozygote carrier 
of the risk-allele. The cumulative risk of PCa, or penetrance, for types AA 
(homozygote carriers) and types AB/BB (heterozygotes and non-carriers) as 
predicted by the recessive model is given in figure 5.1.
The analyses of data from older (>66 years at diagnosis) non-screen detected 
probands also showed that the two non-Mendelian models were clearly rejected 
(table 5.8). Again, the dominant model was rejected relative to the general model 
(x2= 15.32, p=0.004). The codominant and recessive model both fitted the data 
reasonably well (x2=6.44, p=0.092, and x2=9.27, p=0.055, respectively). The 
codominant model did not give any improvement in fit over the more parsimonious 
recessive model (x2=2.83, p=0.093). The estimated risk-allele frequency of 12.6% 
in the recessive model in this population subset implies that 1.6% of the population is 
homozygote carrier (95% CI: 0.4%-3.6%). The penetrance, for types AA and types 
AB/BB, is given in figure 5.1.
Figure 5.1: Predicted cumulative risks for type AA (homozygote carriers o f the high­
risk allele) and AB/BB genotypes, for families o f probands diagnosed < 66 years, 
and >66 years.
age at diagnose, years
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Table 5.3: Characteristics o f first-degree male relatives o f  prostate cancer probands.
Proband population
All
(n =  704)
Diagnosis < 6 6  
yrs (n =  302)
Non-screened Diagnosis < 6 6  yrs, 
(n =  584) non-screened (»=242)
Diagnosis > 6 6  yrs, 
non-screened (n =  342)
Npositive family history (%) 103 (14.6) 47 (15.6) 89 (15.2) 42 (17.4) 47 (13.7)
Affected n / total n (%) 6 8  / 1,306 (5.4) 29 / 522 (5.6) 63 / 1,061 (5.9) 28 / 439 (6.4) 35 / 622 (5.6)
Brothers Mean age at diagnose ± SD 66.0 ± 6.5 62.7 ± 6.2 6 6 . 1  ± 6 . 6 62.6 ± 6.3 69.0 ± 5.3
Mean age at exam*, ± SD 63.6 ± 10.3 60.4 ± 8.1 63.8 ± 10.4 60.4 ± 8.3 6 6 . 2  ± 1 1 . 1
Affected n / total n (%) 57 / 704 (8.1) 29 / 302 (9.6) 48 / 584 (8.2) 25 / 242 (10.3) 23 / 342 (6.7)
Fathers Mean age at diagnose, ± SD 74.0 ± 8.7 73.6 ± 8 . 8 75.1 ± 8 . 6 74.0 ± 8.9 76.4 ± 8.2
Mean age at exam, ± SD 72.2 ± 13.7 71.7 ± 13.7 72.5 ± 13.4 72.5 ± 13.1 72.4 ± 13.6
* Age at diagnosis of PCa, age at time of interview, or age at time of death, whichever came first.
Table 5.4: Parameter estimates from segregation analysis o f prostate cancer in 704 families ascertained
through a single prostate cancer proband.
Hypothesis: -2 In L Df x 2 p  - value qA
Parameter estimates
TAA TAB TBB P a a P ab P bb a y
No major gene 1532.16 6 62.62 < 0 . 0 0 1 [1 .0 ] - - - -51.09 =  P a a =  P a a 0.18 0.31
Dominant 1497.70 4 28.16 < 0 . 0 0 1 0.0194 [1 ] [0.5] [0 ] -74.82 =  P a a -78.92 0.27 0.34
Codominant 1486.52 3 17.00 < 0 . 0 0 1 0.0607 [1 ] [0.5] [0 ] -61.27 -65.61 -69.94 0 . 2 2 1 . 0
Recessive 1489.31 4 19.79 < 0 . 0 0 1 0.1270 [1 ] [0.5] [0 ] -61.65 -6 6 . 6 6 =  P a b 0 . 2 2 1 . 0
Environmental 1512.08 2 42.56 < 0 . 0 0 1 0.3122 0.530 =  TAA =  TAA -73.46 -79.02 -76.93 0.26 0.52
General 1469.52 - - < 0 . 0 0 1 0.9840 0.97 0 0 -92.40 -67.27 -63.68 0.23 1 . 0
y 2 is defined as (-2 In L) of the data under the hypothesis minus (-2 In L) of the data under the general model. Numbers in 
brackets are fixed at the indicated value; q: the frequency of the putative high-risk allele; x: transmission parameter denoting the 
probability that a parent of a given type transmits the disease-producing factor A to his or her offspring; P: baseline parameter; 
a: age adjustment parameter; y: susceptibility parameter describing the cumulative probability of prostate cancer (assuming 
infinite lifespan).
oo
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Table 5.5: Parameter estimates from segregation analysis o f prostate cancer in 302 families ascertained
through a single prostate cancer proband (age at diagnosis proband < 66 years, only).
Parameter estimates
Hypothesis: -2 In L Df 7 2 p  - value qA
TAA TAB TBB PAA P aB PBB
No major gene 701.39 6 36.79 < 0 . 0 0 1 [1 .0 ] - - - -46.77 =  P a a =  P a a 0.16 0.36
Dominant 684.79 4 20.19 < 0 . 0 0 1 0 . 0 0 2 0 [1 .0 ] [0.5] [0 ] -53.15 =  P a a -57.74 0.19 1 . 0
Codominant 676.42 3 11.82 0.008 0.0587 [1 .0 ] [0.5] [0 ] -58.50 -62.93 -67.36 0 . 2 1 1 . 0
Recessive 675.55 4 10.95 0.027 0.1063 [1 .0 ] [0.5] [0 ] -61.48 -6 6 . 6 8 =  P a b 0 . 2 2 1 . 0
Environmental 6 8 6 . 2 0 2 21.60 < 0 . 0 0 1 0.2674 0.54 =  TAA =  TAA -59.84 -124.74 -63.50 0 . 2 1 1 . 0
General 664.60 - _ _ 0.0066 1 . 0 1 . 0 0 -56.13 -59.78 -63.91 0 . 2 0 1 . 0
Table 5.6: Parameter estimates from segregation analysis of prostate cancer in 584 families ascertained
through a single prostate cancer proband (non-screen detected PCa probands, only).
Hypothesis: -2 In L Df x 2 p  - value qA
Parameter estimates
TAA TAB TBB P a a P ab P bb a y
No major gene 1344.42 6 69.24 < 0 . 0 0 1 [1 .0 ] - - - -50.00 =  P a a =  P a a 0.17 0.36
Dominant 1311.26 4 36.08 < 0 . 0 0 1 0.0067 [1 .0 ] [0.5] [0 ] -54.86 =  P a a -59.20 0 . 2 0 1 . 0
Codominant 1292.53 3 17.35 < 0 . 0 0 1 0.0541 [1 .0 ] [0.5] [0 ] -64.90 -69.42 -73.94 0.23 1 . 0
Recessive 1295.56 4 20.38 < 0 . 0 0 1 0.1160 [1 .0 ] [0.5] [0 ] -64.19 -69.30 =  P a b 0.23 1 . 0
Environmental 1319.51 2 44.33 < 0 . 0 0 1 0.0601 0.30 =  TAA =  TAA -79.85 -77.80 -81.76 0.28 0.32
General 1275.18 - - - 0.9846 1 . 0 0 0 -66.53 -62.99 -59.48 0 . 2 1 1 . 0
00
00
00 Table 5.7: Parameter estimates from segregation analysis o f prostate cancer in 242 families ascertained
through a single prostate cancer proband (non-screen detected PCa probands with age at diagnosis < 66 years
Hypothesis: -2 In L Df x 2 p  - value qA
Parameter estimates
TAA TAB TBB P a a P ab P bb a y
No major gene 635.21 6 35.87 < 0 . 0 0 1 [1 .0 ] - - - -45.28 =  P a a =  P a a 0.16 0.39
Dominant 618.12 4 18.78 < 0 . 0 0 1 0 . 0 0 2 0 [1 .0 ] [0.5] [0 ] -53.50 =  P a a -58.12 0.19 1 . 0
Codominant 608.26 3 8.92 0.030 0.0599 [1 .0 ] [0.5] [0 ] -61.14 -65.86 -70.58 0 . 2 2 1 . 0
Recessive 607.29 4 7.95 0.093 0.1005 [1 .0 ] [0.5] [0 ] -64.29 -69.76 =  P a b 0.23 1 . 0
Environmental 613.51 2 14.17 < 0 . 0 0 1 0.0520 0.99 =  TAA =  TAA -73.49 -71.89 -76.74 0.26 0.31
General 599.34 - - - 0.0363 1 . 0 1 . 0 0 . 1 -67.71 -72.14 -77.88 0.26 1 . 0
Table 5.8: Parameter estimates from segregation analysis of prostate cancer in 342 families ascertained through
a single prostate cancer proband (non-screen detected PCa probands with age at diagnosis > 6 6  years only).
Hypothesis: -2 In L Df x 2 p  - value qA
Parameter estimates
TAA TAB TBB P a a P ab P bb a y
No major gene 694.66 6 24.60 < 0 . 0 0 1 [1 .0 ] - - - -60.63 =  P a a =  P a a 0 . 2 1 0.31
Dominant 685.38 4 15.32 0.004 0.0044 [1 .0 ] [0.5] [0 ] -62.45 =  P a a -67.27 0 . 2 2 1 . 0
Codominant 676.50 3 6.44 0.092 0.0569 [1 .0 ] [0.5] [0 ] -72.88 -77.33 -81.77 0.26 1 . 0
Recessive 679.33 4 9.27 0.055 0.1264 [1 .0 ] [0.5] [0 ] -70.65 -15.60 =  P ab 0.25 1 . 0
Environmental 682.66 2 12.60 0 . 0 0 2 0.3764 0.99 =  TAA =  TAA -73.49 -75.44 -75.44 0.26 0.27
General 670.06 - - - 0.0139 1 . 0 1 . 0 0 -63.34 -66.60 -70.49 0 . 2 2 1 . 0
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■ Discussion. The results of this study suggests the existence of a rare recessively 
inherited PCa susceptibility gene that causes an early age at diagnosis among 
homozygote carriers. Although most of the previous segregation analyses favored a 
dominantly inherited PCa risk,4-7 others previously suggested a recessively (or X- 
linked) inherited risk of PCa. This suggestion is based on the observation of higher 
risks of PCa among brothers of PCa probands compared to fathers or sons of 
probands.20,21 Of course, underreporting of PCa in fathers who, unlike brothers, 
were not likely to be diagnosed by PSA, could explain this finding. An unaffected 
man whose brother was recently diagnosed with PCa may be inclined to have a PSA 
test himself. This in turn may lead to a higher occurrence and a much earlier 
diagnosis of PCa.
Last year, Cui and colleagues suggested that among PCa families from Australia, the 
familial aggregation of PCa was best explained by both the Mendelian recessive as 
well as the dominant model.8 The dominantly inherited risk mainly contributed to 
early-onset PCa (< 5 5  years at diagnosis), whereas the recessively inherited risk 
contributed predominantly to later-onset PCa. Although both Cui et al. and this study 
both report on a recessively inherited component in hereditary PCa, there are some 
differences. The proportion of early-onset PCa probands in our study was relatively 
small (5.0 % of all probands were diagnosed < 56  years) compared to the study of 
Cui et al. (16.2% of all probands, and 6.2% of their first-degree relatives were 
diagnosed at < 56 years at diagnosis). Furthermore, Cui et al. analyzed pedigrees 
including first- and second-degree family members of PCa probands, whereas we 
performed analyses using first-degree relatives only (which makes it more difficult to 
evaluate autosomal dominant inheritance).
In this study the autosomal recessive model predicted that the high-risk allele 
accounts for a large proportion (70%) of all PCa diagnosed before the age of 56, 
while for all PCa (by age 85) 7% is due to the inherited form of PCa. Although the 
high-risk allele in our study accounts for a larger proportion of PCa diagnosed before 
the age of 56 compared to the first reported segregation analysis by Carter et al. 
(70% vs. 43%, respectively),4 others reported similar results.6,7 The life-time risk of 
PCa due to the inherited high-risk allele(s) was found to be similar to the studies by 
Carter et al. and Verhage et al. (figure 5.2).467 Furthermore, we found that the 
penetrance of the putative disease-allele was different for male family members of 
younger (< 6 6  years) probands compared to male family members of older (>66 
years) probands (figure 5.1). We contribute these results to the genetic heterogeneity 
of PCa.
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Figure 5.2: Predicted cumulative risks for hereditary and sporadic prostate cancer. 
Comparison with 2 previous segregation analyses.
age at diagnose, years
So far, segregation analyses on PCa pedigrees pointed out that familial aggregation 
may be best explained by autosomal dominant inheritance of a rare susceptibility 
gene.4-8 Most known inherited cancer syndromes display a dominant pattern of 
inheritance, which may be explained by the presence of one or more tumor­
suppressor genes.22 Only several rare cancer syndromes, for example ataxia 
telangiectasia (ATM at 11q22), are inherited in a autosomal recessive fashion. A 
common theme in recessively inherited cancer syndromes is that they occur as a 
result of homozygous inactivations of genes encoding DNA repair proteins.22 
Xu et al. recently found a sequence variant (11657A/G) in the hOOG1 gene at 3p25, 
which differed significantly between 159 hereditary PCa cases and 222 controls.24 
Acting as a low-penetrant PCa susceptibility gene, hOOG1 encodes a DNA repair 
enzyme which has been hypothesized to play an important role in preventing 
carcinogenesis by repairing oxidative damage to DNA. Moreover, some have 
reported mutations in other DNA repair genes in human PCa cell-lines.25,26 
Evidence, however, of DNA repair genes causing multiplex PCa families is still 
lacking. Future linkage studies may shed light on this issue.
Linkage analyses are the traditional instrument for the mapping of chromosomal 
locations of cancer-susceptibility genes. So far, linkage analyses in PCa provided
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evidence for PCa susceptibility genes residing at 1q24-25 (HPC1), 1q42.2-43 
(PCAP), Xq27-28 (HPCX), 1p36 (CAPB), 20q13 (HPC20), and 17p 
(HPC2/ELAC2).9 Furthermore, additional evidence has been found for linkage to 
5p13.3-5q13.1, 12p13.3-12.3, 19p13.3,26 and 8p22-23.27 Although genes have 
successfully been cloned in three of the linked loci (RNASEL at 1q24-25,28,29 MSR1, 
also known as SR-A, located at the 8p22 locus,30 and HPC2/ELAC2 at 17p1131-36), 
the relative importance of variants within these genes to hereditary and sporadic 
disease are still debated. These results were obtained through the use of both 
parametric (presuming that a single locus is causative for a disease phenotype with 
known model of inheritance) and non-parametric (no specification of inheritance 
model required) linkage methods.9 The statistical power of parametric linkage 
methods is much greater than non-parametric methods when the observed disease 
phenotype adheres to the specified model of Mendelian inheritance. Therefore, the 
mode of inheritance and the parameter estimates from this study may facilitate future 
efforts in mapping susceptibility genes.
In conclusion, the results from this study have provided further statistical evidence of 
Mendelian inheritance of PCa and corroborate the concept of PCa being a genetic 
heterogeneous disease.
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C H A P T E R 6
A L L E L I C I M B A L A N C E I N H E R E D I T A R Y 
A N D S P O R A D I C P R O S T A T E C A N C E R
■ Abstract. In this study we evaluate the pattern of allelic imbalance (AI) in both 
sporadic prostate cancer (SPC) and hereditary prostate cancer (HPC) at loci which 
frequently show allelic imbalance in sporadic prostate cancer, or are believed to have 
a putative role in the disease. DNA obtained from 35 sporadic tumors and 46 
hereditary tumors were tested for AI, using a panel of 35 microsatellite markers. 
Chromosomal regions that display high frequencies of AI (>  30%) in HPC include 
1q, 5q, 7q, 8p, 13q, 16q, 17q, 18q, and 20q. In SPC high frequencies of AI were 
found at 5q, 7q, 8p, 10q, 13q. Main differences (A > 20%) in AI between HPC and 
SPC were at 1q, 10q, 17q, 18q, and 20q.
AI at the prostate cancer susceptibility loci HPC1, PCaP, and HPC20 was seen more 
often in HPC compared to SPC. It appears that there are marked differences in the 
pattern of AI between sporadic and hereditary PCa.
■  Introduction. Although prostate cancer (PCa) is the second leading cause of 
cancer related deaths among men in most Western countries, relatively little is 
known about its etiology. Over the last decades numerous studies have provided 
evidence that a positive family history is a major risk factor for prostate cancer.1 Many 
familial cancers are known to be the result of mutations in tumor suppressor genes 
(TSGs), such as BRCA1 and BRCA2 with a high life-time risk for mutation carriers.23 
TSGs are negative regulators of cell growth, which are only inactivated after two 
successive allele altering events, or ‘hits’ (Knudson’s two-hit model).4 The first hit 
may be somatic (sporadic cancer) or germinal (hereditary cancer). The loss of the 
remaining wildtype allele later in life, i.e. the second hit, initiates carcinogenesis. 
Therefore, the involvement of TSGs is indicated by allelic loss or imbalance (AI) in 
tumor tissue. Although there is an enormous variability between studies, cumulative 
data show that the most consistent AIs in (sporadic) PCa include regions on 
chromosomal arms 5q, 7q, 8p, 10q, 13q, 16q, 17q, and 18q.5
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Through linkage analyses of multiplex PCa families several regions have been 
implicated to harbor PCa susceptibility genes. These include 1q24-25 (HPC1),6 
1q42.2-43 (PCaP),7 Xq27-28 (HPCX),8 and 1p36 (CAPB).9 More recent linkage 
studies suggest that 16q,10 20q13 (HPC20),11 and 8p22-2312 may harbor susceptibility 
loci as well. The first PCa susceptibility gene to be cloned was the HPC2/ELAC2 
gene at 17p11,13 but its relative importance in PCa is still under debate.14,15 More 
recently the ribonuclease-L gene was found to be mutated in two families in which 
linkage to HPC1 was evident.16 Very few studies evaluated AI in tumors from 
hereditary prostate cancer (HPC) families, using a limited set of markers.17-19 These 
studies reported on AI at the linked loci on 1q (HPC1, PCAP, and CAPB). All three 
studies reported AI at 1q was low in hereditary cases (HPC1: ~0-10%; PCAP: ~5- 
20%; CAPB: ~4-17%), as was previously reported in sporadic tumors.20 These 
findings suggest that neither HPC1, PCAP nor CAPB act as predominant classic 
TSGs in these populations.
The aim of this study was to evaluate AI in both sporadic and hereditary prostate 
tumors, tested with a panel of 35 microsatellite markers. These markers were chosen 
at loci which (1) frequently show AI in sporadic PCa or (2) are believed to have a 
putative role in the disease.
■  Subjects & Methods. Case selection and tissue evaluation. In total, 162 prostate 
specimens (81 tumor and 81 normal) were analyzed. Sporadic tumors (n=35) of 31 
patients with clinically localized PCa were obtained throughout 1995 -  1999 after 
radical prostatectomy at the University Medical Center St Radboud, Nijmegen, the 
Netherlands and the Canisius Wilhelmina Hospital, Nijmegen, the Netherlands. 
Following surgical resection, prostate specimens were fixed as described before.21 
From 1 sporadic PCa (SPC) case 3 tumor foci were used for analysis. From 2 SPC 
cases 2 tumor foci and from 28 SPC cases 1 tumor focus was used for analysis.
All hereditary tumors (n=46) were resected from HPC cases (n=28) from different 
families. HPC specimens were collected throughout 1995 -  2000 from either (1) the 
University Medical Center Nijmegen (Nijmegen, the Netherlands), and the Erasmus 
University Medical Centre Rotterdam (Rotterdam, the Netherlands); or (2) from the 
registry of the Dutch Foundation for Detection of Hereditary Tumors, Leiden, The 
Netherlands. Tumor specimens of hereditary cases were obtained from trans-urethral 
resections of the prostate (TURP) (n=3), or radical prostatectomies (n=43). From 1 
HPC case 4 tumor foci were used for analysis. From 2 HPC cases 3 tumor foci,
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from 10 HPC cases 2 tumor foci, and from 15 HPC cases 1 tumor focus was used 
for analysis.
From each prostate specimen five 20 ^m sections were obtained for the extraction of 
genomic DNA. Two flanking, hemotoxylin and eosin stained, 4 ^m sections were 
prepared to ensure the composition of its histological components. One pathologist 
(TEGR) reviewed, graded all pathology, and indicated normal and tumor areas on 
the 4 ,um slides.
The tumor foci selected contained at least 80% malignant cells to decrease the 
possibility of masking imbalance by contamination with somatic DNA. Furthermore, 
cancer lesions with a diameter less than 5 mm were not dissected.
Information on family history was obtained through a questionnaire, or by telephone 
interview. All data on PCa in relatives of the study participants were verified 
(whenever possible) with medical records after written consent of the patients 
themselves or, in case of death, their spouses or next of kin. In SPC a family history 
of PCa in the 1st or 2nd degree was absent. HPC cases came from families that had
(1) a cluster of 3 or more 1st degree relatives with PCa; or (2) PCa in each of three 
generations in the paternal or maternal lineage; or (3) 2 or more 1st or 2nd degree 
relatives with PCa under the age of 55. All PCa cases were Caucasian, and Dutch 
residents.
Allelic imbalance analysis and quantification. Genomic DNA of all PCa cases was 
isolated from paraffin embedded prostate tissue. After deparaffinization, DNA was 
extracted using the salt precipitation technique, dissolved in TE buffer (pH 7.4), and 
stored at -20°C.
A panel of 35 microsatellite markers (table 6.1) was selected from available 
databases22 with the following characteristics: (1) a heterozygosity value >60%; and
(2) loci which frequently show AI in prostate cancer. These included 7q31.1, the 
LPL/cathepsin-B locus (8p22), BRCA2 (13q12.3), RB1 (13q14.1-14.3), E-cadherin 
(16q22.1), BRCA1 (17q21), and D C C  (18q21.3). Furthermore, we examined loci 
that have been implicated through linkage studies. These were HPC1 (1q24-25), 
PCaP  (1q42.2-43), HPC20 (20q13). Additionally, loci that are believed to have a 
putative role in this disease were chosen. These were APC/a-catenin  (5q21-22), 
PTEN/MMAC (10q23), FAS (10q24.1), and Mxi1 (10q25).
PCR products were separated on a 7% bisacrylamide gel. A fluorescent Texas Red 
label was included at the 5 ’ end of each sense primer (Amarsham Pharmacia Biotech) 
for detection on a Vistra DNA sequencer 725 (Vistra Systems). The software
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package Image QuanNT v4.2a (Molecular Dynamics) was used to analyze the data 
for AI. Alleles were quantified by peak heights, as recommended by the Perkin- 
Elmer Corp.. The ratio of allele 1 to allele 2 for the tumor was divided by the ratio 
of allele 1 to allele 2 for the normal sample of each study subject. A ratio of less 
than 0.75 or greater than 1.33 was assigned AI, as described previously.23 
Basic descriptive statistics were used to quantify the differences in AI between HPC 
and SPC. All statistical analyses were undertaken with SAS release 6.12 statistical 
software (SAS institute Inc.).24
■  Results. Mean age at diagnosis (±  SD) of HPC and SPC cases was 62.1 (±  6.8) 
years, and 63.1 years (±  4.3), respectively. Of all HPC cases 7% (n=2) had a 
gleason sum less than 6, 79% (n=22) had a gleason sum 6 to 8 , and 14% (n=4) 
had a gleason sum 8 or higher. In SPC cases 26% (n = 8) had a gleason sum less than 
6, 68% (n=21) had a gleason sum 6 to 8 , and 7% (n=2) had a gleason sum 8 or 
higher.
Of the 1610 HPC case loci (46 tumors x 35 markers) 60.1% proved to be 
informative (978/ 1,610). In the SPC group, 66.4% of the case loci was informative 
(814/ 1,225). In HPC the overall percentage AI was 30.0% (293/ 978), whereas the 
overall percentage AI in SPC was 20.6% (168/814). In table 6.1 all AI frequencies 
per microsatellite marker are summarized for both sporadic and hereditary cases. 
Figure 6.1 displays the differences in AI between the HPC and SPC group 
graphically. High frequencies of AI (>  30%) in HPC were seen at 1q24-25 
(D1S2883 and D1S218 at HPC1), 1q25-qter, 5q33-qter, 7q31.1, 7q31.1-31.2, 8p22 
(D8S261 and D8S298 at LPL/cathepsine-B),
8pter-p23. 1, 13q14.1-14.3 and 13q14.3-21.2 (D13S155 and D13S153 at RB1), 
16q13 and 16q24.2, 17q (D17S791 centromere BRCA1), and 20q13 (D20S196 at 
HPC20).
In SPC, highest frequencies of AI (>  30%) were seen at 5q33-qter, 7q31.1, 8p22 
(D8S261 and D8S298 at LPL/cathepsine-B), 10q23-24 (D10S541 and D10S215 at 
PTEN/MMAC), and 13q12.3 (D13S267 at BRCA2).
In HPC, percentages AI differed more than 15% compared to SPC for markers 
D1S412 (1q25-qter), D5S346 (5q21-22, APC/a-catenin), D7S522 (7q31.1-31.2), 
D10S185 (10q24.1, FAS), D13S153 (13q14.1-14.3, intron RB1), D16408 (16q13), 
D16S402 (16q24.2), D17S855 (17q21, intron BRCA1), D17S791 (17q, centromere 
flanking BRCA1), D18S51 (18q21.31, DCC), and D20S196 (20q13, HPC20).
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Differences in percentages AI were statistically significant (p<0.05) for markers 
D1S412, D17S791, D18S51, D20S196.
In SPC, percentages AI differed more than 15% compared to HPC for marker 
D13S267 (13q12.3, BRCA2)(not statistically significant).
Table 6.2 displays HPC («=13) and SPC (n=3) cases with at least 2 tumor foci in 
analysis. This overview is given to check for consistencies in Als within HPC or 
SPC cases. Twelve markers display AI in at least 2 foci within a case, in at least 2 of 
the 13 HPC cases. These markers are D1S2883 (1q24-25, HPC1),
D1S412 (1q25-qter), D5S211 (5q33-qter), D7S522 (7q31.1-31.2), D8S261 (8p22, 
LPL/cathepsine-B), D8S298 (8p22), D13S155 (13q14.3-21.2, RB1), D13S153 
(13q14.1-14.3, intron RB1), D16408 (16q13), D16S402 (16q24.2), D17S85(17q21, 
intron BRCA1), D18S34 (18q12.2-12.3), D18S70 (18q23), and D20S196 (20q13, 
HPC20). Three of these markers have AI in at least 2 foci within a case, in 3 or 
more HPC cases: D5S211, D8S261, and D20S196.
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Table 6.1 (A): Allelic imbalance in hereditary and sporadic prostate cancer.
HPC SPC (HPC -  SPC)
Nr Marker 
. Location (gene)
n Al/n inf* % AIf n AI/n inf. % AI A (95% CI)
D1S2883 
lq24-25 (HPC1) 12/32 37.5 8/28 28.6 8.9
(-14.8 - 32.6)
D1S218
2
lq24-25 (HPC1) 7/21 33.3 5/27 18.5 14.8
(-10.1 - 39.7)
„ D1S2785 
3
lq42.2-43 (PCAP) 7/27 25.9 3/24 12.5 13.4
(-7.8 - 34.6)
D1S412
4
lq25-qter 8/24 33.3 2/29 6.9 26.4
(5.4 - 47.4)
D5S346
5
5q21-22 (APC/a-catenin) 7/29 24.1 2/31 6.5 17.7
(-0.1 - 35.5)
„ D5S107 
6
5ql 1.2-13.3 4/25 16.0 1/28 3.6 12.4
(-3.5 - 28.4)
D5S211
7
5q33-qter 12/27 44.4 7/20 35.0 9.4
(-18.6 - 37.5)
„ D7S486 
8
7q31.1 4/30 13.3 1/24 4.2 9.2
(-5.4 - 23.7)
D7S522
9
7q31.1-31.2 10/30 33.3 3/20 15.0 18.3
(-4.7 - 41.3)
D7S523
10
7q31.1 9/30 30.0 5/26 19.2 10.8
(-11.6 - 33.1)
D7S677
11
7q31.1 6/22 27.3 8/26 30.8 -3.5
(-29.2 - 22.2)
D8S261
12
8p22 (LPL/cathepsine-B) 15/34 44.1 9/28 32.1 12.0
(-12.1 - 36.0)
D8S549
13
8pter-p23.1 7/19 36.8 4/14 28.5 8.3
(-20.9 - 37.6)
D8S298
14
8p22 (centromere flanking) 10/29 34.5 10/23 43.5 -9.0
(-35.6 - 17.6)
D10S541
15
10q23-24 (PTEN/MMAQ 7/24 29.2 8/22 36.4 -7.2
(-34.3 - 19.9)
w D10S215 
16
10q23-24 (.PTEN/MMAQ 5/21 23.8 6/18 33.3 -9.5
(-37.9 - 18.9)
D10S205
17
10q25 (Mxi 1) 3/18 16.7 6/20 30.0 -13.3
(-39.8 - 13.1)
* Number of tumors displaying allelic imbalance divided by the number of informative tumors. f
Percentage of informative tumors displaying allelic imbalance.
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Table 6.1 (B): Allelic imbalance in hereditary and sporadic prostate cancer.
HPC SPC (HPC -  SPC)
Nr
Marker
Location (gene)
n AI/n inf*. % Alf n AI/n inf. % AI A (95% CI)
18
D10S597 
10q25 (Mxi 1) 3/15 20.0 4/17 23.5 -3.5
(-32.1 - 25.0)
19
D10S185 
10q24.1 (FAS) 8/27 29.6 1/13 7.7 21.9
(-0.6 - 44.4)
20
D10S571 
10q24.1 (FAS) 7/28 25.0 5/21 23.8 1.2
(-23.1 - 25.5)
21
D13S155
13ql4.3-21.2 (RBI) 17/43 39.5 9/32 28.1 11.4
(-10.0 - 32.8)
22
D13S153
13ql4.1-14.3 (intron RBI) 13/31 41.9 7/29 24.1 17.8
(-5.5 - 41.1)
23
D13S260 
13ql2.3 (BRCA2) 5/36 13.9 4/27 14.8 -0.9
(-18.5 - 16.6)
24
D13S267 
13ql2.3 (BRCA2) 8/34 23.5 7/18 38.9 -15.4
(-42.0 - 11.3)
25
D16S421
16q22.1 (CDHl/E-cadherin) 2/15 13.3 2/12 16.7 -3.3
(-30.5 - 23.9)
26
D16408 
16ql3 9/24 37.5 4/18 22.2 15.3
(-12.0 - 42.6)
27
D16S402
16q24.2 9/23 39.1 5/25 20.0 19.1
(-6.2 - 44.5)
28
D17S855
17q21 (intron BRCA1) 15/39 38.5 5/25 20.0 18.5
(-3.4 - 40.3)
29
D17S856 
17q21 (BRCA1) 4/16 25.0 3/11 27.3 -2.3
(-36.1 - 31.5)
30
D17S800
17q (centromere BRCA1) 7/36 19.4 1/18 5.6 13.9
(-2.8 - 30.6)
31
D17S791
17q (centromere BRCA1) 13/37 35.1 4/30 13.3 21.8
(2.2 - 41.4)
32
D18S51 
18q21 (DCQ 13/29 44.8 5/29 17.2 27.6
(4.9 - 50.3)
33
D18S34
18ql2.2-12.3 10/38 26.3 6/29 20.7 5.6
(-14.7 - 25.9)
34
D18S70
18q23 8/40 20.0 5/28 17.9 2.1
(-16.7 - 21.0)
35
D20S196 
20ql3 (HPC20) 9/25 36.0 3/24 12.5 23.5
(0.5 - 46.5)
* Number of tumors displaying allelic imbalance divided by the number of informative tumors. f  
Percentage of informative tumors displaying allelic imbalance.
101
Figure 6.1: Graphic representation of percentage allelic imbalances per marker for  
HPC and SPC specimens.*
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Table 6.2: Allelic imbalance in HPC and SPC cases with 2 or more tumor foci 
within the prostate.
S01 S02 S03
1 2 1 2 3 1 2
wm
r r
CASE: H01 H02 H03 H04 H05 H06 H07 H08 H09 H10 H11 H12 H12
LESION: 1 2 3 4 1 2 3 1 2 3 1 2 1 2
-
1 2 1 2 1 2 1 2
-
1 2 1 2
1q
M1
M2
M3
M4
5q
M5
M6
M7
7q
M8
M9
M10 |
M11 1 1 1
8p
M12 |
M13
M14
10q
M15
M16
M17
M18
M19
13q
M20
M21 ■
M22
M23
M24
16q
M25
M26
M27 |
17q
M28
M29
M30
M31
18q
M32
M33 ■
M34 p r . 1
20q M35 H I
Each column per chromosome arm represents a different locus, ordened according to the sequence 
of loci in table 6.1. Black= Al in 2 or more tumor foci within a PCa case, grey= AI in 1 tumor 
focus within a PCa case. Squares with diagonal lines = only one of two, or three, tumors was 
informative and showed allelic imbalance.
103
■  Discussion. The goal of this study was to evaluate AI status of 35 micro-satellite 
markers in both SPC as HPC.
The 2 tested markers at 1q24-25, HPC1,6 showed a higher percentage of AI in both 
SPC (28.6% and 18.5%) as HPC (37.5% and 33.3%) than previously reported 
(HPC: — 0-10%, SPC: — 8—17%).17-20 Previous authors concluded that their findings 
are support against the hypothesis that HPC1 acts as a classic TSG. Our results, 
however, show frequencies of AI that are twice as high (HPC: 33.3 and 37.5%, 
SPC: 18.5 and 28.6%) and are more in favor of the hypothesis that HPC1 may act as 
a TSG within a subset of HPC and SPC. HPC1 has been previously described to 
account for a ‘fraction of HPC’,25 and will therefore not likely show AIs up to 90% 
as BRCA2 in some breast cancer populations.2 When the definition of allelic 
imbalance is more stringent (tumor-normal ratio <0.65 or >1.54), the frequencies 
of AI at HPC1 lower considerably in SPC (3.7 and 17.9%), but remain the same in 
HPC (15.6 and 28.0%).
The other putative PCa susceptibility locus at 1q42.2-43, PCAP,7 has been reported 
to show AI in 5-20% of HPC cases.19 Our results are in agreement with this finding 
(HPC: 25.9%, SPC: 12.5%).
At marker D1S412, 1q25-qter, we found a statistically significant difference in AI 
between HPC (33.3%) and SPC (6.9%). This region has never been implicated in 
linkage analyses to harbor TSGs for PCa. A more detailed set of markers in this 
region may be of help to search for a more specific location where AI occurs in HPC 
Marker D5S346 (5q21-22, APC  and a-catenin) revealed high frequency of AI in 
HPC (24.1%), but not in SPC (6.5%). Although not statistically significant, the 
difference between HPC and SPC in AI was substantial (17.7%). Previous reports 
show AIs of 17% and 43% (based on 3 AI in 7 informative PCas) suggesting that the 
APC gene may be important in PCa pathogenesis.26,27 Marker D5S211 revealed high 
frequencies of AI in both HPC and SPC (44.4, and 35.0%, respectively). 
Additionally, 3 of the 13 HPC cases with multiple tumor foci in analysis displayed 
AI in 2 foci within a HPC case (table 6.2).
Several studies have reported on AI at 7q.26,28,29 In our study, AI frequency at 
D7S486 (7q31.1) was lower than previously reported and did not differ among HPC 
and SPC. D7S523 (7q31.1) showed AIs in HPC and SPC that compare to previous 
reports (30.0 and 19.2% vs. 24%, respectively).26,28 Marker D7S522 (7q31.1-32), 
however, showed frequencies in SPC that were comparable to previous reports 
(15.0% vs —2-23%, respectively),26,28,29 but showed a higher AI in HPC (33.3%, 
statistically significant different from SPC). Marker D7S677 (7q31.1), not
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previously reported on, showed high frequencies of AI in both HPC and SPC (27.3 
and 30.8%, respectively).
Loss of chromosome arm 8p is a common event in PCa, often exhibiting frequencies 
of AI of 50% and over.26,28,30,31 The LPL and cathepsine-B genes both reside on 
8p22. Markers tested at 8p22 (D8S261 and D8S298) both displayed high frequencies 
in HPC and SPC, with AIs of 44.1, and 32.1%, respectively. Furthermore, for 
marker D8S261 we observed that in 4 of the 13 HPC cases with multiple tumor foci 
in analysis, 2 foci within a HPC case displayed AI (table 6.2).
The TSG PTEN/MMAC, located at 10q23.3, has been shown to exhibit AI in 29% of 
sporadic PCa.32 Our data (markers D10S215 and D10S541) are in agreement with 
these findings, and show no differences between HPC and SPC.
Marker D10S185 at 10q24.1 (FAS) displayed a statistically significant difference of 
21.9% in AI between HPC (29.6%) and SPC (7.7%). Although the other marker at 
the FAS locus, D10S571, displayed no differences between HPC and SPC, 
percentages of AI were high in both (25.0 and 23.8%, respectively).
On chromosome arm 13q we examined, besides BRCA2, a distinct region containing 
RB1. Bookstein et al. showed that restoring normal RB1 expression in the human 
prostate cancer cell-line DU-145 tumorigenicity was suppressed.34 Others have 
contradicted this finding.35
The markers at RB1, D13S153 and D13S155, both showed high AI in HPC and 
SPC. Marker D13S153 (intron RB1) showed a significant difference between HPC 
and SPC (41.9 and 24.1 %, respectively). Hyytinen et al. reported an AI of 4% in 26 
informative sporadic PCa tumors,33 whereas others reported AIs of 27 and 60% in 
sporadic PCa.36,37 The relative frequency of this occurrence suggests that inactivation 
of the retinoblastoma gene may be an important event in prostate carcinogenesis.
The role of breast cancer susceptibility genes BRCA1 and BRCA2 in PCa has been 
examined extensively in epidemiological and molecular studies. Overall, it is 
concluded that BRCA1 and BRCA2 play a limited role in sporadic and hereditary 
PCa.38,39 We examined 4 markers at BRCA1 (D17S855, D17S856, D17S800, and 
D17S791), and 2 markers at BRCA2 (D13S260, and
D13S267). Of the 4 markers tested at BRCA1, markers D17S855 and D17S791 
showed substantial differences between HPC and SPC (D17S855: 18.5%, and 
D17S791: 21.8%), with the latter difference being statistically significant. Our 
results in the SPC group, however, display much lower percentage AI than Goa et 
al. reported for marker D17S855 in sporadic PCa (20 versus 44%).40
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BRCA2, at 13q12.3, showed more often AI at marker D13S267 in SPC compared to 
HPC (38.9 and 23.5, respectively), although this difference was not statistically 
significant. Hyytinen et al. report a percentage AI at BRCA2 in sporadic PCa of 
8%.33 Marker D13260 at BRCA2 showed no differences between SPC and HPC.
Of the 3 markers tested for AI at chromosome arm 18q, marker D18S51 at the DCC  
gene (18q21) showed a significant difference between HPC and SPC (44.8 vs. 
17.2%, respectively).
Goa et al. reported that 5 of 11 (45%) informative PCa cases showed AI.41 Others 
reported of lower percentages AI in PCa ( — 25%).42,43
AI at the PCa susceptibility locus linked to 20q13, HPC20,1 has not been reported 
on previously. In line with the hypothesis of HPC20 acting as a TSG, possibly with a 
germline mutation in HPC, our results show that in HPC AI occurs significantly 
more often compared to SPC (36.0% vs. 12.5%, respectively). Furthermore, in 3 of 
the 13 HPC cases with multiple tumor foci in analysis, 2 or more foci within a HPC 
case displayed AI (table 6.2). These findings await confirmation in independent data 
sets to establish its relative importance for PCa.
AI has been reported at sites where TSGs have been lost in many familial cancers. 
For example, at 13q12-13, the site of breast cancer predisposing gene BRCA2, it was 
found that AI was present in 90% AI of tumors from individuals linked to BRCA2.26 
In our study we did not observe such high percentages of allelic loss at this particular 
site. Dunsmuir et al. specifically evaluated AI at the putative HPC1 locus.18 AI was 
found in 9%, 8%, and 9% for markers D1S2883, D1S158, and D1S422 at 1q24-25 
in sporadic tumors, respectively. For hereditary tumors percentages of 4, 7, and 6 
were reported for markers D1S2883, D1S158, and D1S422, respectively.
It should be noted that the families we used in the hereditary group (3-5 affected 
family members) were relatively small compared to the population in the linkage 
report of Smith et al.6 Also, our population consisted of Caucasians only.
Genetic heterogeneity within and among tumor foci within a given case makes 
interpretation of molecular analyses of PCa specimens difficult.44 In order to come to 
a better and unambiguous interpretation of the molecular analyses, it is a necessity 
not only to distinguish between normal and tumor cells but also between sub-clones 
of tumor cells. Furthermore, it is possible that regions exhibiting allelic loss could, 
in fact, be the target of allelic gains. This could result in a wrongful focus of 
attention on a chromosomal region that does not contain any TSGs. Therefore, other 
complementary methods such as CGH (which distinguishes genomic losses and
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gains) can be useful tools. Currently we are conducting CGH analyses on the tumor 
specimens of hereditary cases presented in this report.
In the present study the PCa specimens, from which DNA was isolated, were mainly 
radical prostatectomy specimens (96%). An eligibility criterion for this surgery is 
confined disease. Therefore, our results may not apply to all stages of PCa.
Over the years it is observed that sporadic tumors often have the same somatic 
changes in the genes involved in germ line mutations seen in hereditary tumors. The 
difference being that in sporadic tumors both copies of these disease-producing genes 
have to be inactivated through loss or mutation. Most tumors arise because of these 
mutations or losses of crucial genes rather than germ line mutations (which are rare 
in the general population). Therefore, this study provides insight on the 
carcinogenesis of both hereditary and sporadic PCa. This study is the first to report 
on AI in both sporadic and hereditary PCa cases using an extensive panel of 35 
markers. In conclusion, we found high frequencies of AI on multiple chromosome 
arms in PCa, with statistically significant differences in AI at D1S412 (1q25-qter), 
D17S791 (BRCA1), D18S51 (DCC), and D20S196 (HPC20). These sites of high 
frequency AI include regions described previously, as well as new regions that that 
may harbor TSGs relevant in PCa carcinogenesis.
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C H A P T E R 7
G E N E T I C A N A L Y S I S O F H E R E D I T A R Y 
P R O S T A T E C A N C E R B Y C O M P A R A T I V E 
G E N O M I C H Y B R I D I Z A T I O N
■ Abstract. To identify chromosomal alterations in families with prostate cancer 
predisposition, tumor DNAs were analyzed by comparative chromosomal 
hybridization. Nine DNAs were from tumor specimens obtained by radical 
prostatectomy, 1 specimen was obtained by transurethral resection. Most frequent 
chromosomal deletions were found for chromosomal arms 8p and 16q (50%), 
followed in frequency by deletion of 6q and 13q. Most frequent amplification was 
for 8q. Because these chromosomal alterations were also most common in sporadic 
prostate cancer, our data indicate that hereditary and sporadic tumors arise according 
to similar genetic patterns.
■  Introduction. Prostate cancer is the most frequently diagnosed cancer in men in 
industrialized countries, and, following lung cancer, the second leading cause of 
male cancer death in these countries. Epidemiological studies,1 twin studies,2-4 and 
segregation analyses5-8 have provided convincing evidence for a hereditary 
component in prostate cancer. Segregation studies predicted that 5 to 10 percent of 
all prostate cancers show this predisposition to prostate cancer.
Hereditary prostate cancer studies have been hampered by the limited number of 
large families with a high incidence of prostate cancer, the high lifetime incidence 
and the heterogeneity of the disease. Linkage studies implicated prostate cancer 
susceptibility loci on chromosomes 1q24-25 (HPC1),910 1q42-43 (PCAP),11 1p36 
(CAPB),12 Xq27-28 (HPCX),13 20q13 (HPC20)14 and more recently 8p22-23.15 
Mutations in the RNASEL gene in part of the families linked to 1q24-25 makes this 
gene a strong HPC1 candidate.16 However, for none of the other loci a candidate 
gene has been identified.
Comparative Genomic Hybridization (CGH) has been applied in the analysis of 
chromosomal alterations in sporadic prostate cancer.17-20 Although some differences 
have been reported, most frequent deletions were found for 8p, 13q and 16q,
111
followed in frequency by 6q, 10q and 17p deletion. Amplifications were seen for 7p, 
7q and 8q.
Comparison of chromosomal alterations in sporadic breast cancer, and BRCA1 and 
BRCA2 families revealed differences in chromosome patterns.21 In the present study 
we addressed the question of chromosomal alterations in hereditary prostate cancer. 
We performed CGH analysis and compared our findings with two previous 
studies.22,23
■ Samples & Methods. Tumor samples. Data of prostate cancer families were 
obtained by written consent of the patients and their relatives, and were collected 
according to the guidelines of the ethics committees of the Academic Hospital 
Dijkzigt, Rotterdam and the St Radboud Hospital, Nijmegen. Selection criteria of 
heriditary tumors were 3 first degree relatives with prostate cancer, or two first 
degree relatives with age of diagnosis at 55 years or younger. Formalin-fixed, 
paraffin-embedded prostate cancer tumor specimens were obtained from the archives 
of Pathology Departments of collaborating hospitals. From the 20 available 
specimens, 10 had to be excluded because of low percentage of tumor (less than 
75%), poor quality of DNA, limited amount of DNA, or poor labeling. Out of the 
10 samples analyzed, 9 tumor specimens were obtained by radical prostatectomy 
(RP), 1 sample was from a transurethral resection (TURP).
To isolate tumor cells, 5 consecutive 20 ^m sections were cut, flanking 5 ^m 
sections were utilized for routine hematoxylin, eosin staining. Specimens were 
reviewed by two pathologists (T.H. Van der Kwast, Dept. Pathology, Erasmus 
University and E. Ruiter, Dept. Pathology, University of Nijmegen). Tumor cells 
were isolated by scalpel scraping or by laser microdissection (Pixcell II; Arcturus 
Mountain View, CA).
DNA isolation. Genomic DNA was isolated from the tumor cells by overnight 
proteinase K incubation at 55°C, followed by phenol extraction and ethanol 
precipitation. DNA was further purified by RNAse treatment.
Comparative genomic hybridization. CGH was performed, essentially as described.24 
In brief, tumor DNAs were labelled with bio-UTP and normal reference DNA with 
digoxigenin by nick translation (nick translation system, Life Sciences, Rockville, 
MD). Labelled DNAs (200 ng each) and 15 ^g COT-1 DNA were ethanol
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precipitated and dissolved in 10 ^l hybridization mix. The probe mixture was 
denatured (5 min at 72 °C) and applied to normal lymphocyte metaphase spreads 
(Vysis Inc., Downers Grove, IL). Hybridization was for 3 days at 37 °C. Next, 
slides were washed and fluorescent detection of the biotin- and digoxigenin-labeled 
DNA probes was by fluorescein isothiocyanate(FITC)-conjugated avidin (Vector 
Labs, Burlingame, CA) and anti-digoxigenin-rhodamine (Roche Diagnostics, 
Almere, The Netherlands), respectively. Chromosomes were counterstained with 
DAPI (4’,6’-diamidino-2-phenylindole) (Sigma, St. Louis, MO) in vectrashield anti­
fade solution (Vector Labs). Images were acquired with a Leica epifluorescent 
microscope, equipped with a cooled CCD camera (Photometrics Inc., Tucson AZ). 
For CGH analysis, Quips XL software from Vysis (version 3.1.1) was used. 
Chromosomal regions were scored as deleted, if the mean green to red ratio was 
below 0.85, and gained of this ratio was above 1.15. At least 10 chromosomes were 
analyzed per sample.
■ Results & Discussion. DNAs from 10 hereditary prostate cancer specimens were 
analyzed by CGH as described in Samples and Methods. Family history and tumor 
characteristics are summarized in table 7.1.
Table 7.1: Characteristics o f study subjects.
Sample Tissue Gleason Sum Age at diagnosis
Number of 
affected relatives
1 RP 10 66 3
2 RP 7 67 3
3 TUR 9 68 3
4 RP 7 50 3
5 RP 6 53 2
6 RP 7 67 4
7 RP 7 69 6
8 RP 7 56 3
9 RP 7 60 3
10 RP 6 43 4
RP= radical prostatectomy; TURP= transuretral resection
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An example of a CGH profile is depicted in figure 7.1. In this sample, parts of, or 
the complete chromosome arms 6q, 8p, 11q, 12p, 12q, 13q, 16p, 16q and 22q are 
deleted. Gain is seen for chromosomes 3, 7, 8q and 10. A summary of all data is 
shown in figure 7.2. In 8 samples chromosomal alterations were detected (80%). All 
these samples showed chromosomal losses. Most frequent deletions were found for 
8p and 16q (both 5 times), followed by loss of 6q and 13q (3 times).
Figure 7.1: CGH profile of an individual hereditary prostate cancer DNA sample. 
Amplifications are shown at the right side o f the chromosome ideogram; loss at the 
left side.
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In 5 samples chromosomal amplification was observed, in all cases this included 8q. 
Figure 7.2 summarizes the percentages of most frequent chromosomal alterations 
and the minimal regions affected.
Figure 7.2: Summary of chromosomal losses and gains in hereditary prostate cancer 
(n = 10). Bars at the left side of the ideograms indicate loss; bars at the right side 
indicate gain of chromosomal material.
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Large-scale chromosomal analysis of hereditary prostate cancer is hampered by the 
poor quality and limited availability of archival DNAs. From the available samples 
only 50% were suited for CGH analysis. So far, two studies have reported the 
genome wide genetic analysis of prostate cancer by CGH. Rokman et al. described 
most frequent deletion of chromosomal regions 6q, 8p and 13q, and amplification of 
7q,19p and 19q.23 Verhagen et al. reported loss of 3p, 7q, 10q and 16q, and gain of 
8q in their families.22 Our data deviate at several points from both previous studies.
115
Deletions found in our CGH analysis are most closely related to the findings of 
Rokman et a l. ; amplification of 8q was also reported by Verhagen et al. All studies 
lack accuracy, due to the small number of samples analyzed.
Furthermore, selection of specific prostate cancer families with linkage to HPC-1 
and HPCX. In our series, such a linkage has not been established.
Our data strongly correlate with chromosomal alterations in sporadic prostate cancer, 
which also show most frequent deletion of 6q, 8p, 13q and amplification of 8q.17-20 
This is indicative for an identical genetic pattern of prostate cancer growth in both 
types of prostate cancer. This contrasts, the observation in breast cancer, showing 
some differences between BRCA1 and BRCA2 tumors and sporadic tumors.21
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C H A P T E R 8
L O W P E N E T R A N C E S U S C E P T I B I L I T Y I : 
T H E H  P  C 2 /  E  L  A  C 2  P O L Y M O R P H I S M
■  Abstract. Two polymorphisms were observed in the first cloned prostate cancer 
(PCa) susceptibility gene, HPC2/ELAC2 at 17p11. These two missense variants 
result in a serine (Ser) to Leucine (Leu) substitution at amino acid 217 and an alanine 
(Ala) to threonine (Thr) substitution at amino acid 541. The initial two studies from 
the US among hereditary prostate cancer (HPC) and sporadic prostate cancer (SPC) 
cases suggested that the 541Thr variant is associated with a 2.4-fold increased risk of 
PCa. Four subsequent studies from the US, and one from Finland, failed to replicate 
this association in HPC, SPC, and screen-detected PCa populations. To investigate 
whether the genotype and allelotype distributions of these polymorphisms in an 
independent Western-European population agree with the initial 2 positive reports or 
the subsequent negative reports, we initiated a pilot study.
Genomic DNA from radical prostatectomy specimens of hereditary prostate cancer 
(HPC, n=26) and sporadic prostate cancer (SPC, n=57) patients were genotyped for 
the Ser217Leu and the Ala541Thr polymorphisms in the HPC2/ELAC2 gene.
Among HPC cases we found that the Ser217Leu genotype frequencies were 62%, 
33%, and 5%, for types Ser/Ser, Ser/Leu, and Leu/Leu, respectively. Regarding the 
Ala541Thr polymorphism, the observed genotype frequencies were 92%, 8%, and 
0%, for types Ala/Ala, Ala/Thr, and Thr/Thr, respectively. In SPC cases the 
Ser217Leu genotype frequencies were 55%, 41%, and 4%, for types Ser/Ser, 
Ser/Leu, and Leu/Leu, respectively. The Ala541Thr frequencies in SPC were 98%, 
2%, and 0%, for types Ala/Ala, Ala/Thr, and Thr/Thr, respectively.
The genotype and allelotype frequencies of the Ser217Leu and Ala541Thr variants of 
HPC2/ELAC2 among patients with HPC or SPC from the Netherlands are not 
substantially different, compared to previous studies that reported no association. 
Therefore, for reasons of efficiency we decided not to genotype controls in order to 
estimate the risk of PCa among carriers of the 541Thr allele.
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■  Introduction. Over the past decades, epidemiological and molecular evidence has 
accumulated in favor of a significant hereditary component in prostate cancer (PCa) 
susceptibility.1,2
Tavtigian and colleagues were the first to identify a PCa susceptibility gene at 17p11, 
designated HPC2/ELAC2.3 A genome-wide scan of eight large Utah pedigrees 
provided suggestive evidence for linkage near marker D17S520. Fine mapping in a 
larger set of 33 families, using dense markers in the 17p11 region, revealed 
significant evidence for linkage (maximum 2-point LOD score of 4.5 at D17S1289). 
Sequence analyses of the HPC2/ELAC2 gene revealed four sequence variants, 
including a rare frameshift, and three missense changes. Two of these variants were 
found to be associated with PCa: a serine to leucine change at amino acid 217 
(Ser217Leu), and an alanine to threonine change at amino acid 541 (Ala541Thr). 
The frequency of the Leu217 allele was found to be higher among hereditary PCa 
(HPC) cases compared to unaffected men who had married into the pedigrees under 
study (13.3% vs. 6.1%, respectively). The Thr541 allele was also more prevalent in 
HPC cases compared to controls (9.8% vs. 3.4%, respectively).
Rebbeck et al. found that in an independent US population of 359 PCa cases, 
unselected for family history, and 266 controls that the 541Thr allele was associated 
with a 2.4-fold increased risk of PCa (541Thr allele frequency for PCa and controls: 
7.5% vs. 3.5%).4 The Ser217Leu genotypes did not differ among cases and 
controls.4 Subsequent studies from the US among HPC,5-7 sporadic (SPC),5 and 
screen-detected PCa families8 failed to demonstrate an increased risk of PCa due to 
either the Ala541Thr variant, the Ser217Leu variant, or their combination. In 
addition, Rokman et al. concluded that the 541Thr carrier rates in Finnish HPC and 
SPC cases did not differ from those in controls (7.5%, 7.7%, and 7.4%, 
respectively).9
The aim of the present study is to determine the genotype and allelotype distributions 
of the HPC2/ELAC2 variants in an independent Western-European population from 
the Netherlands of both SPC and HPC cases.
■  Population and Methods. Subjects. In total, 83 prostate specimens from PCa 
patients were analyzed. Prostate specimens from sporadic PCa patients (n=57) with 
clinically localized PCa were obtained after radical prostatectomy at the University 
Medical Centre St Radboud, Nijmegen, and Canisius Wilhelmina Ziekenhuis, 
Nijmegen, The Netherlands. All sporadic PCa (SPC) patients were diagnosed
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between 1996 and 1998. Family history of PCa was excluded by means of a 
questionnaire. All hereditary specimens (n=26) were from prostates resected from 
PCa cases from families that fulfilled one of the following three criteria:10 (1) A 
cluster of 3 or more first-degree relatives with PCa; or (2) PCa in each of three 
generations in the paternal or maternal lineage; or (3) 2 or more 1st or 2nd degree 
relatives with PCa under the age of 55. All hereditary prostate cancer (HPC) 
specimens were collected from 1992 to 1998 through either the University Medical 
Center, Nijmegen and the Erasmus University Medical Centre Rotterdam, 
Rotterdam, the Netherlands; or the Dutch Foundation for the Detection of Hereditary 
Tumors, Leiden, The Netherlands.
From each prostate cancer specimen five 20 ^m sections were obtained for the 
extraction of genomic DNA. Two flanking, hemotoxylin and eosin stained, 4 ^m 
sections were prepared to ensure the composition of the histological components. 
One pathologist (TEGR) evaluated all specimens and assigned normal and tumor 
areas on the 4 ^m slides. Normal areas were used for DNA extraction. All pathology 
was reviewed and graded by the same pathologist (TEGR). All cases and controls 
were male, Caucasian, and Dutch residents.
Genotyping. Genomic DNA of all PCa cases was isolated from paraffin embedded 
prostate tissue. After deparaffinization, DNA was extracted using the salt 
precipitation technique, dissolved in TE buffer (pH 7.4), and stored at -20°C.
Both variants in HPC2/ELAC2, Ser217Leu and Ala541Thr, were detected through 
amplification of the regions containing the polymorphisms of interest. First, the 
region containing the Ser217Leu variant was amplified using sense primer 5 ’- 
AGGAGGGGA-AAGCACCAACCATGGC-3 ’ and anti-sense primer 5 ’- 
CGCAAGCCTTTCTGCTGC-TCTG-3’ (Gibco Brl, Invitrogen Life Technologies, 
Breda, the Netherlands) with a 35-cycle protocol of 95°C for 3 min for 1 cycle; 94°C 
for 40 s, 55°C for 40 s, and 72°C for 40 s for 35 cycles. The Ser217Leu variant was 
detected by digestion of the amplified 152-bp fragment for 3 hours at 65°C by TaqI 
(Bio-Rad Laboratories, Veenendaal, the Netherlands). In case of the Leu-allele, the 
152-bp fragment was divided into two fragments of 84-bp and 68-bp, respectively. 
Second, the region containing the Ala541Thr variant was amplified using sense 
primer 5 ’-GTCATTACGGAGACCAGGTGG-3’ and anti-sense primer 5 ’- 
CCAGCTTTGTGG-TCCAGCCCAAC-3’ (Gibco Brl, Invitrogen Life Technologies, 
Breda, the Netherlands) with a 35-cycle protocol of 95°C for 3 min for 1 cycle; 94°C 
for 40 s, 64°C for 40 s, and 72°C for 40 s for 35 cycles; followed by an elongation
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cycle of 72°C for 10 min. Finally, the 112-bp amplified fragment was then digested 
for 3 hours with Fnu4HI (Bio-Rad Laboratories, Veenendaal, the Netherlands) at 
37°C. In case of the Thr-allele, the 112-bp fragment was divided into two fragments 
of 69-bp and 43-bp, respectively. The digested samples were separated and 
visualized on a 3% agarose gel containing ethidium bromide.
Furthermore, of 10 HPC and 3 SPC cases, we analyzed multiple tumor foci. Besides 
the tumor focus with the greatest volume, 14 additional tumor foci of the 10 HPC 
cases and 3 additional foci were analyzed of the 3 SPC cases.
Statistical Analysis. Chi-square tests were performed to evaluate Hardy-Weinberg 
equilibrium (HWE) using the statistical software SPSS version 9.1. HWE was tested 
with 1 degree of freedom.
■  Results. Of all prostate cancers 1% (n = 1) had a gleason sum less than 5, 89% 
(n=74) had a gleason sum 5 to 7 , and 10% (n = 8) had a gleason sum higher than 7. 
These percentages did not differ substantially over the HPC and SPC subgroups. 
Genotype and allele specific frequencies of the study population are shown in table 
8.1.
Among HPC cases we found that the Ser217Leu genotype frequencies were 62%, 
33%, and 5%, for types Ser/Ser, Ser/Leu, and Leu/Leu, respectively. The analysis 
of five HPC samples failed due to technical problems. These were regarded as 
missing. Regarding the Ala541Thr polymorphism, the observed genotype 
frequencies were 92%, 8%, and 0%, for types Ala/Ala, Ala/Thr, and Thr/Thr, 
respectively.
In SPC cases the Ser217Leu genotype frequencies were 55%, 41%, and 4%, for 
types Ser/Ser, Ser/Leu, and Leu/Leu, respectively. The Ala541Thr frequencies in 
SPC were 98%, 2%, and 0%, for types Ala/Ala, Ala/Thr, and Thr/Thr, 
respectively. Five SPC samples could not be determined for the Ser217Leu 
genotype, whereas 1 SPC sample failed in the determination of the Ala541Thr 
genotype. All 6 samples were regarded as missing.
Overall, neither the Ser217Leu genotypes nor the Ala541Thr genotypes differed 
significantly between the HPC and SPC subgroups (p=0.82 and p=0.24, 
respectively). The Leu allele was observed in 38% of all SPC, whereas among HPC 
the Leu-allele was present in 45.1%. The Thr allele was more prevalent among HPC 
(8% and 2%, for HPC and SPC, respectively). Moreover, the Thr allele was 
observed only in combination with (at least) one Leu allele.
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In HPC cases and SPC cases, of whom we analyzed multiple tumor foci, all 
genotypes were concordant. None of the observed allele distributions in HPC or SPC 
deviated significantly from the Hardy-Weinberg equilibrium.
Table 8.1: Genotypes o f Ser217Leu and Ala541Thr in hereditary and sporadic 
prostate cancer patients.
HPC SPC All PCa
(»=21) (»=57) (n=12)
n (%) Literature %* n(%)  Literature %f
Age at diagnosis, ± SD 61.9 ± 6.9 - 64.6 ± 5.1 - 63.8 ± 5.8
Ser/Ser 13 (62) 43-47 28 (55) 48-50 41 (57)
Ser217Leu Ser/Leu 7 (33) 44-46 21 (41) 42 28 (39)
Leu/Leu 1(5) 9-11 2(4) 8 3(4)
Test for HWEt (/;) 0.96, N.S. - 0.42, N.S. - 0.50, N.S.
Ala/Ala 24 (92) 90 55 (98) 91-92 79 (94)
Ala541Thr Ala/Thr 2(8) 9-10 1(2) 9 3(4)
Thr/Thr 0(0) 0-2 0(0) 0 2(2)
Test for HWE ( r ) 0.84, N.S. 0.95, N.S. 0.87, N.S.
Any Leu 8 (38) 42-57 23 (45) 47-52 31 (43)
Any Thr 2(8) 8-11 1(2) 8-9 3(4)
HPC=hereditary prostate cancer, SPC = sporadic prostate cancer, N .S.=not significant (p>0.05). * 
Genotype and allelotype frequencies for HPC, as reported by references [3,5,6,7,9]. f  Genotype 
and allelotype frequencies for SPC, as reported by references [4,5,9]. $ Hardy-Weinberg 
equilibrium was tested with DF=1.
■  Discussion. In the first two studies on HPC2/ELAC2, among populations of both 
HPC and SPC cases from the US, it was suggested that the variants in the gene may 
increase the risk of PCa to a modest extent.3,4 This 2.4-fold increased risk of PCa 
was not modified by race or family history. Furthermore, the Leu217/Thr541 variant 
was estimated to account for 5% of all PCa in the general population. While not 
causing multiplex families, such polymorphisms may play an important role on a 
population level, because of relatively high allele frequencies. Other examples of 
genes conferring a modestly increased PCa risk include genes encoding the vitamin 
D receptor, the androgen receptor, the 5a-reductase enzyme, and the insulin-like 
growth factors.11-14 So far, the initially reported increased risks of PCa due to 
variants in HPC2/ELAC2 have not been replicated by others in US and Finnish 
populations of HPC,5,6,7,9 SPC,5,9 or screen-detected PCa.8 Although differences
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between the first two and the five subsequent studies are unexplained, several issues 
may have contributed to this discrepancy. The odds ratios from the study by 
Tavtigian et al.. 3 may have been overestimated, as not all cases were from 
independent pedigrees. Whenever the 541Thr variant was present in a pedigree, 
from which several PCa cases were sampled, the frequency of the 541Thr allele 
would, on average, be higher compared to the situation where PCa cases are sampled 
from independent pedigrees. Moreover, the presented associations in the first two 
studies were marginal,3,4 and a single misclassified genotype may have influenced the 
main outcome.
In comparison to previous reports on the HPC2/ELAC2 variants in HPC,3 5 6 7 9 the 
overall carrier rate of the Leu allele in our study was lower (31% vs. 42-57%). 
Regarding the Ala541Thr polymorphism, the observed genotype frequencies in our 
HPC population were in line with previous reports.3,5,6,7,9 In SPC, we observed a 
lower Thr allele carrier rate in our population (2% vs. 9%).4,5,9 
In the present study the PCa specimens, from which DNA was isolated, were radical 
prostatectomy specimens. An eligibility criterion for this surgery is confined disease. 
Therefore, our results may not apply to all stages of PCa. Of course, all comparisons 
based on formal statistical testing procedures need to be interpreted cautiously, 
because of the small numbers observed, particularly among Leu/Leu, Ala/Thr, and 
Thr/Thr genotypes.
As the preliminary results of this pilot study showed that there were no marked 
differences compared to previous reports that could not replicate the associations 
reported by the initial two studies we decided, for reasons of efficiency, not to 
pursue the determination of the HPC2/ELAC2 variants in a control population.
In conclusion, the present data suggest that the genotype frequencies of the 
Ser217Leu and Ala541Thr variants of HPC2/ELAC2 are not substantially different in 
the Dutch populations of HPC or SPC, compared to previous reports on HPC and 
SPC population from North-America5-8 and Finland9 which found no association with 
PCa. Therefore, our data do not support the hypothesis that the variants in the 
HPC2/ELAC2 gene play a major role in the causation of either HPC or SPC.
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C H A P T E R 9
L O W P E N E T R A N C E S U S C E P T I B I L I T Y I I : 
T H E E  -  C A  D  H  E  R I N  G E N E P R O M O T E R 
P O L Y M O R P H I S M
■ Abstract. E-cadherin plays a major role in intercellular adhesion, cell polarity, 
and tissue architecture. We determined the relative risk of prostate cancer (PCa) 
associated with a previously reported C/A single nucleotide polymorphism at -160 
bp relative to the transcriptional start site of the E-cadherin gene promoter. Eighty- 
two PCa patients and 188 controls were genotyped.
Genotype and allele frequencies differed significantly among cases and controls. A- 
allele carriers had a higher relative risk of PCa (OR=3.6; 95% CI: 2.0-6.4) 
compared to C-only carriers.
AC and AA genotypes have an increased risk of prostate cancer (OR=3.8; 95% CI: 
2.1-6.8, and OR=1.7; 95% CI: 0.4-6.6, respectively) compared to CC genotypes.
■  Introduction. Although prostate cancer (PCa) is a common lethal malignancy 
among men in the Western world, its etiology remains unclear. Over the past 
decades, epidemiologic and molecular evidence has accumulated in favor of a 
significant hereditary component in prostate cancer susceptibility. Through linkage 
studies of multiplex PCa families , investigators have mapped PCa susceptibility loci 
at 1q24-25 (HPC1), 1q42.2-43 (PCAP), Xq27-28 (HPCX), 1p36 (CAPB), 20q13 
(HPC20), and 17p (HPC2).1 Recently, additional evidence has been found for 
linkage to 5p13.3-5q13.1, 12p13.3-12.3, 19p 13.3,2 and 8p22-23.3 These studies 
partly explain the excess risk of PCa due to rare, highly penetrant gene(s) in selected 
multiplex PCa families. The majority of all PCa, however, is sporadic (~90% ). 
Lower penetrance PCa susceptibility genes may increase the risk of PCa to some 
extent while not causing multiplex families. Nevertheless, such genes may play an 
important role on a population level, because of high allele frequencies. A number of 
genes have been implicated to confer a modestly increased PCa risk. These include 
genes encoding the vitamin D receptor, the androgen receptor, the 5a-reductase 
enzyme, and the insulin-like growth factors.4-7
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Another gene that plays a role in prostate carcinogenesis is the E-cadherin gene at 
16q22.1.
E-cadherin has been observed to act as a tumor-suppressor gene (TSG) in diffuse- 
type gastric carcinomas and lobular breast cancer, following Knudson’s two-hit 
model where methylation of the promoter serves as the second hit.8,9 This 
mechanism, however, is still under debate.10
Disruption of E-cadherin may also play an initiating role in carcinogenesis through 
the Wnt signaling pathway.11 To our knowledge, data on these initiating roles of E- 
cadherin in PCa carcinogenesis are lacking.
Aberrations in E-cadherin expression have been associated with malignant 
degeneration of prostatic epithelium, metastasis, and poor prognosis.12-14 In a study 
by Li et al. a C/A single nucleotide polymorphism (SNP) was identified at -160 bp 
relative to the transcriptional start site of the E-cadherin promoter.15 In a transient 
transfection experiment it was shown that the A-allele decreased transcriptional 
efficiency by 68% compared to the C allele. Through electrophoretic mobility shift 
and footprinting assays the C allele displayed a stronger transcriptional factor 
binding strength than the A-allele, indicating that the -160 C/A SNP has a direct 
effect on E-cadherin gene transcriptional regulation. To date however, no 
independent epidemiological evidence on the genotype and allele specific risks of the 
PCa has been reported in the literature.
■  Population and Methods. Subjects. In total, 82 prostate specimens from PCa 
patients were analyzed. Sporadic tumors (n=57) of patients with clinically localized 
PCa were obtained after radical prostatectomy at the University Medical Centre St 
Radboud, Nijmegen, and Canisius Wilhelmina Ziekenhuis, Nijmegen, The 
Netherlands. All sporadic PCa (SPC) were diagnosed between 1996 and 1998. 
Family history of PCa was excluded by means of a questionnaire. All hereditary 
specimens (n=25) were from prostates resected from PCa cases from families that 
fulfilled one of the following three criteria:16 (1) A cluster of 3 or more first-degree 
relatives with PCa; or (2) PCa in each of three generations in the paternal or 
maternal lineage; or (3) 2 or more 1st or 2nd degree relatives with PCa under the 
age of 55. All hereditary prostate cancer (HPC) specimens were collected from 1992 
to 1998 through either (1) the University Medical Center, Nijmegen and the 
Academic Hospital Dijkzigt, Rotterdam, The Netherlands; or (2) the Dutch
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Foundation for the Detection of Hereditary Tumors registry, Leiden, The 
Netherlands.
From each prostate cancer specimen five 20 ^m sections were obtained for the 
extraction of genomic DNA. Two flanking, hemotoxylin and eosin stained, 4 ^m 
sections were prepared to ensure the composition of its histological components. One 
pathologist (TEGR) assessed all patients and assigned normal and tumor areas on the 
4 ,um slides (normal areas were used in analyses). All pathology was reviewed and 
graded by the same pathologist (TEGR). Of all prostate cancers 1% (n = 1) had a 
gleason sum less than 5, 96% (n=79) had a gleason sum 5 to 8 , and 2% (n=2) had 
a gleason sum higher than 8.
Controls were subjects with benign prostatic hyperplasia (BPH; n=60), visitors to 
the urology ward (n=24), and subjects requesting vasectomy at the Dept. of 
Urology, University Medical Centre Nijmegen (n=104). From all controls venous 
blood was collected in a 10 ml vacuette® with EDTA (Greiner Labortechnik, 
Austria). Blood samples were stored at -80 oC. Controls were all ascertained from 
1997 to 2000.
All cases and controls were male, Caucasian, and Dutch residents.
Genotyping. Genomic DNA of all PCa cases was isolated from paraffin embedded 
prostate tissue. After deparaffinization, DNA was extracted using the salt 
precipitation technique, dissolved in TE buffer (pH 7.4), and stored at -20°C. 
Control DNA was isolated from peripheral blood (10 ml) by the same approach.
A 190bp fragment containing the C/A single nucleotide polymorphism at position -  
160 relative to the transcription start site in the E-cadherin promoter was amplified 
using sense primer 5 ’-TCCCAGGTCTTAGTGAGCCA-3’ and anti-sense primer 
5’-GGCCAGAGCCAATCAGCA-3’. The PCR protocol was as follows: 94°C for 1 
min for 1 cycle; 94°C for 40 s, 64°C for 40 s, and 72°C for 40 s for 35 cycles; 
followed by an elongation cycle of 72°C for 10 min. The C-allele was detected by 
digestion of the amplified 190-bp fragment by BstPI (Takara Biomedicals, Japan). 
The A-allele was detected by digestion by HincII (Takara Biomedicals, Japan). All 
study subjects were analyzed using both restriction enzymes. Genotypes were 
visualized on a 3% agarose gel (figure 9.1). Negative and positive controls were 
assessed during analysis to ensure (1) PCR products were not polluted, and (2) the 
digestion enzymes worked as they supposed to do.
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Figure 9.1: Gel-electrophoresis o f the C/A polymorphism in the E-cadherin promoter
M=Marker. 1-3=HincII digestions: CC, CA, and AA genotypes respectively. 4-6=BstPI 
digestions: CC, CA, and AA genotypes respectively.
Statistical Analysis. Statistical analyses were performed using the statistical software 
SPSS version 9.1. The odds ratios (ORs) for PCa and 95% confidence intervals 
(95% CIs) were calculated using logistic regression. As expected, no relation 
between age and genotype was present in the control group. Therefore, it was not 
necessary to correct for age. Hardy-Weinberg equilibrium (HWE) was tested with 
the chi-square test (1 degree of freedom).
■  Results. Genotype and allele specific frequencies of the study population are 
shown in table 9.1. Genotype of all study subjects were assessed using both 
restrictions enzymes. In all instances that the 5stPI-restriction was positive, the 
HincII-restriction was negative (and vice versa).
HPC cases did not differ from SPC cases with respect to genotype frequencies (chi- 
square p=0.172) or A-allele frequency (p=0.819). Among the subgroups of controls 
(BPH, vasectomy, and visitors) no differences were observed regarding genotype (p 
= 0.348) or A-allele frequency (p=0.176). Allele distributions were in Hardy- 
Weinberg equilibrium (HWE) for HPC, BPH, vasectomy, and visitors. For SPC 
(p< 0.001), and overall PCa (p< 0.001), allele distributions were not in HWE.
For PCa cases (HPC and SPC together) frequencies for the AA, CA, and CC 
genotypes were 0.04, 0.70, and 0.26, respectively. In controls (BPH, vasectomy, 
and visitors together) these frequencies were 0.05, 0.40, and 0.55, and differed 
significantly from PCa cases (p< 0.001). The A-allele was more frequent among 
cases compared to controls (0.39 vs. 0.25, p<  0.001).
Table 9.2 presents the genotype and allelotype specific odds ratios for SPC, HPC, 
and overall PCa. AA genotypes had a 1.9-fold increased risk (95% CI: 0.4-10.0) of
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SPC compared to CC genotypes, whereas the risk for CA genotypes was 5.0 (95% 
CI: 2.5-10.1) times higher than for CC genotypes. The relative risk of SPC for all 
A-allele carriers was 4.6 (95% CI: 2.3-9.3).
Table 9.1: Frequencies o f genotypes and alleles.
n
Mean age Genotype (%) Allele freq. HWE*
+ SDf AA CA CC (% ‘A’) (X2, p-value)
HPC 25 61.9 + 6.9 1 (4.0) 15 (60.0) 9 (36.0) 34.0 2.84. N.S.
SPC 57 64.6 +5.1 2 (3.5) 43 (75.4) 12 (21.1) 41.2 17.66, p< 0.001
All PCa 82 63.8 + 5.8 3 (3.7) 58 (70.7) 21 (25.6) 39.0 19.39, p< 0.001
Visitors 24 53.1 + 10.9 1 (4.2) 7 (29.2) 16 (66.7) 18.8 0.04, N.S.
BPH 60 66.0 + 7.5 3 (5.0) 24 (40.0) 33 (55.0) 25.0 0.27, N.S.
Vasectomy 104 40.0 + 5.8 5 (4.8) 44 (42.3) 55 (52.9) 26.0 1.05, N.S.
Controls t 188 50.0 + 13.8 9 (4.8) 75 (40.0) 104 (55.3) 24.7 0.96, N.S.
HPC=hereditary prostate cancer, SPC = sporadic prostate cancer, N .S.=not significant (p>0.05).
* Hardy-Weinberg equilibrium tested with x2 (DF=1). f  For prostate cancer cases mean age at 
onset of prostate cancer (± SD) is given, for controls mean age at exam is given. $ Controls 
constitute visitors, BPH patients and subjects requesting vasectomy.
Table 9.2: Genotype and allelotype specific odds ratios (95% confidence intervals) 
for sporadic, hereditary, and overall prostate cancer.
Genotype
SPC 
OR (95% CI)
HPC 
OR (95% CI)
All PCa 
OR (95% CI)
AA 1.9 (0.4-10.0) 1.3 (0.2-11.3) 1.7 (0.4-6.6)
CA 5.0 (2.5-10.1) 2.3 (1.0-5.6) 3.8 (2.1-6.8)
(reference) CC 1.00 1.00 1.00
AA and CA 4.6 (2.3-9.3) 2.2 (0.9-5.2) 3.6 (2.0-6.4)
(reference) CC 1.00 1.00 1.00
Compared to CC genotypes, AA genotypes have a relative risk of HPC of 1.3 (95% 
CI: 0.2-11.3). The relative risk of HPC among CA genotypes was 2.3 (95% CI: 
1.0-5.6). A-allele carriers had a relative risk of HPC of 2.2 (95% CI: 0.9-5.2). 
Overall, compared to the CC genotype, CA genotypes had an increased risk of PCa 
(OR=3.8; 95% CI: 2.1-6.8). AA individuals had an increased, although not 
statistically significant relative risk of PCa (OR=1.8; 95% CI: 0.4-6.6). Carriers of 
the A-allele had a higher relative risk of PCa compared to C-only carriers (OR=3.6; 
95% CI: 2.0-6.4).
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■  Discussion. We found that carriers of the A-‘risk’-allele had a 3.6-fold increased 
risk of PCa compared to C-only carriers. CA genotypes of the C/A SNP had an 
almost 4-fold increased risk of PCa compared to CC genotypes. AA individuals had 
a 1.7-fold (not statistically significant) increased risk of PCa. Notably, the risk of 
heterozygous CA individuals is higher than the risk of PCa for homozygous AA 
individuals. This effect is also seen in separate analyses of HPC and SPC. Logically, 
one would expect AA genotypes to have a greater risk of PCa compared to AC 
genotypes. Additional epidemiological data may prove useful to estimate the risks of 
PCa for homozygous ‘A ’ individuals more accurately.
In the HPC subgroup the effect of the A-allele and AA/CA genotype was less strong 
than in the SPC subgroup. This discrepancy between HPC and SPC may be due to 
the fact that in the etiology of HPC the C/A SNP plays a less prominent role 
compared to higher penetrance PCa susceptibility genes.1
The A-allele frequencies among PCa cases (0.39) and controls (0.25) in our study 
were notably lower than the frequencies reported in an abstract by Li et a l. .17 The A- 
allele frequency among 50 PCa cases and 113 controls was 0.54 and 0.39, 
respectively. From these data by Li et al. we derived that in their study population 
A-allele carriers have an increased risk of PCa, although not statistically significant 
(OR=1.8, 95%CI: 0.9-3.8). Of course, this could be due to a lack of statistical 
power.
The control group in this report consisted of BPH patients, visitors to the urology 
ward, and subjects requesting vasectomy. Analyses showed no differences among 
these control subgroups regarding genotype or allele frequencies and the allele 
distributions were in HWE (table 9.1). We chose to combine these three subgroups 
in order to increase statistical power. Analyses using either BPH, or visitors to the 
urology ward and subjects requesting vasectomy, as separate control groups showed 
similar results.
In the present study the PCa specimens, from which DNA was isolated, were radical 
prostatectomy specimens. An eligibility criterion for this surgery is confined disease. 
Therefore, our results may not apply to all stages of PCa.
In conclusion, our data show that the C/A SNP is a novel risk factor of substantial 
magnitude for PCa. This finding, along with additional independent data on this SNP 
in the future, may prove helpful in identifying susceptible individuals, ultimately 
facilitating effective intervention.
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C H A P T E R 1 0 
D I S C U S S I O N
In this thesis we have studied genetic epidemiological and molecular biologic aspects 
of hereditary prostate cancer (HPC). The study of the inherited form of prostate 
cancer (PCa) may provide knowledge of the etiology and pathogenesis of PCa in 
general. Here, all findings of the empirical studies of this thesis, and the implications 
for future research, will be briefly discussed.
© The risk of prostate cancer is influenced by a significant hereditary 
component.
In our investigation of familial aggregation of PCa (chapter 2) we found an almost 
threefold increased risk of PCa among first-degree relatives of PCa cases. The 
magnitude of the observed familial risk among male relatives corresponded to 
previous studies which reported two- to threefold familial risks.1 
Also, as reported previously by others,2 this risk was somewhat more pronounced 
for brothers of PCa probands (HR=3.9, 95% CI: 2.4-6.4) compared to fathers 
(HR=2.5, 95% CI: 1.7-3.6). The observed difference in PCa risk for fathers and 
brothers of PCa probands may be explained by an X-linked or recessive component 
in the inheritance of PCa. Another explanation is that brothers of PCa probands are 
more likely to have been diagnosed with PCa, due to the introduction of PSA testing 
in the 1990s.
Although the excess risk among family members of cancer cases could be due to 
shared environment, genetic factors, a combination of both, or chance, segregation 
analysis of the 704 PCa families from the Netherlands implied the existence of a 
Mendelian inherited ‘major gene’ (chapter 5).
In addition, the segregation analysis of 1,199 pedigrees from the Division of 
Urologic Surgery, Washington University (St Louis, MO, USA) also attributed 
familial aggregation of PCa to a Mendelian inherited major gene (chapter 4).
In conclusion, our familial aggregation and segregation analyses confirm that the 
susceptibility to PCa is determined by a significant hereditary component.
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As evidence from our and other studies for a hereditary component in PCa is 
consistent and unambiguous, we do not recommend any future familial aggregation 
or segregation analyses of PCa.
© Hereditary prostate cancer in the Netherlands is ‘site-specific’.
To date, several studies have studied the co-aggregation of PCa with malignancies at 
other sites.3-10 Among first-degree relatives of PCa cases the most consistent 
evidence for co-aggregation of PCa with other malignancies are slightly increased 
risks for tumors of the central nervous system,3,4 gastric cancer,5,6 colorectal 
cancer,3,7 and breast cancer.5,8
In line with studies from the US and Sweden,9,10 in our population from the 
Netherlands no evidence was found to support the co-aggregation of PCa with 
malignancies at other sites.
Thus, study outcomes have not been consistent so far. Discrepancies among study 
results may be due to genetic heterogeneity (PCa is probably caused by many 
different malfunctioning genes) or type I or II errors.
We conclude that PCa, at least in our population from the Netherlands, is site- 
specific and not part of an inherited cancer syndrome, such as the BRCA1 -associated 
breast and ovarium cancers.11 We do not believe that additional family studies,12 in 
order to explore the co-aggregation of PCa with other malignancies, are worthwhile. 
Of course, the identification of genetic homogeneous (sub)populations remains 
important.13 For this, other research approaches may provide evidence for a shared 
genetic mechanism underlying PCa and other malignancies in a more efficient way 
compared to family studies. For instance, linkage analysis of 12 multiplex PCa 
families with an additional family history for primary brain cancer, revealed a brain- 
PCa susceptibility locus linked to 1p36.14
© Spouse controls are valid and convenient controls in particular family studies.
In family studies, based on the case-control method, the comparison of disease 
frequency takes place among relatives of cases and controls and not among cases and 
controls themselves. Therefore, spouses may be used as ‘controls’ (of course, the 
relatives constitute the real control group), even when the condition under study is 
sex specific (chapter 3). The fact that some study participants may be unmarried or 
widowed constitutes an efficiency issue rather than a validity problem. Moreover,
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spouses have a better incentive to participate, potential recall bias is minimized, 
considerable time and financial effort is saved, and proxy data can be provided if 
necessary.
A theoretical drawback of spouse controls is the possibility of assortative mating 
related to genetic susceptibility of the disease under study. In our view, however, 
assortative mating will not lead to substantial selection bias when using the case- 
control family study for multi-factorial diseases, such as PCa, because of the 
following. First, to be of any quantitative consequence assortative mating must occur 
with respect to a common phenotypical trait. The choice of a mating partner has to 
depend to a large extent on this common phenotype. When assortative mating on a 
certain trait only accounts for a small percentage of all mating partner choices, its 
influence will be limited. Subsequently, this selective phenotype has to be strongly 
linked to the predisposition of the condition under study. Suppose only a fraction of 
disease among cases in families can be attributed to the predisposition linked to the 
selective trait, then the influence of assortative mating will, again, be limited. 
Furthermore, the predisposition of the disease also has to be present in the other 
family members in order to have a noticeable effect on familial aggregation.
With a simulation study it is illustrated that even strong assortative mating on a 
factor, which is strongly correlated with a true risk factor under study, will have a 
small to negligible effect on the observed extent of familial aggregation.
We therefore propose that spouses are valid controls in studies of familial 
aggregation of disease.
© The familial aggregation of prostate cancer is best explained by Mendelian 
inheritance.
In order to infer on the causation of the observed familial aggregation in our 
population of 704 PCa families (chapter 2), and the PCa families obtained from 
Washington University (St Louis, MO, USA), we performed complex segregation 
analyses (chapters 4 and 5).
The segregation analysis of the 1,119 St Louis pedigrees revealed that the familial 
aggregation of prostate cancer can be best explained by one (or more) autosomal 
dominant inherited risk-allele(s), carried by 0.7% of the male population. According 
to the best fitting autosomal dominant model, 97% of all carriers will be affected by 
the age of 85 years compared to 10% of the non-carriers. Furthermore, the 
autosomal dominant model predicts that the high-risk allele accounts for a large
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proportion (65%) of all prostate cancer cases diagnosed prior to the age of 56 years. 
However, of all prostate cancer a relatively small proportion is inherited (8% by the 
age of 85 years).
In the Dutch study we found that in both families of young (<  66 years at diagnosis) 
and older (>66 years) symptom-diagnosed probands, the autosomal recessive model 
described the data best. The recessive model fitted to the family data of young 
probands predicted that the high-risk allele accounts for a large proportion (70%) of 
all PCa diagnosed before the age of 56, while for all PCa (by age 85) 7% is due to 
the inherited form of PCa. The life-time risk of PCa due to the inherited high-risk 
alleles (1% of the male population is homozygote carrier) was found to be similar to 
the St Louis study and previous segregation analyses.15
The mode of inheritance and the parameter estimates from our two segregation 
analyses strengthen the evidence for an inherited form of PCa and may facilitate 
future efforts in mapping PCa susceptibility genes. The statistical power to map a 
disease-locus with parametric linkage methods, using estimates from segregation 
analyses, is much greater than non-parametric methods. However, one needs to 
realize that complex segregation analysis is unable to distinguish between the effect 
of a single locus that underlies a trait and the effects of two, or more, independently 
acting loci with similar transmission patterns. For example, multiple HPC loci would 
be detected as if they were a single locus with a disease-allele frequency equaling 
that of the sum of several disease genes.16 The erroneous use of an overestimated 
risk-allele frequency may lead to (1) an overestimate of the statistical power to detect 
a disease locus in linkage analysis, and (2) model misspecification, which reduces 
power to detect linkage.
© Hereditary and sporadic prostate cancer display both similar as well as 
different genetic abnormalities.
In the study of allelic imbalance (AI) in HPC and sporadic PCa (SPC) (chapter 6) we 
observed AI more often in HPC compared to SPC (difference in AI > 20%) at 
1q25-qter, 10q24.1 (FAS), 17q (centromere BRCA1), 18q21 (DCC), and 20q13 
(HPC20). On the one hand, these results suggest that HPC is characterized by the 
involvement of specific genetic events (AI) in the pathogenesis of the disease. On the 
other hand, of the 35 tested markers, 30 markers differed less than 20% over the 
HPC and SPC categories. Additionally, our data from comparative genomic 
hybridyzation (CGH) analyses (chapter 7) on HPC tumors showed similar
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chromosomal alterations, also suggesting that HPC and SPC arise according to 
similar genetic patterns.
In the study of HPC2/ELAC2 in chapter 8 the distribution of the genotypes of the 
HPC2/ELAC2 gene polymorphisms was found to be similar in HPC and SPC. In the 
study of the E-cadherin gene promoter polymorphism (chapter 9) we observed a less 
strong effect of the A-allele and AA/CA genotype in the HPC group compared to the 
SPC group. These results of the studies on HPC2/ELAC2 and E-cadherin suggest 
that in the etiology of HPC and SPC differences exist with respect to the involvement 
of low-penetrant susceptibility genes.
We conclude that, although most genetic alterations in prostatic carcinogenesis are 
shared, some differences in AI were observed between SPC and HPC. Further data 
on this subject will have to define these differences in genetic alterations more 
clearly.
© Prostate cancer is a genetic heterogeneous disease.
In the study of susceptibility to PCa it has become evident that great variety exists 
between independent study populations. This is illustrated by the findings from 
linkage analyses. For instance, the PCAP locus at 1q42.2-43 is the most frequent 
known locus causing multiplex PCa families in Western and Southern Europe.17,18 By 
contrast, Gibbs et al. reported that in the US PCAP may only account for a relatively 
small proportion of HPC families.19 Moreover, many attempts of replicating linkage 
to high-risk loci like 1q24-25 (HPC1), 1p36 (CAPB), and Xq27-28 (HPCX) failed 
when examined in independent study populations.13
These studies stress the importance of subgroup identification which allow for 
defining genetic homogeneous populations, facilitating the mapping of disease- 
producing loci possibly harboring PCa susceptibility genes.
Clues to the genetic heterogeneic nature of prostatic carcinogenesis and pathogenesis 
are also given by molecular studies. Similar to the findings by Ruijter et al.,20 the 
results from the AI study in chapter 4.1 show that great variability exists in genetic 
alterations among separate tumor foci within a given case. In order to come to a 
better and unambiguous interpretation of molecular analyses, with the aim of 
discerning specific cancer-pathways and the involved genetic changes, it is a 
necessity not only to distinguish between normal and tumor cells but also between 
sub-clones of tumor cells. Although this was anticipated in this study as well, it 
proved not to be feasible because of limited man-power.
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® The HPC1, PCAP, and HPC20 loci may account for a significant proportion 
in the causation of multiplex prostate cancer families.
Several genomic regions have been implicated to harbor PCa tumor suppressor genes 
(TSGs), including 1q24-25 (HPC1),21 1q42.3-42 (PG4P),16 and 20q13 (HPC20).22 
Due to the ‘two-hit’ mechanism underlying the inactivation of TSGs,23 the 
involvement of TSGs is indicated by AI in tumor tissue. The first three studies on AI 
of HPC from the UK, Sweden, and Iceland at the linked loci at 1q (HPC1, PCAP) 
reported relatively low percentages AI in hereditary cases (HPC1: 7-11%; PCAP: 
20%),24-26 similar to previously reported AI in sporadic tumors.27 In our study higher 
percentages of AI were observed (HPC1: 38%; PCAP: 26%; HPC20: 36%). 
Moreover, Cancel-Tassin et al. estimated the proportion of HPC due to PCAP up to 
50%.18 The aggregate of these findings support the PCa susceptibility loci at 1q and 
20q as important determinants in the causation of HPC in western Europe. 
Identification of mutations in genes residing at these loci, which may explain our 
findings, is still awaited.
® The contributions of variants in the HPC2/ELAC2 gene in the Netherlands to 
prostate cancer etiology is limited.
The first two studies on the HPC2/ELAC2 gene polymorphisms, in populations of 
both HPC and SPC cases from the US, suggested that the Ala541Thr variant in the 
gene may increase the risk of PCa up to 2.4-fold.28,29 Subsequent studies from the 
US among HPC,30-32 SPC,30 and screen-detected PCa families33 failed to 
demonstrate an increased risk of PCa due to either the Ala541Thr variant, the 
Ser217Leu variant, or their combination. Likewise, Rokman et al. concluded that the 
541Thr carrier rates in Finnish HPC and SPC cases neither differed from those in 
controls.34
Results from our study of HPC2/ELAC2 (chapter 8) show that the genotype 
frequencies of the Ser217Leu and Ala541Thr variants of HPC2/ELAC2 are not 
substantially different in the Dutch populations of HPC or SPC, compared to 
previous reports on HPC and SPC population from North-America30-33 and Finland34 
which found no association with PCa. Therefore, our data suggest that the role of the 
variants in the HPC2/ELAC2 gene in our western European population is probably 
limited in the causation of both HPC or SPC.
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® The E-cadherin gene promoter polymorphism is a candidate low-pentrance 
PCa susceptibility gene.
In 2000, Li et al. reported a C/A single nucleotide polymorphism (SNP) at -160 bp 
relative to the transcriptional start site of the E-cadherin promoter, in which the A- 
allele decreased transcriptional efficiency by 68% compared to the C allele.35 As 
disruption of E-cadherin protein expression has been hypothesized to play an 
initiating role in carcinogenesis through the Wnt signaling pathway,36 we genotyped 
HPC and SPC cases, and controls for the C/A SNP (chapter 9). AC and AA 
genotypes had an increased risk of prostate cancer (OR=3.8; 95% CI: 2.1-6.8, and 
OR=1.7; 95% CI: 0.4-6.6, respectively) compared to CC genotypes. Overall, A- 
allele carriers had a higher relative risk of PCa (OR=3.6; 95% CI: 2.0-6.4) 
compared to C-only carriers. As such genes often have high allele frequencies, they 
may play, from a public health perspective, a more important role in PCa etiology 
than high-penetrant PCa susceptibility genes which cause multiplex PCa families. 
The risks of PCa associated with the C/A polymorphism, are relatively high 
compared to the risks associated with known PCa-associated polymorphisms, such as 
the vitamin D receptor gene and the androgen receptor.37
Of course, the importance of the reported associated between the C/A SNP and 
cancers at different sites will become clear only after corroboration from independent 
study populations. Additional study of the C/A SNP and its role in human cancer is 
currently performed at our institution.
■ HPC: implications for screening strategies and the urologist. A study from 
Sweden found that most men with affected fathers were interested in knowing 
whether PCa could be inherited.38 Furthermore, they were inclined to undergo 
screening and, when possible, genetic testing. In a similar study from the US 
comparable results were obtained.39 To date, however, susceptibility for the 
development of PCa cannot be evaluated by means of a laboratory test. Despite the 
fact that 3 high-penetrant PCa susceptibility genes have been cloned, it will take 
some time before specific clinical genetic tests will become commonly available. 
Another complicating factor is that research on HPC has suggested that one or a few 
HPC genes will not account for the majority of hereditary disease (as BRCA1 and 
BRCA2 do in hereditary breast cancer for instance). Rather, there are likely to be 
quite a number of susceptibility genes, some interacting with each other or the 
environment, that will contribute to PCa occurrence.
141
At present, unaffected individuals from multiplex PCa families may be screened 
using PSA, possibly supplemented by digital rectal examination (DRE) and 
transrectal ultrasound (TRUS).
The relevance of screening PCa in men from HPC families seems obvious, but so far 
evidence is sparse that a lower PCa mortality or improved patient survival can be 
achieved through early detection in both the general population and in high-risk PCa 
families.40,41
In many medical centers it is recommended that screening is to be offered to men with 
a positive family history. Although it is suggested that screening within HPC families 
should commence early (before the age of 50),42 there is no consensus yet about the 
starting age for screening. Of course, research on HPC shows that hereditary disease 
occurs at a younger age compared to sporadic PCa, but it remains unclear whether 
PSA screening in HPC families should start prior to the age of 50.
The Netherlands Foundation for the Detection of Hereditary Tumors, in association 
with the Dutch Urological Association (DUA), advises to start screening within HPC 
families according to an adaptation of the screening protocol of the European 
Randomized Study of Screening for Prostate Cancer (ERSPC) (figure 10.1). 
First-degree relatives should be examined by the general practitioner once every 2 
years from the age of 50, or 5 years younger age than the youngest patient in the 
family (with the youngest patient < 70 years) by means of PSA. By comparison, in the 
ERSPC a screening interval of 4 years is employed.
In case of a PSA value > 3.0 ng/ml the suspected patient is referred to a urologist, 
who performs DRE, TRUS with systematic needle biopsies and additional sextant 
biopsies. In case no histological abnormalities are found, a reevaluation takes place 
after 2 years (figure 10.1).
■ Conclusions and future perspectives. So far, research of HPC has shown that 
the inherited genetic predisposition to PCa is very complex. Besides the identification 
of some low penetrant PCa susceptibility genes implicated in PCa etiology, linkage 
analyses have revealed several high penetrant PCa susceptibility loci potentially 
harboring tumor-suppressor genes. At three of these loci genes have been cloned and 
mutations identified (HPC2/ELAC2, RNASEL, and MSRI). One reason for trying to 
clone PCa susceptibility genes is to gain the ability to test for an inherited 
susceptibility to PCa. However, the development of such tests are complicated as 
PCa presents itself as a tremendous genetically heterogeneous disease.
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Figure 10.1: Protocol for screening PCa in healthy men from HPC families 
according to the Netherlands Foundation for the Detection of Hereditary Tumors 
(STOET), in association with the Dutch Urologic Association (DUA).
Additionally, the PCa susceptibility genes cloned so far are suspected to play a 
limited role in both SPC and HPC.
Until now, the elucidation of the genetic basis of cancer has been accomplished 
typically by one gene at a time. The newly developed microarray technologies and 
the advancements made over the last years in sequencing the entire human genome, 
together with the mapping of thousands of genes and variations in DNA, will have a 
dramatic impact on future research.43 Molecular analyses (AI and CGH) have 
provided a first map of chromosomal and allelic alterations in PCa. Unfortunately 
many target genes remain to be identified, in particular the suspected TSG(s) at 
commonly deleted chromosomal arms 8p and 13q and the putative amplified 
oncogene(s) at 8q. Using microarray technology, numerous genes which are possibly 
involved in carcinogenesis can be monitored simultaneously with respect to their (1) 
expression, e.g. cDNA arrays, and their (2) sequence, e.g. oligonucleotide arrays.44 
This technology enables researchers to pinpoint differences in genes, and their 
expression level, from HPC, SPC, and ‘normal’ subjects much more efficiently
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compared to studies using conventional AI, CGH, or genotyping of single nucleotide 
polymorphisms. Once genes have been found that play a role in PCa, tissue 
microarray (TMA) technology may be applied in order to determine their clinical 
significance by analyzing candidate genes in hundreds of individual tissue samples 
simultaneously.45 Inherent to these techniques, valid statistical procedures need to be 
developed in order to process the abundance of biological data that will become 
available.
Through the recognition and understanding of the molecular mechanisms underlying 
prostatic carcinogenesis it is hoped that better tools for prevention, diagnosis, 
prognostic evaluation, and treatment can be developed. Microarray technology is 
expected to be the first major step towards the implementation of genome based 
‘tailor-made’ medicine: through the evaluation of gene expression profiles, 
individual tumors and disturbed molecular pathways may be classified, which may 
facilitate targeted treatment practices.
In 2000, almost 16 million individuals inhabited the Netherlands.46 Of these, over 2 
million individuals were aged 65 years or older. Statistics Netherlands estimated that 
the latter population may almost double in the next 50 years. Whereas the ratio of 
individuals aged 65 years or older versus individuals 64 years or younger was 21.9 
percent in the year 2000, this ratio will reach 34.5 and 38.9 percent by the years 
2025 and 2050, respectively. 46
Furthemore, the latest report from the Netherlands Cancer Registry shows that since 
1998 PCa is the most often diagnosed malignancy among males in the Netherlands.47 
This may, in part, be due to the increased screening activities.
Nevertheless, the growth and ageing of the Dutch population, and the population of 
the Western world in general, will lead to a staggering increase in the number of 
PCa diagnoses, which in turn will have an enormous impact on Western health care 
systems.
This necessitates an increase of our research activities in order to comprehend the 
mechanisms underlying prostatic carcinogenesis and ultimately control the disease.
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S U M M A R Y
Although prostate cancer (PCa) is a common lethal malignancy among men in the 
Western world, many questions concerning its etiology remain unanswered. The 
growth and ageing of the population of the Western world will lead to a staggering 
increase in the number of PCa diagnoses, which in turn will have an enormous 
impact on Western health care systems. This stresses the importance to gain insight 
in the etiology of the disease. However, besides age and race, family history remains 
the only well established risk factor for PCa. In the etiology of the sporadic and the 
inherited forms of PCa, the same malfunctioning genes may be involved. As genetic 
defects are typically more easily detected in inherited cancer cases, the study of 
inherited PCa may provide important leads for prostatic carcinogenesis in general. 
Chapter 1 provides an extensive review on the literature of the etiology of hereditary 
PCa (HPC).
Chapter 2 addresses the issue of the familial aggregation of PCa. Also, to assess 
possible genetic heterogeneity, we investigated the co-aggregation of PCa with 
malignancies at other sites. In a population-based family study, information on 
12,575 first-degree relatives of 704 PCa patients (‘probands’) and 1,371 controls was 
collected through postal questionnaires and telephone interviews. All probands were 
Caucasian and newly diagnosed with PCa between July 1996 and December 1999. 
All reported PCa occurrence in first-degree relatives was verified through medical 
records. In order to estimate the familial risk, cancer occurrence among case- 
relatives was compared to control-relatives using random-coefficient proportional 
hazards regression analyses.
PCa was diagnosed 125 times among the 2,010 male first-degree relatives of cases. 
Of the 704 probands used in the analyses, 103 (14.6%) had a positive family history: 
50 probands had an affected father only; 43 probands had 1 affected brother, and 5 
of these probands had an affected father as well; 8 probands had 2 affected brothers, 
of whom 2 also had an affected father; 1 proband had 4 affected brothers; and 1 
proband had 5 affected brothers.
In our population, PCa has a strong familial component which is reflected by a 2.9- 
fold increased risk (95% Confidence Interval (CI): 2.2-3.9) of PCa for first-degree
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relatives of PCa patients. This familial risk was higher among brothers (3.9, 95% 
CI: 2.4-6.4) compared to fathers (2.5, 95% CI: 1.7-3.6). Cancers at other sites did 
not co-aggregate with PCa. Our data suggest that familial PCa, at least in this 
Western European population, is ‘site-specific’, and not part of an inherited cancer­
syndrome.
In the study described in chapter 2, spouses of PCa cases (and patients having 
urothelial cell carcinomas) were used as controls. Chapter 3 evaluates the 
(dis)advantages of spouses as controls in studies of familial aggregation of disease. It 
is argued that the use of spouse controls can be time and cost efficient, because of 
easy accessibility and their ability to provide proxy data on the patients’ relatives if 
necessary. Furthermore, with spouse controls a higher response rate and less recall 
bias can be expected compared to population controls. A theoretical drawback is the 
possibility of assortative mating related to genetic susceptibility of disease under 
study.
Using a simulation study it is illustrated that even strong assortative mating on a 
factor, which is strongly correlated with a true risk factor under study, will have a 
small quantitative effect on the observed extent of familial aggregation.
To evaluate the underlying mechanism of the observed familial aggregation of PCa, 
segregation analyses were performed to assess the possible existence of a Mendelian 
inheritance of PCa (chapters 4 and 5). First, 1,199 PCa pedigrees were analyzed, 
which were ascertained through single, unrelated, PCa probands (chapter 4). All 
probands were diagnosed between January 1991 and December 1993, and presented 
for radical prostatectomy at the Division of Urologic Surgery, Washington 
University in St Louis, MO (USA). Previously it was shown that men from this 
population with a family history of PCa are at a significantly increased risk for PCa: 
the relative risk for PCa was 3.5 (95% confidence interval (CI): 2.4-5.0) in the case 
of an affected father and 4.7 (95% CI: 3.0-7.5) in the case of an affected brother. 
Maximum likelihood segregation analysis was used to test specifically for Mendelian 
inheritance of prostate cancer.
Segregation analyses revealed that the familial aggregation of prostate cancer can be 
best explained by autosomal dominant inheritance of a rare (q=0.0037) high-risk 
allele. According to the best fitting autosomal dominant model, 97% of all carriers 
will be affected by the age of 85 compared to 10% of the non-carriers. Furthermore, 
the autosomal dominant model predicts that the high-risk allele accounts for a large
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proportion (65%) of all prostate cancer cases diagnosed prior to the age of 56. 
However, of all prostate cancer a relatively small proportion is inherited (8% by the 
age of 85).
In the second study of segregation analysis of PCa we evaluated the observed 
familial aggregation of PCa of chapter 2 using all 704 PCa probands from the 
Netherlands (chapter 5).
None of the initially tested models adequately explained the familial clustering of 
PCa, we performed stratified analysis. In both families of young (< 6 6  years at 
diagnosis) and older (>66 years) symptom-diagnosed probands, the autosomal 
recessive model described the data best. The model predicted that the high-risk allele 
accounts for a large proportion (70%) of all PCa diagnosed before the age of 56, 
while for all PCa (by age 85) 7% is due to the inherited form of PCa. The life-time 
risk of PCa due to the inherited high-risk allele(s) was found to be similar to 
previous studies.
The results of both studies on segregation analysis of PCa support the hypothesis of 
the existence of a rare inherited PCa susceptibility gene that causes an early age at 
diagnosis among ‘carriers at risk’ (i.e. heterozygotes and homozygotes in chapter 4, 
homozygotes in chapter 5).
In chapter 6 we evaluate the pattern of allelic imbalance (AI) in both sporadic 
prostate cancer (SPC) and hereditary prostate cancer (HPC) at loci which frequently 
show allelic imbalance in sporadic prostate cancer, or are believed to have a putative 
role in the disease. DNA was obtained from 35 sporadic tumors and 46 hereditary 
tumors. The latter specimens were collected throughout 1995-2000 from either (1) the 
University Medical Center Nijmegen (Nijmegen, the Netherlands), and the Erasmus 
University Medical Centre Rotterdam (Rotterdam, the Netherlands); or (2) from the 
registry of the Dutch Foundation for Detection of Hereditary Tumors, Leiden, The 
Netherlands. All tumors were tested for AI, using a panel of 35 microsatellite 
markers.
Chromosomal regions that display high frequencies of AI (>  30%) in HPC include 
1q, 5q, 7q, 8p, 13q, 16q, 17q, 18q, and 20q. In SPC high frequencies of AI were 
found at 5q, 7q, 8p, 10q, 13q. Main differences (A >  20%) in AI between HPC and 
SPC were at 1q, 10q, 17q, 18q, and 20q. AI at the prostate cancer susceptibility loci 
HPC1, PCaP, and HPC20 was seen more often in HPC compared to SPC.
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We conclude that, although most genetic alterations in prostatic carcinogenesis are 
shared, some differences in AI were observed between SPC and HPC. Further data 
on this subject will have to define these differences in genetic alterations more 
clearly.
In chapter 7 we investigated possible chromosomal alterations in HPC, using the 
comparative genomic hybridization (CGH) technique. Nine DNAs were from tumor 
specimens obtained by radical prostatectomy, 1 specimen was obtained by 
transurethral resection. Most frequent chromosomal deletions were found for 
chromosomal arms 8p and 16q (50%), followed in frequency by deletion of 6q and 
13q. Most frequent amplification was for 8q. Because these chromosomal alterations 
were also most common in sporadic prostate cancer, our CGH data suggests that 
hereditary and sporadic tumors arise according to similar genetic patterns.
The studies presented in chapters 8 and 9 describe two polymorphisms which have 
been associated with PCa risk. First, we investigated the previously described 
HPC2/ELAC2 polymorphisms (chapter 8). These two missense variants in the 
ELAC2 gene at 17p11 result in a serine (Ser) to Leucine (Leu) substitution at amino 
acid 217 and an alanine (Ala) to threonine (Thr) substitution at amino acid 541. The 
initial two studies from the US among hereditary prostate cancer (HPC) and sporadic 
prostate cancer (SPC) cases suggested that the 541 Thr variant is associated with a 
2.4-fold increased risk of PCa. Four subsequent studies from the US, and one from 
Finland, failed to replicate this association in HPC, SPC, and screen-detected PCa 
populations.
Genomic DNA from radical prostatectomy specimens of hereditary prostate cancer 
(HPC, n=26) and sporadic prostate cancer (SPC, n=57) patients were genotyped for 
the Ser217Leu and the Ala541Thr polymorphisms in the gene.
Among HPC cases we found that the Ser217Leu genotype frequencies were 62%, 
33%, and 5%, for types Ser/Ser, Ser/Leu, and Leu/Leu, respectively. Regarding the 
Ala541Thr polymorphism, the observed genotype frequencies were 92%, 8%, and 
0%, for types Ala/Ala, Ala/Thr, and Thr/Thr, respectively. In SPC cases the 
Ser217Leu genotype frequencies were 55%, 41%, and 4%, for types Ser/Ser, 
Ser/Leu, and Leu/Leu, respectively. The Ala541Thr frequencies in SPC were 98%, 
2%, and 0%, for types Ala/Ala, Ala/Thr, and Thr/Thr, respectively.
The genotype and allelotype frequencies of the Ser217Leu and Ala541Thr variants of 
HPC2/ELAC2 among patients with HPC or SPC from the Netherlands are not
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substantially different, compared to previous studies that reported no association. 
Therefore, for reasons of efficiency we decided not to genotype controls in order to 
estimate the risk of PCa among carriers of the 541Thr allele.
The other polymorphism we investigated is the C/A single nucleotide polymorphism 
at -160 bp relative to the transcriptional start site of the E-cadherin gene promoter 
(chapter 9). E-cadherin plays a major role in intercellular adhesion, cell polarity, and 
tissue architecture. We determined the relative risk of PCa associated with this 
polymorphism by genotyping eighty-two PCa patients and 188 controls.
Genotype and allele frequencies differed significantly among cases and controls. A- 
allele carriers had a higher relative risk of PCa (OR=3.6; 95% CI: 2.0-6.4) 
compared to C-only carriers. AC and AA genotypes have an increased risk of PCa 
(OR=3.8; 95% CI: 2.1-6.8, and OR=1.7; 95% CI: 0.4-6.6, respectively) 
compared to CC genotypes.
In the HPC subgroup the effect of the A-allele and AA/CA genotype was less strong 
compared to sporadic PCa, which may be due to the fact that in the etiology of HPC 
the C/A SNP plays a less prominent role compared to higher penetrance PCa 
susceptibility genes.
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S A M E N V A T T I N G
Hoewel prostaatkanker (PCa) één van de meest voorkomende vormen van kanker is 
onder mannen in de westerse wereld (in Nederland is PCa de meest voorkomende 
kanker), is over de oorzaken van deze ziekte nog maar weinig bekend. Door de groei 
en vergrijzing van de bevolking in de westerse wereld zal het aantal PCa-diagnoses 
schrikbarend hoog worden, wat zijn weerslag zal hebben op de gezondheidszorg. 
Mede hierdoor is het van belang inzicht te krijgen in de oorzakelijke factoren van 
PCa. Tot op heden zijn leeftijd, ras en familiegeschiedenis de enige bekende 
risicofactoren voor PCa.
Mogelijkerwijs zijn in de etiologie van de sporadische en erfelijke vorm van PCa 
dezelfde disfunctionerende genen betrokken (zoals eerder is waargenomen bij andere 
type tumoren). Omdat genetische defecten vaak gemakkelijker op te sporen zijn in de 
erfelijke vormen van kankers kan de studie naar erfelijk PCa (HPC) belangrijke 
inzichten verschaffen voor de prostaatcarcinogenese in het algemeen. Hoofdstukl 
geeft een uitgebreid overzicht van de literatuur op het gebied van HPC.
Hoofdstuk 2 behandelt de familiaire aggregatie van PCa. Ook werd de co-aggregatie 
van PCa met andere maligniteiten onderzocht om mogelijke genetische heterogeniteit 
vast te stellen. In deze studie werd met behulp van vragenlijsten, en indien nodig met 
telefonische interviews, informatie verzameld van 12575 eerstegraads familieleden 
van 704 PCa patiënten (‘probanden’) en 1371 controles. Alle probanden waren 
Kaukasisch en zijn in de periode van juli 1996 tot en met december 1999 met PCa 
gediagnosticeerd. Alle gerapporteerde PCa onder de familieleden werden, indien 
mogelijk, geverifiëerd met medische dossiers. Het risico op PCa en andere vormen 
van kanker van eerstegraads familieleden van de probanden werd vergeleken met 
diezelfde risico’s van eerstegraads familieleden van de controles. Hiervoor werd het 
Cox proportional hazards model gebruikt.
PCa werd 125 keer gediagnosticeerd bij de 2010 mannelijke eerstegraads 
familieleden van probanden. Van de 704 probanden die gebruikt zijn in de analyse 
hadden 103 (14,6%) een positieve familiegeschiedenis ten aanzien van PCa: 50 
probanden hadden alleen een vader met PCa; 43 probanden hadden 1 broer met PCa, 
waarvan er 5 ook een aangedane vader hadden; 8 probanden hadden 2 aangedane
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broers, van wie 2 ook een aangedane vader hadden; 1 proband had 4 broers met 
PCa; en 1 proband had 5 broers met PCa.
Uit deze studie bleek dat PCa een sterke familiaire component had: het risico op PCa 
onder mannelijke eerstegraads familieleden van probanden was 2.9 maal zo hoog 
(95% betrouwbaarheidsinterval (BI): 2.2-3.9) vergeleken met mannelijke 
eerstegraads familieleden van controles. Dit familiaire risico was hoger onder broers 
(HR=3.9, 95% BI: 2.4-6.4) vergeleken met vaders (HR=2.5, 95% BI: 1.7-3.6). 
Maligniteiten, anders dan PCa, vertoonden geen co-aggregatie met PCa. Onze 
gegevens suggereren derhalve dat PCa, ten minste in onze West-Europese populatie, 
geen onderdeel uitmaakt van een erfelijk kanker syndroom.
In de studie in hoofdstuk 2 zijn partners van PCa- (en blaaskanker)patiënten als 
controles gebruikt. In hoofdstuk 3 worden de na- en voordelen van het gebruik van 
partners als controles in onderzoeken naar familiaire aggregatie van ziekte 
onderzocht. Het gebruik van partners als controles kan efficiënter zijn vergeleken 
met andere soorten controles, zowel ten aanzien van tijd als geld. Dit vanwege de 
gemakkelijke toegankelijkheid (via de patiënten) en de mogelijkheid van het 
verstrekken van gegevens over de patiënt, bijvoorbeeld in het geval dat de patiënt 
overleden is. Ook is de verwachting dat de respons hoger en de mate van recall bias 
kleiner is bij partners in vergelijking met controlepersonen uit de ‘algemene 
populatie’. Een mogelijk probleem van partnercontroles is wanneer selectieve 
partnerkeuze (assortative mating) gerelateerd is aan de genetische gevoeligheid voor 
de aandoening die bestudeerd wordt. Dit zou kunnen leiden tot een onderschatting 
van de mate van familiaire aggregatie. De uitgevoerde simulatiestudie laat zien dat 
het kwantitatieve effect op de mate van familiaire aggregatie beperkt is, zelfs 
wanneer de partnerkeuze in hoge mate bepaald is door overeenkomstigheid van een 
factor die gerelateerd is aan een sterke risicofactor voor de ziekte.
In hoofdstukken 4 en 5 werd het onderliggende mechanisme van de geobserveerde 
familiaire aggregatie van PCa nader bestudeerd met behulp van segregatie-analyses. 
Ten eerste werden 1199 PCa probanden, afkomstig van de Division of Urologic 
Surgery, Washington University in St Louis, MO (USA), geanalyseerd (hoofdstuk 
4). Deze probanden zijn tussen januari 1991 en december 1993 gediagnosticeerd en 
voldeden aan de criteria voor radicale prostatectomie. In een eerdere studie werd 
aangetoond dat zowel vaders (Relatief Risico (RR)=3.5, 95% BI: 2.4-5.0) als broers 
van probanden (RR=4.7, 95% BI: 3.0-7.5) een verhoogd risico op PCa hadden.
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De segregatie-analyses lieten zien dat de familiaire aggregatie van PCa het best 
verklaard kan worden door een autosomaal dominant (AD) overervend allel, dat 
door 0.74% van de St Louis populatie gedragen wordt. Volgens het AD model zal 
97% van alle dragers PCa hebben ontwikkeld voor hun 86ste levensjaar vergeleken 
met 10% bij de niet-dragers. Verder voorspelt het AD model dat dit hoge-risico allel 
verantwoordelijk is voor een groot gedeelte (65%) van alle PCa diagnoses voor de 
leeftijd van 56. Daar staat tegenover dat van alle PCa een relatief klein gedeelte het 
gevolg is van dit AD overervend allel (8% bij leeftijd 85).
In de tweede segregatie analyse van PCa werden alle 704 PCa probanden uit 
Nederland, en hun eerstegraads familieleden, gebruikt om de in hoofdstuk 2 
geobserveerde familiaire aggregatie te verklaren (hoofdstuk 5).
Omdat geen van de initiële modellen de familiaire aggregatie van PCa afdoende 
konden verklaren werden gestratificeerde analyses uitgevoerd.
In zowel families van jonge (< 66  jaar bij diagnose) als oudere ((>66 jaar bij 
diagnose) symptoom-gediagnostiseerde probanden beschreef het autosomaal 
recessieve model de data het beste. Dit model voorspelde dat het autosomaal 
recessieve allel verantwoordelijk is voor 70% van alle PCa diagnoses voor de leeftijd
56. Van alle PCa diagnoses (voor de leeftijd 85) is 7% het gevolg van het 
autosomaal recessieve overervend allel. Deze schattingen komen overeen met wat 
gevonden werd in voorgaande studies.
De segregatie-analyses van hoofdstukken 4 en 5 ondersteunen de hypothese van een 
autosomaal overervend PCa ‘gevoeligheidsgen’ dat bij dragers (heterozygote en 
homozygote dragers in hoofdstuk 4, homozygote dragers in hoofdstuk 5) als gevolg 
heeft dat PCa op relatief jonge leeftijd ontstaat.
In hoofdstuk 6 werd het patroon van allelic imbalance (AI) in zowel sporadische PCa 
(SPC) als HPC bestudeerd op loci die veelvuldig AI vertonen in SPC, of waarvan 
aangenomen wordt dat ze een rol hebben in de ziekte.
Van 35 SPC en 46 HPC tumoren werd DNA geëxtraheerd. De HPC tumoren werden 
verzameld in de periode 1995-2000 van ofwel (1) het Universitair Medisch Centrum 
Nijmegen en het Erasmus Universitair Medisch Centrum Rotterdam; of (2) uit de 
registratie van STOET (Stichting Opsporing Erfelijke Tumoren) te Leiden. Alle 
tumoren werden getest op AI waarbij gebruik werd gemaakt van een panel van 35 
microsatelliet markers.
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Chromosomale gebieden die een hoge frequentie van AI (>  30%) vertonen in HPC 
zijn 1q, 5q, 7q, 8p, 13q, 16q, 17q, 18q, en 20q. In SPC werden hoge frequenties 
van AI gezien van chromosoomarmen 5q, 7q, 8p, 10q, 13q. De voornaamste 
verschillen (A >  20%) in AI tussen HPC en SPC waren ten aanzien van 1q, 10q, 
17q, 18q, and 20q. AI van PCa gevoeligheidsloci HPC1, PCaP  en HPC20 werd 
vaker geobserveerd voor HPC vergeleken met SPC.
Uit deze resultaten concluderen wij dat er enkele specifieke verschillen zijn in AI 
tussen HPC en SPC, hoewel de meeste genetische veranderingen gedeeld worden. 
Verdere onderzoeksresultaten over dit onderwerp zullen deze verschillen in 
genetische veranderingen scherper kunnen definiëren.
In hoofdstuk 7 werden mogelijke chromosomale veranderingen in HPC bestudeerd 
waarbij gebruik gemaakt werd van de Comparative Genomic Hybridization (CGH) 
techniek. Negen van de tien geanalyseerde DNAs waren afkomstig van radicale 
prostatectomie preparaten, één was afkomstig van een transurethrale resectie 
(TURP).
De meest frequente chromosomale deleties werden gevonden voor 
chromosoomarmen 8p en 16q (50%), gevolgd in frequentie door deleties van 6q en 
13q. De meest frequente amplificatie was op 8q. Omdat deze chromosomale 
veranderingen de meest voorkomende zijn in SPC, suggereren onze data dat HPC en 
SPC optreden volgens vergelijkbare genetische patronen.
In de twee studies uit hoofdstukken 8 en 9 worden twee polymorfismen beschreven 
die met een verhoogd PCa risico worden geassocieerd. Allereerst werd het 
HPC2/ELAC2 polymorfisme bestudeerd in hoofdstuk 8. De twee missense varianten 
in het ELAC2 gen op 17p11 resulteren in een serine (Ser) tot leucine (Leu) substitutie 
bij aminozuur 217 en een alanine (Ala) tot threonine (Thr) substitutie bij aminozuur 
541. De eerste twee studies uit de VS in populaties van HPC en SPC patiënten 
suggereerden dat de 541 Thr variant is geassocieerd met een 2.4-maal verhoogd 
risico op PCa. Vier daaropvolgende studies uit de VS en Finland konden dit resultaat 
niet repliceren in populaties van HPC, SPC en screeningsgedetecteerde PCa.
Van 26 HPC en 57 SPC patiënten werd het genotype bepaald voor de Ser217Leu en 
de Ala541Thr varianten in het ELAC2 gen, waarbij gebruik gemaakt werd van 
genomisch DNA afkomstig uit radicale prostatectomie preparaten.
Onder de HPC patiënten werden Ser217Leu genotypefrequenties geobserveerd van 
respectievelijk 62%, 33% en 5% voor type Ser/Ser, Ser/Leu en Leu/Leu. Ten
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aanzien van het Ala541Thr polymorfisme waren de genotypefrequenties 
respectievelijk 92%, 8% en 0% voor type Ala/Ala, Ala/Thr en Thr/Thr.
Onder de SPC patiënten werden Ser217Leu genotypefrequenties geobserveerd van 
respectievelijk 55%, 41% en 4% voor type Ser/Ser, Ser/Leu en Leu/Leu. Voor het 
Ala541Thr polymorfisme waren de genotypefrequenties respectievelijk 98%, 2% en 
0% voor type Ala/Ala, Ala/Thr en Thr/Thr.
De genotype- en allelotypefrequenties van de Ser217Leu en Ala541Thr varianten in 
HPC en SPC patiënten uit Nederland verschillen in hoofdzaak niet van de frequenties 
gerapporteerd in eerdere studies (waarin geen associatie werd gevonden tussen de 
varianten en een verhoogd risico op PCa). Uit oogpunt van efficiëntie werd besloten 
geen genotypes te bepalen van een controlepopulatie om vervolgens een risico te 
schatten voor dragers van het 541Thr allel.
Het in hoofdstuk 9 bestudeerde polymorfisme is het C/A enkelvoudige polymorfisme 
op -160 bp relatief aan de transcriptionele startplaats van de E-cadherine gen 
promoter.
E-cadherine speelt een grote rol in de intercellulaire adhesie, celpolariteit en 
weefselarchitectuur. Het relatieve risico op PCa geassocieerd met dit polymorfisme 
werd bepaald door 82 PCa patiënten en 188 controles te genotyperen.
Genotype- en allelfrequenties verschilden statistisch significant tussen cases en 
controles. Dragers van het A-allel hadden een verhoogd risico ten opzichte van C­
alleen dragers (Odds Ratio (OR)=3.6; 95% CI: 2.0-6.4). De AC and AA genotypes 
hadden een verhoogd risico op PCa vergeleken met CC genotypes (respectievelijk 
OR=3.8; 95% BI: 2.1-6.8 en OR=1.7; 95% BI: 0.4-6.6).
In de HPC subgroep was het effect van het A-allel en AA/AC genotype minder sterk 
dan in de SPC subgroep. Dit kan het gevolg zijn van verschillen in etiologie tussen 
SPC en HPC, waarbij in HPC wellicht een grotere rol is weggelegd voor hogere 
penetrante PCa gevoeligheidsgenen.
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S T E L L I N G E N  
behorende bij het proefschrift
1. Eerstegraads mannelijke familieleden van prostaatkankerpatiënten hebben een 
driemaal verhoogd risico op prostaatkanker. Dit risico neemt toe naarmate er meer 
gevallen in de familie voorkomen.
2. Erfelijk prostaatkanker in Nederland maakt geen deel uit van een erfelijk 
kankersyndroom, zoals de 5^G47-geassocieerde borst- en ovariumtumoren.
3. Bloedverwanten van partners van prostaatkankerpatiënten vormen een valide en 
efficiënte controlegroep in de studie van familiaire aggregatie van prostaatkanker.
4. Mannen met het A-allel van het -160 bp E-cadherine genpromoter polymorfisme 
hebben een verhoogd risico op prostaatkanker.
5. Het grootste obstakel in de ontrafeling van de genetische basis van prostaatkanker is 
de grote genetische heterogeniteit van de ziekte.
6. Dat homeopathica enerzijds door het College ter Beoordeling van Geneesmiddelen, 
in tegenstelling tot ‘reguliere’ geneesmiddelen, alleen op aspecten van veiligheid en 
kwaliteit worden beoordeeld en níet op werkzaamheid en anderzijds na registratie het 
predikaat ‘homeopathisch geneesmiddel’ mogen dragen is misleidend voor de 
consument en bovendien een stimulans voor kwakzalverij.
7. A [human] is really the [human] genes’ way of making more copies of themselves. 
(vrij naar E.O. Wilson)
8. Astrologen die hun diensten tegen betaling aanbieden maken zich schuldig aan 
oplichting.
Hereditary prostate cancer: genetic epidemiology and allelotype analysis
Bas AJ Verhage, 19 mei 2003
